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The production of recombinant biotherapeutic proteins is usually achieved at an industrial 
scale using cultured cell systems with a number of host systems used including bacteria, 
yeast, insect cells and mammalian cells, depending on the needs of the protein to be 
produced. In the last 2-3 decades, the market for recombinant protein production has been 
dominated by monoclonal antibodies (mAbs), glycoproteins with complex post-
translational modifications necessary for their therapeutic function. For the production of 
such molecules, mammalian cells and particularly Chinese hamster ovary (CHO) cells are 
often the host expression system of choice for their ability to correctly fold and assemble 
such complex molecules and to perform human-like glycosylation. The ability of CHO host 
cells to generate high levels (>5 g/L) of mAbs in particular has been enhanced and attained 
over the years via the implementation of different strategies including the design of media 
and feeding strategies, use of high throughput screening approaches to identify high 
producing cell lines, redesign of processes during bioprocessing, manipulation of genetic 
constructs to drive recombinant gene expression and protein engineering to improve CHO 
host cell productivity and product quality. Despite these approaches, there remains a 
desire to further improve the ability of CHO and other host cell systems to be improved to 
enhance their ability even further with regard to production and quality of 
biopharmaceuticals, paƌtiĐulaƌ ŵoƌe diffiĐult to eǆpƌess ŵoleĐules thaŶ ͚staŶdaƌd͛ ŵAďs. 
One strategy that has been undertaken to enhance the cellular capacity for recombinant 
protein expression is cell line engineering, where a desired phenotype of the host is 
achieved by genetic manipulation. In this study, the secretory pathway of the CHO cell has 
been manipulated to investigate whether its engineering can improve the secretory 
capacity of two different CHO host cell lines under batch and fed-batch conditions. 
Specifically, members of the SNARE family, a family of proteins involved in the fusion 
machinery of vesicles which have been suggested to be a bottleneck in the secretory 
pathway, were ectopically over-expressed and the effect(s) of the overexpression on 
growth, culture viability and recombinant protein productivity of the CHO hosts 
determined. In a CHO-S cell line, overexpression of specific levels of syntaxin 17 (STX17) 
and SNAP29 fused to eGFP increased culture longevity and late culture viability, possibly 
through an impact on the autophagy pathway. Assessment of the impact of the ectopic 
expression of these SNAREs in CHO-S during transient expression of model proteins under 
batch culture conditions, IgG1 Adalimumab and the fusion protein Etanercept, showed an 
increase in titre up to 5-fold (STX17) and 2.4-fold (SNAP29) respectively. Specific levels of 
SNARE expression were required to observe a titre increase. Indeed, only cell lines 
overexpressing to a lower level of SNAP29 demonstrated an increased titre whereas a more 
linear effect was observed for cell lines expressing STX17, with higher STX17 expressing cell 
lines having a greater increase in titre than low STX17 overexpressers. Cells expressing 
STX18 also revealed an increase, up to 3-fold, in yield when producing Adalimumab, but not 
Etanercept, suggesting a molecule specific effect. Transferability of this approach to a 
second CHO host in the industrial environment was then investigated by engineering of an 
industrial host Đell liŶe, ͞CloŶe Ϯϳ͟, a CHO-DG44 derived cell line. No increase in product 
titre was observed when the SNAREs were over-expressed in already high expressing 
recombinant mAb cell lines. The differences in the approaches and environment, as well as 
the intrinsic differences in the CHO host cell lines, might explain the divergence of observed 
effects between the cell lines. Nonetheless, a positive impact upon the overexpression of 
target SNAREs at specific levels was observed with regard to growth and productivity in 
CHO-S host cells suggesting SNARE manipulation was successful for the engineering of 
CHO-S cells. Moreover, the mechanisms by which the overexpressed SNAREs potentially 
elicit their changes in secretory phenotypes in the CHO-S host offers up new areas of 
interest for future cell line engineering strategies such as autophagy and mitophagy. 
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CHAPTER 1: Introduction 
 
1.1. The biopharmaceutical market  
With the development and improvement of our ability to manipulate recombinant DNA in 
the 1970s, the protein biopharmaceutical market also developed and expanded rapidly. 
The first drug produced from recombinant DNA approved by the FDA was Humulin in 1982 
(Walsh 2014). This drug developed by Eli Lilly was produced in Escherichia coli to provide 
recombinant insulin. In 2017, the biopharmaceutical market was worth $160 billion 
(Morrison and Lähteenmäki 2018) and composed of a variety of products of differing 
complexity from recombinant insulin to therapeutic antibodies. The first FDA approved 
antibody was OKT3 or muronomab a muƌiŶe IgGϮ α CDϯ used as a tƌaŶsplaŶt ƌejeĐtioŶ dƌug 
in 1983 (Hooks, Wade, and Millikan 1991). In the past 10-15 years, monoclonal antibodies 
have emerged as the prominent class of protein based drug in terms of sales, with 6 of the 
top 10 drugs in 2014 by value being monoclonal antibodies worth a staggering $70 billion 
(Walsh 2014). By 2020, 70 monoclonal antibodies are expected to be on the market with 
combined world-wide sales of $125 billion (Ecker, Jones, and Levine 2015). Antibodies 
being more complex to produce than other proteins that might consist of just one 
polypeptide with few or no post-translational modifications, antibody production 
necessitates a host with the cellular machinery able to undertake complex post 
translational modifications (PTM), notably glycosylation and disulphide bond formation. For 
example, mammalian cells are able to undertake such human-like glycosylation. 
Cultured mammalian cells have been used for recombinant protein production since 1986 
when they were used for the production of tissue plasminogen activator, and now around 
60% of biotherapeutic protein products are manufactured in mammalian cells (Walsh 
2014). Different mammalian cell hosts are available, but the most commonly used 
mammalian cell host is the Chinese hamster ovary (CHO) cell. This is discussed in more 
detail below. The commercially viable production of monoclonal antibodies and other 
complex protein based drugs is possible due to constant improvement in the ability to 
generate cell biomass rapidly and of the productivity from mammalian cells, particularly in 
chemically defined, protein free media. All of the combined improvements has allowed 
improvements in titres from around 50 mg/L in 1986 to 4.7 g/L in 2004 (Wurm 2004). Since 
2004, titres in excess of 5 g/L (Handlogten et al. 2018; Reinhart et al. 2015) and even 
greater than 10 g/L have now been reported (Huang et al. 2010). Such improvements are 
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the results of overall efforts in the development of host selection, media and feed 
improvement, process engineering, enhancement of vectors and cell lines engineering.  
 
1.2. Cultured host cell systems for the expression of recombinant 
proteins 
1.2.1. Bacteria cell expression systems 
One of the most common hosts for the production of proteins at the laboratory scale and 
for protein biopharmaceuticals are bacterial strains, and particularly E. coli strains. E. coli 
strains have been used for decades, not only for protein biopharmaceutical production, but 
also for basic research, resulting in accumulation of a profound knowledge about the host 
giving significant advantage for their utilisation. E. coli expression systems have been used 
to produce principally non-glycosylated molecules such as somatostatin, insulin, bovine 
gƌoǁth hoƌŵoŶe foƌ ǀeteƌiŶaƌǇ appliĐatioŶs, α-1 antitrypsin, interleukin-2, tumor necrosis 
faĐtoƌ, β-interferon, and γ-interferon (Fernández and Vega 2016), constituting a large 
segment of the biopharmaceutic products market. Advantages of protein expression in E. 
coli are its fast growth rate, ability to generate high viable cell concentrations, high titre, its 
simplicity to manipulate and engineer, and its affordability. Often, expression analysis of a 
target molecule is performed in E. coli with the product of interest if it does not require 
human-like post-translational modifications or complex folding and assembly to assess the 
compatibility of production with the system.  
Nonetheless, this system is not perfect, bacteria being prokaryotes organisms they are 
unable to perform human like glycosylation or complex folding and assembly processes 
vital for the production of antibodies and other molecules. Those proteins that require 
disulphide bonding or complex folding and assembly tend to form inclusion bodies in the 
cytoplasm of the cell and need supplementary processing (e.g. refolding) and this can cause 
a large loss of product (Singh et al. 2015). The presence of endotoxins (notably 
lipopolysaccharides, an essential component of the bacteria external membrane) can also 
be a problem if the product is targeted for a biopharmaceutical usage and need to be safe 
for use in humans (Raetz and Whitfield 2002). E. coli, being a gram negative strain, the 
outer membrane impacts on the secretion of the recombinant product which, if targeted 
into the periplasm is retained here and hence extra steps are required in downstream 
processing to recover the product from within the cell (Mergulhão, Summers, and 
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Monteiro 2005). The reducing environment in E coli in the cytoplasm is not optimal for the 
formation of disulphide bonds although proteins may be directed to the periplasm where 
the environment can facilitate disulphide bond formation. As many proteins require 
disulphide bond formation as a PTM for correct folding and activity, some strains have 
been specifically developed (e.g. overexpression of oxydoreductases such as PDI or 
exportation of protein of interest into the periplasm (de Marco 2009)) to address this issue 
(Ke and Berkmen 2014). Nonetheless, 20% of drugs approved since 1984 are produced in E. 
coli (Walsh 2014). Other bacteria strains than E. coli are also used for protein production, 
such as some Bacillus strains that are mainly favoured for production of proteases 
(detergent industry) and amylases (food industry) (Westers, Westers, and Quax 2004). 
1.2.2. Yeast cell expression systems 
Yeast organisms have been developed as cell factories for the recombinant production of 
proteins over many years. The main yeast strain used in industry is Saccharomyces 
cerevisiae although Pichia pastoris is also used. Like bacteria hosts, yeasts have been used 
and studied for decades, giving a large amount of genetic tools and history around there 
use compared to other hosts. Yeasts are generally considered GRAS hosts (generally 
recognised as safe) due to the long history of their use in the food industry for brewing and 
baking purposes. As for bacteria hosts, yeast strains are able to reach high viable cell 
concentrations rapidly, and as a eukaryotic host have the required organelles and cellular 
machinery to undertake complex PTMs and glycosylation. Specifically with regard to 
glycosylation, there are 2 types known as N- and O-linked glycosylation. It has been 
demonstrated that N-glycosylation is often important for protein function and 
immunogenicity while less is known about O-glycosylation. In this regard, S. cerevisiae N-
glycosylation processing in the early Golgi is limited to addition of mannoses and 
mannosylphosphate sugars often resulting in hyperglycosylation (abundance of mannoses 
residues) which are immunogenic (Teh, Fong, and Mohamed 2011) and hence limit the use 
of this system for making proteins destined for human use. Pichia pastoris is sometimes 
preferred to S. cerevisiae because it does not have a α-1,3-mannosyltransferase in the Golgi 
leading to a reduced mannose pattern (Wildt and Gerngross 2005). A strain of P. pastoris 
has also been engineered to give human glycosylation patterns (Irani et al. 2016), although 
this has not seen wide up as of yet in industry. S. cerevisiae and other yeast can secrete 
proteins into the media when using an appropriate ER peptide signal facilitating entry into 
the secretory pathway and presenting an advantage compared to bacteria hosts (Demain 
and Vaishnav 2009).  
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Yeast strains other than S. cerevisiae are therefore used for recombinant protein 
production, notably methylotrophic yeasts such as P. pastoris. Methylotrophic yeasts have 
the ability to grow using only one source of carbon, methanol. Compare to S. cerevisiae, P 
pastoris have advantages such as a higher protein production, the ability to grow on high 
concentrations of methanol able to kill most of microorganisms and less hyperglycosylation 
(Demain and Vaishnav 2009).  
1.2.3. Insect cell expression systems 
The first use of the baculovirus expression system in insect cells was in 1983 (Pennock, 
Shoemaker, and Miller 1984) and since then this has been used as an alternative system for 
the production of recombinant proteins. The main host used with baculovirus is the fall 
armyworm (Spodoptera frugiperda) in suspension culture. Insect cells, compared to 
bacterial and yeast systems, can perform more complex PTMs, notably glycosylation closer 
to human cells as a result of the activity of glycosylation enzymes in the Golgi. The main 
vector used to engineer insect cells is the baculovirus, that naturally targets invertebrate 
cells (Agathos 1991) assuring high levels of biosafety. Insect cells cultures are cheap, easy 
to scale up and can reach high cell concentration cultures. Since their first utilisation, more 
than 200 different recombinant proteins have been produced successfully in insect cells 
demonstrating their wide adaptability (Demain and Vaishnav 2009). One drawback of 
insect cell systems is that unexpected PTMs specific to insect cells might apply to the 
recombinant protein used and the glycosylation profiles are similar to, but not exactly the 
same as, that from mammalian cells. Some engineering has been undertaken in this area to 
obtain similar glycosylation (Jarvis 2003; Mabashi-Asazuma and Jarvis 2017). The yields 
from insect cell expression systems are also much lower than those that can be achieved 
from cultured mammalian cells. 
1.2.4. Mammalian cell expression systems 
Culture mammalian cells, compared to the other hosts described above, have traditionally 
been much more labour intensive and time consuming. Mammalian cells traditionally 
generate less biomass, reaching lower maximum viable cell concentrations and achieve 
lower product titres, but have become the host of choice for many commercial 
biotherapeutic recombinant proteins due to their ability to undertake complex folding and 
assembly process and to give human-like PTMs, particularly N-glycosylation. Glycosylation 
has been demonstrated to impact on different characteristics of recombinant proteins such 
as their immunogenicity, stability, biological activity and in vivo half-life (Walsh and Jefferis 
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2006). Different types of cultured mammalian cells are used, for example HEK (Human 
embryonic kidney), BHK (baby hamster kidney) and NS0 cells (Dumont et al. 2016; Lalonde 
and Durocher 2017; Mead et al. 2012), but the main host cell line currently used for the 
commercial production of biotherapeutic recombinant proteins is the Chinese hamster 
ovary (CHO) cell line. Compared to the other potential mammalian cell hosts, CHO cells 
display good growth in suspension culture in chemically defined, protein free media, are 
less susceptible to various pathogenic viruses (Berting, Farcet, and Kreil 2010) and are 
easier to manipulate. Moreover, CHO cells have been approved by the FDA and other 
authorities as a safe host for the production of recombinant proteins. CHO cells also give 
͚huŵaŶ-like͛ glǇĐosǇlatioŶ pƌofiles aŶd haǀe a histoƌǇ of ŵoƌe thaŶ ϯϬ Ǉeaƌs of pƌoduĐiŶg 
biotherapeutic recombinant proteins that have been safely administered to humans. 
Nonetheless, CHO cells are not perfect; they doŶ͛t peƌfoƌŵ ideŶtiĐal glǇĐosǇlatioŶ to 
human cells and can generate glycol forms that result in immunogenic recombinant 
products (Butler and Spearman 2014) and, although these can produce large quantities (>5 
g/L) of IgG monoclonal antibodies (Reinhart et al. 2015), the yields of many other proteins 
remain much lower. Approaches to improve the CHO cell expression platform as discussed 
in more detail below. 
The different host cell systems described above therefore all have their specific 
dis/advantages and choosing one for the production of recombinant protein is a considered 
process. This includes the protein folding and assembly requirements of the target protein, 
the complexity of the target protein and the required PTMs. Since the production of the 
first recombinant proteins, improvements of the different hosts, but also of the processes 
used to generate recombinant expressing strains or cell lines and approaches to the 
culturing of these have been performed to enhance the ability of the different systems to 
commercially manufacture target biopharmaceuticals. Here, a general review of the 
approaches and improvements to enhance the productivity of mammalian cells, and 
particularly CHO cells, is provided as the host cell line of investigation in this thesis. 
 
1.3. Approaches undertaken to increase growth and recombinant 
protein yields from CHO host cell systems in industrial processes 
The development of a CHO cell expression systems involves the assessment of the impact 
of a number of elements including the isolation/development of the host cell line itself, the 
media and fed used to grow the cells during manufacturing, and elements of the expression 
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vectors used to select for integration of the gene(s) of interest into the host genome and 
drive transcription and translation of the target recombinant genes and mRNAs. There have 
been huge amounts of work undertaken in each of these areas and below a general review 
of these is provided. 
1.3.1. Development of Media and feeding strategies 
As well as manipulating the CHO cell host or the vectors integrated in the host for protein 
production, process and media improvement have been performed to increase productivity 
and growth. This is often specific to an individual host cell line and will reflect the 
metabolism of the specific CHO host cell and its requirements for growth and that of the 
recombinant protein. When mammalian cells were initially cultured in vitro, the cultivation 
media contained animal serum which was a source of nutrients, hormones, growth factors 
and protease inhibitors. This also provided protection against shear stress, a common 
problem in bioreactors when growing mammalian cells in suspension culture (Hesse and 
Wagner 2000). Serum-free media was developed to solve the issue of using undefined 
serum which could be a source of contamination/viruses, was not consistent in its nature 
from batch-to-batch and could have undesired effects on the performance of the cells.  
Media optimisation has been a large part of process optimisation taken over the years in 
order to at best the needs of the cells during the culture and brings all the nutrients 
necessary. For example, early reports showed maximum viable cell numbers achievable to 
be 2 x 106 cells/mL, however now viable cell numbers in excess of 30 x 106 cells/mL are 
reported (Westoby et al. 2011). As product titre is the sum of the number of cells, their cell 
specific productivity and the length of the culture, higher cell numbers, maintained for 
longer underpin increased product yields. As such, much work has been undertaken to 
develop chemically defined media and the improvement of the feeding strategies in fed-
batch cultures. Fed-batch culture is a culture mode with addition of nutrients to the media 
(feed) at various times through culture to replace depleted nutrients. Feed is added into 
the media to address the limit in nutrient encountered in batch processes and obtain 
extended and more viable cultures. Fed-batch processes are easier to work with and to 
optimise than continuous processes, although continuous processes are now being 
developed that allow smaller culture sizes to be run. Continuous or perfusion processes 
involve replacement of media at constant rates with cell retention. This process enables to 
reach high cell concentrations (>20 x 107 cells/mL) for extended periods of time (>40 days) 
(Clincke et al. 2013; Ritacco, Wu, and Khetan 2018). 
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Culture process improvements have also been an important part of increases in 
productivity of different cell lines, with notably induction systems or application of cold 
shock to increase the production of recombinant protein by slowing down transcription 
and translation during the process (Kaufmann et al. 1999). Improvements to the design of 
the equipment have also been reported such as more friendly methods of agitation or 
optimised controls of different parameters in the vessels (pH, temperature, and 
oxygenation). 
1.3.2. Different CHO host cells and selection systems 
The CHO cell host cell lines used for the commercial production of biopharmaceutical 
products are different from the original CHO Đell liŶe isolated ďǇ PuĐk iŶ the ϭϵϱϬ͛s (Puck 
1958). Indeed, through years of selection, CHO host cell lines have evolved and being 
chosen for specific characteristics making them desirable for commercial manufacturing of 
recombinant biotherapeutic proteins. In particular, different metabolic selection markers 
have been developed to give different CHO cell hosts in order to introduce genetic material 
for the expression of a gene(s) of interest. The CHO cell line was established for the first 
time in 1956 in the laboratory of Theodorus Puck (Puck 1958). From this original cell line, 
different cell lines have been derived such as the CHO-K1 subclone of the original CHO cell 
line; CHO-DG44, a depleted cell line for dhfr generated in 1981 by Urlaub et al.; and CHO-S 
another cell line derived from the original source in 1991 (Reinhart et al. 2018). For the 
selection of cells expressing exogenous DNA in CHO cells, two systems are popular in 
industry, the glutamine synthetase (GS) system and the dihydrofolate reductase (DHFR) 
system using the CHO-DG44 cell line. 
The glutamine synthetase (GS) system is widely used for the selection of host cells 
containing the desired genetic material. The GS system is based on a metabolic selection 
around the conversion of glutamate and ammonia into glutamine by glutamine synthetase. 
The chemical methionine sulfoximine (MSX) is an irreversible inhibitor of the glutamine 
synthetase enzyme (Noh, Shin, and Lee 2018) although it is not specific for GS. In media 
without glutamine, only cells expressing GS at high enough levels to generate their own 
glutamine in the presence of the GS inhibitor MSX are able to grow and proliferate, 
selecting for those cells where the integration of genetic vectors containing a GS expressing 
gene has occurred. Addition of MSX helps to obtain high levels of stringency for the cells in 
order to obtain cells with the genetic construct of interest whereby the GS gene is on the 
same piece of DNA (usually a plasmid vector) as the gene(s) of interest. Thus, expression of 
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exogenous GS and selection of this helps to select for those cells also expressing the 
recombinant protein genes of interest too. The system has now been optimised with the 
use of CHO cells depleted of GS (GS knockout) (Fan et al. 2012). 
The dihydrofolate reductase (DHFR) system is used complementarily with CHO-DG44 cell 
lines. Established in 1981 by Urlaub et al., this cell line is DHFR deficient, an important 
enzyme for the synthesis of purines and amino acids (Chen et al. 1984). Cells deficient in 
DHFR can be grown without this enzyme by the addition of a supplement to the media. 
Methotrexate (MTX) is an inhibitor of DHFR. DHFR deficiency can be overcome by 
expression of exogenous DHFR in cells by integration of a genetic construct expressing a 
dhfr gene (Goodsell 1999). Selection of highly expressing dhfr cells is undertaken by 
culturing in the presence of MTX which also simultaneously selects for the expression of 
cells with the recombinant product gene(s) of interest on the genetic construct securing 
the integration into the cell line genome. Increasing concentrations of MTX are sometimes 
used to amplify the number of gene copy numbers in the genome of selected cells 
(Hausmann et al. 2018).  
More classic systems for the selection of recombinant gene expressing cells are through the 
use of antibiotics and the expression of a rescue gene (e.g. hygromycin, puromycin). These 
are usually eluted for commercial manufacturing as the use of antibiotics is best avoided 
and hence the metabolic selection systems described above tend to be used. 
1.3.3. Design of expression vectors for enhanced recombinant gene and protein 
expression from CHO cells 
For the production of a recombinant protein from a mammalian cell line, a method of 
introducing the gene and of controlling its expression is required and this is usually 
achieved using a plasmid based expression vector. The expression vector contains basic 
elements necessary for metabolic (or antibiotic) selection of integration of the DNA into the 
host and for the expression of the recombinant gene, including an appropriate promoter(s), 
aŶd the ϱ͛ aŶd ϯ͛ uŶtƌaŶslated ƌegioŶs, iŶĐludiŶg a polyA tail. Much optimisation work has 
been performed over the years on the different elements of genetic vectors to generate 
vectors that support high expression of the product with long term genetic stability. 
Promoters are sequences needed to recruit polymerases in order to generate RNA via a 
process known as transcription with the resulting RNA further processed to generate a 
mature mRNA in the nucleus. Common promoters are often derived from viruses such as 
the cytomegalovirus immediate early promotor (CMV) (Xia et al. 2006), but more recently 
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endogenous mammalian cell promoters have been used to drive constitutive expression of 
recombinant genes such as the EF-ϭ α pƌoŵoteƌ iŶ CHO Đells (RunningDeer and Allison 
2004). Promoters can be coupled to enhancer sequences able to increase a promoters 
activity by facilitating recruitment of transcription factors (Riethoven 2010). Genes for 
selection markers or antibiotics are often present on expression vectors for cell selection. 
Common selection systems in CHO are the DHFR/MTX or the GS/MSX selection described in 
section 1.3.2 above (Kingston et al. 2002). A polyadenylation (PolyA) sequence or tail are 
pƌeseŶt at the ϯ͛ eŶd of the seƋueŶĐe of the gene of interest as this is required for 
transport out of the nucleus and impacts mRNA stability (Makrides 1999). Addition of other 
elements such as introns or untranslated regions (UTRs) are also known to improve 
translation in some cases (Makrides 1999). A further area that has received much attention 
is that of codon optimisation whereby the gene sequence is optimised to use codons that 
are thought to improve the rate of polypeptide elongation and improve mRNA stability 
(Chung et al. 2013). Optimisation of each individual component of the vector of expression 
has the potential to improve transcription and subsequent translation and hence impact 
upon product production.  
1.3.4. Cell engineering for enhance cell growth and secretory recombinant 
protein production 
1.3.4.1. Approaches applied to date for mammalian cell line engineering 
Improvements to the media used for culturing of cells, feed or process, host cell line 
selection and enhancement of vectors for gene expression have all been extensively 
investigated to improve recombinant protein yields from cultured cell systems as they are 
easier to perform than targeted cell line engineering and have a controlled impact on the 
performance of the process. Modification of the host by cell line engineering is a more 
complex approach due to the intricacy of the host and wide genetic variability within a host 
cell line population of cells. Cell line engineering of a host sets out to have a direct impact 
on the phenotype of the host by adding, increasing or removing a specific characteristic. 
Two approaches to cell line engineering are typically used, overexpression or 
knockout/down of genes of interest. Overexpressing a gene gives the opportunity to 
amplify or add a new characteristic to the cell line phenotype. Multiple genes can be 
(over)expressed and entire pathways can be redesigned in some cases. With regard to gene 
knockout or down, the expression of targeted genes can be abolished/reduced using 
techniques such as CRISPR. There are important differences between knockdown and 






















































































































































































































































Table 1.1. Exemple of cell line engineering strategies with their target genes and resulting phenotypes
Celular pathway strategy target gene Engineered phenotype reference
apoptosis Overexpression E2F-1 Increased culture times and 20% higher viable cell concentration  Majors et al. (2008)
apoptosis Overexpression Bcl-xL Increase of 88% in cell viability and >2 fold in titre Chiang and Sisk (2005)
apoptosis Overexpression Bcl-2 Increase of 75% in maximum viable cell concentration Tey et al. (2000)
apoptosis Knockout Bak/Bax Increase of 5-fold in titre Cost et al. (2010)
apoptosis Overexpression XIAP
Increased resistance to apoptosis and culture times, decreased 
proliferation 
Liew et al. (2010)
apoptosis Knockdown caspase-3/caspase-7 Increase of 55% in titre and extension of culture time Sung et al. (2007)
apoptosis Knockdown caspase-8/caspase-9 
Increased the viability in both batch and fed-batch suspension 
cultures
Yun et al. (2007)
cell cycle Overexpression c-Myc 
Increase >70% in maximal cell concentration without additional 
supply of nutrients
Kuystermans and Al-Rubeai (2009)
glycosylation Knockout FUT8
Production of completely non-fucosylated antibodies resulting in 100-
fold enhanced antibody-dependent cellular cytotoxicity
Yamane-Ohnuki et al. (2004)
glycosylation Overexpression αϮ,ϲ-sialǇltƌaŶsfeƌase PƌoduĐtioŶ of αϮ,ϲ-liŶked sialiĐ aĐid aŶd iŶĐƌeased total sialiĐ aĐid 
conten
Lin et al. (2015)
glycosylation Knockout β-ϭ,ϰ-galaĐtosǇltƌaŶsfeƌase isofoƌŵ geŶes Reduced galactosylated N-glycans levels to 1% Amann et al. (2018)
metabolism Overexpression malate dehydrogenase II
Increase in intracellular ATP and NADH, and up to 1.9-fold 
improvement in integral viable cell number
Chong et al. (2010)
metabolism Overexpression CPS I and OTC
Reduction of ammonium ion levels by 33% and increase of 30% in 
growth rate
Park et al. (2000)
metabolism Knockdown LDHA
Reduction of glucose consumption rates up to 87% and specific 
lactate production ratesup to 79%
Kim and Lee (2007)
proliferation Overexpression cyclin-dependent kinase like 3
Increase of 9% in specific growth rate and 5% in maximum viable cell 
concentration
Jaluria et al. (2007)
proliferation Overexpression valosin-containing protein Increase up to 30% in viable cell concentration Doolan et al. (2010)
protein folding Overexpression calreticulin/calnexin Increase of 1.9-fold productivity Chung et al. (2004)
protein folding Overexpression ERp57 Increase of 2.1-fold in productivity Hwang, Chung, and Lee (2003)
secretion Overexpression SRP14 Increase up to 6-fold in titre Le Fourn et al (2014)
UPR Overexpression XBP-1 spliced Increase of 4-fold in productivity Gulis et al. (2014)
protein folding Overexpression Increase of 1.37-fold in productivity Borth et al. (2005)
Decrease in productivity up to 1.6-fold Hansen et al. (2015)




maximum viable cell concentrations (or total biomass) and as such improving growth 
kinetics has been an aspect of interest. Faster growth and therefore time to obtain higher 
maximum viable cell concentrations can help deliver more cost effective and faster 
processes. To impact on these parameters, engineering targets investigated have been 
proteins involved in control of the cell cycle. To deliver faster growth and high cell 
concentrations, overexpression of the c-Myc protein has resulted in improvements in these 
key phenotypic cell characteristics (Kuystermans and Al-Rubeai 2009). Protein c-Myc is a 
nuclear localised phosphoprotein involved in cell cycle progression and apoptosis. Other 
proteins impacting the cell cycle such as cyclin-dependent kinase like 3 and E2F-1 resulted 
in improved cellular growth rates and increased maximum viable cell concentrations when 
engineered in mammalian cells (Jaluria et al. 2007; Majors et al. 2008). Strategies involving 
proteins in pathways other than the cell cycle have also been successfully investigated, 
such as the overexpression of the malate dehydrogenase II portion of the tricarboxylic acid 
cycle (TCA) cycle for energy production in the mitochondria or valosin-containing protein 
involved in invasion, metastasis and cell proliferation but its function are not fully 
elucidated (Chong et al. 2010; Doolan et al. 2010). 
1.3.4.2.2. Apoptosis engineering 
Apoptosis is a programmed cell death mechanism triggered by stresses such as nutrient 
depletion, accumulation of toxic metabolites, and shear stress (Krampe and Al-Rubeai 
2010). It has been widely studied because it impacts on culture viability and longevity 
(Arden and Betenbaugh 2004) but also can impact upon product concentration and quality 
by the effect of proteases realised in media when cells burst (Kaneko, Sato, and Aoyagi 
2010). Apoptosis is mainly controlled by the Bcl-2 family which contains proteins conveying 
anti- and pro-apoptotic signals sensed by the cell and is subdivided into three sub-families: 
(i) anti-apoptotic Bcl-2 homologs containing Bcl-2 homology (BH) domains 1, 2, 3 and 4; (ii) 
pro-apoptotic members containing BH1, 2, and 3 homology domains; and (iii) BH3 only pro-
apoptotic members (Adams and Cory 2001). The Bcl-2 pathway is detailed in Figure 1.1 
(Ashkenazi et al. 2017). By the manipulation of the expression of members of the Bcl-2 
family, it has been shown that it is possible to impact the onset of apoptosis and increase 
culture viability and longevity (Fischer, Handrick, and Otte 2015; Kim and Park 2003). In 
CHO cells, overexpression of Bcl-xL or Bcl-2, both anti-apoptotic proteins, increased culture 
viability (Chiang and Sisk 2005; Kim and Lee 2000; Tey et al. 2000) whilst knockout of pro-
apoptotic proteins from the Bcl-2 family such as Bak and Bax also resulted in improved 




Caspases are proteins that also play a central role in apoptosis and are activated by a 
proteolytic cascade of cleaved caspases (Parrish, Freel, and Kornbluth 2013). Thus, 
suppression of their activation or disruption of their proteolytic effect on cells has become 
a promising strategy to prevent or delay apoptosis. Caspases can be divided in two groups: 
initiator caspases involved in interaction with upstream molecules and 
22 
 
activating/processing effector caspases and effector caspases responsible for cleaving 
cellular components (Li and Yuan 2008). Overexpression of intracellular caspase inhibitors 
such as X-linked inhibitor of apoptosis protein (XIAP) has been a strategy investigated and 
showed in the case of XIAP an inhibition of caspase-3 activity leading into reduced 
apoptosis, prolonged cultures times and decreased proliferation (Liew et al. 2010). 
Knockdown of caspase-3 and -7, and overexpression of double negative mutants of 
caspase-8/caspase-9 (Sung et al. 2007; Yun et al. 2007) were also successful approaches for 
caspase engineering. The result of these strategies was an increase in viability of culture in 
batch and fed-batch conditions when overexpressing double negative mutants of caspase-
8/-9 while knockdown of caspase-3 and -7 not only increased culture times and culture 
viability but also raised productivity by 55%. 
1.3.4.2.3. Engineering to enhance the protein folding capacity of the cell 
When using strong promoters to drive gene expression or with the insertion of multiple 
copies of a gene, it has been observed that the amount of protein product generated is not 
proportional between the amount of transcript (mRNA) and protein. It was therefore 
suggested that there is a bottleneck or limitation in mRNA translation instead of 
transcription once a mRNA threshold is exceeded. For secretory recombinant proteins, the 
nascent polypeptide is translated on ribosomes on the ER where the polypeptide is fed co-
translationally into the ER where the polypeptides are folded and assembled in the case of 
multi-chain proteins such as antibodies. ER localised chaperones and foldases are involved 
in the protein folding in the ER and a number of these have been investigated as possible 
limiting factors via cell engineering approaches (Mohan et al. 2008). Overexpression of ER 
chaperones such as calreticulin, calnexin or ERp57 have been shown to increase by 
approximatively 2 fold the recombinant protein productivity of some cell lines (Chung et al. 
2004; Hwang, Chung, and Lee 2003) but more varied results have been reported for over-
expression of PDI (Borth et al. 2005; Hansen et al. 2017; Mohan and Lee 2010). PDI through 
its ability to form and reduce disulphide bonds of nascent proteins and also to inhibit 
aggravation of folding intermediates through its chaperone function (Appenzeller-Herzog 
and Ellgaard 2008) have been a target of interest to increase productivity. For example, 
while Borth et al. (2005) observed an increase of 1.37 fold in productivity when 
overexpressing PDI, null or even decrease in productivity have been observed (Hansen et 
al. 2015; Hayes, Smales, and Klappa 2010) suggesting that overexpression of an effector 




1.3.4.2.4. Glycosylation modifications and tuning via cell engineering approaches 
Despite CHO cells being mammalian aŶd geŶeƌatiŶg pƌoteiŶs ǁith ͚huŵaŶ-like͛ 
glycosylation patterns, glycosylation between CHO and human cells is not identical. 
Moreover, glycosylation is an important biological modification that can impact 
immunogenicity, protein stability, biological activity and half-life of a protein molecule 
(Walsh and Jefferis 2006). Thus, ensuring a particular glycosylation pattern window is 
important when manufacturing a glycoprotein and the ability to tailor and control 
glycosylation is an important aspect. For example, it has been demonstrate that 
monoclonal antibodies lacking a core fucose residue have a stronger antibody-dependent 
cell-mediated cytotoxicity at lower doses (Yamane-Ohnuki and Satoh 2009). In this regard, 
strategies to generate CHO cells not capable of performing fucosylation have been 
implemented successfully, notably by knockout of the alpha-1,6-fucosyltransferase (FUT8) 
enzyme (Malphettes et al. 2010; Yamane-Ohnuki et al. 2004). Yang et al. (2015) have taken 
the process further and studied the knockout of 19 glycosyltransferase genes enabling the 
generation of host able to process only desired glycosylation. The advent of CRISPR 
technology has simplified the knockout of genes in cells and is an adapted and successful 
strategy for tailored glycosylation. For example, successful work has been undertaken to 
generate CHO cells producing agalactosylated antibodies using a CRISPR approach (Amann 
et al. 2018). Work has also been focused on the sialic acid modulation important for 
therapeutic molecule half-life and efficacy (Bhide and Colley 2017). Indeed, due to the 
aďseŶĐe of αϮ,ϲ-sialǇltƌaŶsfeƌase eǆpƌessioŶ CHO Đells aƌe Ŷot aďle to peƌfoƌŵ αϮ,ϲ-linked 
terminal sialic acid. Lin et al. (2015) deŵoŶstƌated that oǀeƌeǆpƌessioŶ of αϮ,ϲ-
sialǇltƌaŶsfeƌase ǁas suffiĐieŶt to iŵpƌoǀe sialǇlatioŶ aŶd peƌfoƌŵ αϮ,ϲ-linked terminal 
sialic acid in CHO cells. 
1.3.4.2.5. Metabolic engineering of CHO cells 
During the culture of CHO cells, nutrients required to support cellular properties including 
growth, and their consumption can be inefficient and generate toxic by-products of which 
some are released into the media. The main by-products that are produced by in vitro 
cultured CHO cells that have been well studied are lactate and ammonia, known to impact 
upon the growth and productivity of cells at particular concentrations in the media (Lao 
and Toth 1997). They are generated from the breakdown or metabolism of glutamine and 
glucose present in the media. Different approaches have been taken to limit or remove the 
production of by-products or increase the energy efficiency of cells. In order to reduce 
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ammonia production, carbamoyl phosphate synthetase I (CPS I) and ornithine 
transcarbamoylase (OTC), both enzymes involved in the urea cycle (Park et al. 2000) were 
overexpressed in CHO cells and resulted in ammonia media reduction by generation of 
carbomoyl phosphate by CPS I necessitating ammonium cations. Because carbomoyl 
phosphate is unstable, it is converted into citrulline by the OCT. Another strategy taken for 
the reduction of ammonia was the introduction of glutamate into the media instead of 
glutamine. Glutamate is a less ammoniagenic substrate and when coupled with 
overexpression of glutamine synthetase which requires glutamate and ammonia as 
substrates to generate glutamine, ammonia generation was reduced (Zhang et al. 2006). 
The main source of lactate during in vitro culture of mammalian cells, which causes 
acidification of the media as a result of lactic acid formation, is the conversion of pyruvate 
via lactate dehydrogenase A (LDHA) to lactate. Knockout of the LDHA gene has been shown 
to be lethal (Yip et al. 2014), whereas knockdown of LDHA by siRNA has been shown to 
decrease the production of lactate by up to 89% compared to control cell lines without 
affecting growth or recombinant protein production (Kim and Lee 2007) proving to be a 
successful strategy to reduce lactate formation and the effects of this. 
Other strategies to manipulate cell metabolism have also been undertaken successfully, 
such as the overexpression of malate dehydrogenase II involved in the TCA cycle leading to 
increased amounts of ATP, NADH and higher maximum viable cell numbers (Chong et al. 
2010). A further successful example is that of the overexpression of the taurine transporter 
involved in transport of nutrients leading to improved culture viability and higher 
recombinant protein titres (Tabuchi et al. 2010) . 
1.3.4.2.6. Engineering to increase the secretion capacities of CHO cells 
When therapeutic recombinant proteins are made using mammalian cell expression 
systems, they are targeted to the secretory pathway which results ultimately in their 
secretion out of the cell into the culture media initially via an ER signal sequence. The 
secretory pathway starts with the translocation of nascent proteins into the ER directed by 
an ER signal peptide and finishes with the secretion of the fully folded, assembled and post-
translationally modified (when required) protein into the external environment at the 
plasma membrane (Figure 1.2). As highly efficient transcriptional control of recombinant 
genes is achievable associated with efficient mRNA translation, the capacity of the 
secretory pathway is potentially limiting in terms of the recombinant protein load that a 
cell can process. This work described in this thesis focusses upon trafficking within the 
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secretory pathway and the manipulation of this important component of the secretory 
pathway, and thus the different steps within this are discussed in detail below, as well as 




1.4. The mammalian secretory pathway 
1.4.1. Translocation of nascent polypeptides into the endoplasmic reticulum 
The first step in the secretory pathway is the targeting of the nascent polypeptide to the 
endoplasmic reticulum (ER)(Figure 1.3) (Wickner and Schekman 2005). Recognition of 
polypeptides to be targeted to the secretory pathway or requiring to transit through the ER 
is achieved by recognition of an ER signal sequence as it emerges from the ribosome entry 
tunnel by the signal recognition particle (SRP) composed of 6 protein subunits and the 7S 
RNA (Walter and Blobel 1982). ER targeting signal sequences are N-terminal motifs of 15 to 
50 amino acids and comprise 3 distinct regions; a positively charged N-terminus, a central 
hydrophobic region and a more polar C-terminal region that defines the cleaving site. ER 
signal sequences contain a huge diversity in terms of variation in length and composition. 
Signal sequences, by their variety, are able to provide different efficiencies of recognition 
by the SRP and therefore of targeting to the ER. Different protein families have different ER 
sequences and SRP recognition is thought to be a more structural basis rather than 
sequence specific (von Heijne 1985; Von Heijne 1983; Martoglio and Dobberstein 1998). 
The recognition of the signal sequence by the SRP is achieved as soon as the nascent 
peptide is translated and a key step is that interaction between the SRP and the ribosome 
complex, through the SRP54 subunit, results in the attenuation of mRNA translation. The 
SRP-nascent-polypeptide-ribosome complex is targeted to the rough ER membrane by the 
binding of the SRP to the signal recognition particle receptor (SRPR) that is present on the 
rough ER. The SRPR is a heterodimer, consisting of α aŶd β subunits, localised at the ER 
thƌough its β suďuŶit. IŶteraction between the SRPR and the complex formed by the SRP 
and the ribosomes is GTPase regulated and causes dissociation of SRP54 from the signal 
sequence and hence dissociation of the SRP and the ribosome (Connolly, Rapiejko, and 
Gilmore 1991). This also causes attachment of the nascent protein to the Sec translocon 
complex. The nascent polypeptide is translocated into the ER through the channel formed 
by the Sec61 heterotrimeric complex composed of SeĐϲϭαϭ, SeĐϲϭβ aŶd SeĐϲϭγ. AdditioŶal 
elements are necessary to ensure the polypeptide is fed through the channel such as the 
chaperone BiP. BiP has roles in closing the sec61 channel (Hamman, Hendershot, and 
Johnson 1998), helping the insertion of the nascent polypeptide into the channel (Dierks et 
al. 1996) aŶd haǀiŶg a ͞pull͟ effeĐt oŶ the polypeptide in the translocon complex (Nicchitta 
and Blobel 1993). Other proteins are involved in forming the translocon complex such as 




1.4.2. Protein folding and quality control in the endoplasmic reticulum  
Once polypeptides are directed into the ER, several steps occur to fold the protein and 
check the correct folding. The signal peptide is cleaved from the polypeptide to release this 
from the ER lumen membrane by specific signal sequence peptidases (Martoglio and 
Dobberstein 1998). The initial N-linked glycan structure is also added to N-glycosylation 
sequences as the polypeptide is delivered into the ER (Koenig and Ploegh 2014). To be 
functional, proteins need to achieve correct folding and for this purposes some proteins 
have a role to help folding and assure the quality control within the ER. They are termed 
chaperones proteins and belong to the Hsp (heat shock protein) family (Hartl 1996). 
Chaperone proteins are joined by foldases such as protein disulfide isomerase (PDI) and 
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peptidyl-prolyl isomerases (PPi) which accelerates reactions otherwise too slow such as 
disulphide bond generation or isomerisation of peptidylprolyl bonds. The ER also possess 
unique oxidising conditions compared to other compartment to aid folding (Hwang, 
Sinskey, and Lodish 1992).  
BiP (also known as GRP78 or glucose regulated protein 78), a member of the Hsp70 family, 
is an important chaperone in the ER. Peptides contain a BiP binding domain approximately 
every 36 amino acids (Rüdiger, Buchberger, and Bukau 1997). The binding of BiP prevents 
mis-folding of the polypeptide before it can be correctly folded and BiP is removed during 
folding in an ATP dependent manner. BiP is also a master regulator in the signalling of 
accumulation of unfolded protein in the ER and hence of the unfolded protein response 
(UPR) (Lewy, Grabowski, and Bloom 2017). BiP binds to the UPR sensing ATF6, PERK and 
IRE1 ER transmembrane transducing proteins in the ER lumen and prevents the activation 
of the signalling pathways these elicit. However, as BiP is removed from these as it binds 
polypeptides in the ER, these sensors can sense and activate the UPR as BiP is released 
from them and they dimerise (Hetz 2012). Thus, an overload of recombinant polypeptide in 
the ER can activate the UPR as BiP is required to bind the unfolded recombinant material in 
the ER. Activation of the UPR initially upregulates expression of the folding and processing 
chaperones in the ER to try and alleviate the load of unfolded protein, but if this cannot be 
achieved the UPR ultimately activates apoptosis (Hetz and Papa 2018). BiP functions 
alongside a number of co-factors (Hsp40 family) and other proteins associating with it to 
aid in the folding and assembly of proteins in the ER. 
Quality control of protein folding in ER is achieved through the calreticulin/calnexin cycle. 
When entering the ER, nascent polypeptides get preassembled N-glycan 
(Glc3Man9GlcNAc2) structures attached to them by the oligosaccharide transferase 
complex where N-glycan sequences are present (Parodi et al. 1972). Addition of the N-
linked glycans occurs co-translationally as polypeptides enter the ER. The initial donor sugar 
complex contains 3 glucose residues and 2 of these glucoses are removed from the N-
glycans by sequential action of the glucosidase I and II to yield a Glc1Man9GlcNAc2 
structure. The monoglucosylated structures are binding sites for calreticulin and calnexin 
(Kapoor et al. 2003). Calreticulin and calnexin slow down folding events which improves 




When correct protein folding is achieved, the last glucose is removed from the glycan 
structure by glucosidase II which inhibits rebinding to the chaperones (Araki and Nagata 
2012). Unfolded/misfolded proteins can go through the calreticulin/calnexin cycle by the 
addition of a glucose by UDP-glucose:glycoprotein glucosyltransferase (GT). GT ignores 
folded protein that is targeted for transport to the Golgi in a COPII dependent process 
(Caramelo and Parodi 2015). Proteins are able to be subjected to several cycles in the 
calnexin/calreticulin cycle to obtain correct folding of the proteins but if this is not 
achieved, proteins are directed to the ER-associated degradation (ERAD) pathway (Hebert 
and Molinari 2007). 
1.4.3. Transit from the endoplasmic reticulum to the Golgi apparatus and protein 
maturation in the different cistern of the Golgi apparatus 
Folded proteins gather at ER exit sites to be exported from the ER to the Golgi. The sorting 
of the proteins to be exported is done via the COPII coat protein and a GTPase, Sar1-GTP. 
The coat binds and concentrates proteins into secretory vesicles (Barlowe 2002). The 
recruitment of the different elements of COPII complex is via the small GTPase SarI. The 
minimal components of a COPII complex are the Sec23/Sec24 heterodimer, the 
Sec13/Sec31 heterotetramer and SarI (Matsuoka et al. 1998). Sorting of the 
transmembrane cargo proteins is achieved through Sec24 and its several binding sites 
(Mancias and Goldberg 2008). For soluble cargo proteins, cargo receptors are from the 
ERGIC-53 family, the p24 family, or the Erv family (Szul and Sztul 2011). Membrane 
invagination is performed by Sar1 and the Sec23/24 complex while the Sec13/31 complex 
stabilises the vesicle. 
Once the vesicle is formed, the COPII coat is shed and targeting and fusion to specific 
destination compartment, here the cis-Golgi, is mediated through the interaction of SNARE 
proteins. SNAREs are proteins with targeting and fusion properties (Bonifacino and Glick 
2004). Promotion of fusion by SNAREs is helped by the action of tethering factors activated 
by Rab proteins. Figure 1.4 details the different stages of vesicle formation and budding 
between two compartments. The content of the vesicle is realised into the Golgi where 
PTM modifications such as glycosylation undergo further processing. As previously stated, 
glycosylation is an important PTM for recombinant glycol-proteins and glycosylation has 
effects on folding, function, immunogenicity, stability and/or half-life (Walsh and Jefferis 
2006). The Golgi apparatus has a major role in secretion as it is a crossroad for the 
secretion, lysosome and endosome routes (Mellman and Warren 2000). Traffic in the 
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different cistern of the Golgi is not fully understood and several models have been 
proposed. For a full review of the different models refer to Glick and Luini (2011). 
 
1.4.4. Trans-Golgi traffic and exocytosis through the plasma membrane 
After maturation and travel through the different compartment of the Golgi apparatus, 
secretory proteins arrive at the trans-Golgi network (TGN) where final PTM processing 
occurs and proteins are sorted for their final destination. The TGN is an important hub for 
protein secretion and sorting, directing proteins to their final destination such as the 
plasma membrane, the early endosome or the lysosome. It is believed that export to the 
plasma membrane or other destinations from the TGN is completed by the tubular export 
of domains acting as export carriers (De Matteis and Luini 2008). The sorting of cargo 
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proteins is processed by the recognition of specific domain motifs by cargo receptors and 
coat proteins. PTMs also play a key role in the recognition of cargo proteins, for example 
glycosylation (Yeaman et al. 1997) and phosphorylation (Hinners 2003). Once cargos are 
sorted, they are segregated to different TGN domains using sorting motifs or 
microenvironment conditions for which cargo have a specific selectivity. The main players in 
these functions are protein from the ERF and Rab family, adaptors, GRIP-golgins and lipids. 
When the different cargo proteins are segregated into TGN domains, tubular domains are 
generated. A number of mechanisms are thought to be involved in the bending of the 
membrane to form tubular domain including action of the BAR Family (Neubrand et al. 
2005) or the GRIP-golgins (Gleeson et al. 2004). Enzymes linked to lipid metabolism are also 
proposed to play a role, for example CERT and FAPP2 (Godi et al. 2004; De Matteis and 
Luini 2008). Extrusions of the tubular domain from the TGN are observed after interaction 
with a motor. During extrusion of the mature domain from the TGN compartment, fission is 
observed at the thinnest section of the tubular domains (Polishchuk et al. 2003). Different 
fission machineries can be involved with perhaps the best studied being dynamin (McNiven 
et al. 2000). Targeting and fusion of the tubular domain with the plasma membrane, 
exocytosis, is performed using SNARE proteins and SM associated proteins such as 
Munc18c (Rizo and Südhof 2002). 
 
1.5. Engineering strategies to enhance the capacity of the secretory 
pathway 
1.5.1. Improving the efficiency of translocation of nascent polypeptide into the 
endoplasmic reticulum 
The secretory pathway is complex and integrates several steps, the first being the 
translocation of the nascent polypeptide into the ER. Translocation is thought to be a rate 
limiting step so different strategies have been investigated to improve the efficiency of this 
step and increase the production of secreted recombinant proteins with some success. Le 
Fourn et al (2014) engineered CHO cells to overexpressed one component of the SRP, 
SRP14. Overexpression of SRP14 in cell lines expressing difficult-to-express and more easy-
to-express products improved the secretory productivity of the cells by up to 6 fold 
suggesting this was indeed a rate limiting step in the secretory pathway. SRP14, along with 
SRP9 is responsible for the arrest of translation of the nascent peptide once the ER signal 
sequence has emerged from the ribosome exit tunnel (Akopian et al. 2013). It is supposed 
32 
 
that overexpression of SRP14 allows a more stringent control of mRNA translation arrest, 
leading to improved and more efficient targeting to the ER and the SRP receptor, 
resumption of mRNA translation and cleavage of the peptide signal. 
Another strategy that has been investigated to enhance the translocation step is to 
manipulate the signal sequence so that the nascent peptide is more efficiently recognised 
by the SRP. Several reports have demonstrated that production of a secreted protein can 
be altered by using different ER targeting peptide signals (Knappskog et al. 2007; L. Zhang, 
Leng, and Mixson 2005). Kober et al (2013) screened 16 different ER signal peptides from 
different origins and investigated the impact these had on the expression of a light and 
heavy chain of an antibody. The different signal peptides gave a range of HC and LC 
secretory productivities and the productivity of the cells could be increased by 50-100% 
from the lowest expression with different signal peptides. 
1.5.2. Endoplasmic reticulum and unfolded protein response cell engineering 
The ER is an important organelle which is the first destination of secretory proteins and is 
where folding and assembly of secretory proteins and quality control checks for correct 
folding is undertaken. Attempts to improve the folding of secretory polypeptides in the ER 
through the overexpression of different chaperone proteins has been undertaken and is 
discussed in section 1.3.4.2.3. Successful strategies where overexpression has enhanced 
secretory productivity includes BiP(GRP78), PDI, Calreticulin/Calnexin, and ERp57 proteins 
which are all ER resident proteins that are chaperones or foldases with a number involved 
in formation or isomerisation of disulphide bonds. 
A specific stress response pathway that senses and responds to stress in the ER has also 
being engineered, the unfolded protein response pathway (UPR). The UPR is a mechanism 
triggered by the cell in the presence of abnormal levels of unfolded proteins. When 
expressing a recombinant polypeptide, the ER can become overwhelmed with polypeptides 
to fold and the amount of unfolded protein is elevated. To cope with the situation, the UPR 
is triggered and through ER stress sensors and the responses this elicits, tries to alleviate 
this bottleneck of unfolded protein in the ER of the secretory pathway. When the stress is 
too intense, the UPR eventually activates signals that triggers ER mediated apoptosis. An 
important response of the UPR that is mediated in response to unfolded protein is the XBP-
1 protein which is a transcription factor. The UPR has 3 stress sensors, PERK, ATF6 and 
I‘Eϭα ǁhiĐh haǀe theiƌ aĐtiǀatioŶ ƌegulated ďǇ BiP. IŶ the pƌeseŶĐe of high amounts of 
unfolded protein, BiP disassociates from the stress sensors and binds the unfolded proteins 
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alloǁiŶg aĐtiǀatioŶ of the diffeƌeŶt stƌess seŶsoƌs. I‘Eϭα aĐtiǀates XBP-1 using its 
exonuclease activity to generate XBP-1 mRNA that is spliced to generate a powerful 
transcription factor that binds to UPR response elements (UPRE) upstream of chaperone 
and foldase genes (Yoshida et al. 2001). Spliced XBP-1, as a transcription factor, activates 
the transcription of a number of genes in the secretory pathway (Shaffer et al. 2004) such 
as chaperones and foldases but also pro-apoptotic proteins. Different reports have 
successfully demonstrated that the overexpression of the active form of spliced XBP-1 can 
improve secretory recombinant protein production up to 4-fold increase(Becker et al. 2008; 
Gulis et al. 2014; Ku et al. 2008; Tigges and Fussenegger 2006). 
1.5.3. Engineering of vesicle formation and trafficking 
Another strategy implemented to improve the secretory pathway is the manipulation of 
vesicle formation and trafficking. The ER and Golgi apparatus are important in protein 
folding and PTMs that are thought to be rate limiting steps in the secretory pathway, 
however another essential step in the secretory pathway is the trafficking of cargo 
(proteins) to/from the different organelles and out of the cell. The traffic is mediated 
through vesicles formed and regulated by different protein complexes. As such, Peng and 
Fussenegger (2009) overexpressed two proteins of the Sec1/Munc18 (SM) family, Sly1 and 
Munc18c. The SM family is suggested to be involved in catalysing the fusion of the 
membranes after docking of the vesicle on the target membrane (Jahn, Lang, and Südhof 
2003). Sly1 modulates fusion of the vesicle from the ER with the Golgi (Peng and Gallwitz 
2002) whereas Munc18c modulates fusion between trans-Golgi vesicles and the plasma 
membrane (Rizo and Südhof 2002). Overexpression of Sly1 or Munc18c in CHO-K1 cells 
increased productivity of the cells up to five-fold, demonstrating that vesicle fusion could 
be a limiting step in at least CHO-K1 cells. 
Another approach reported with regard to engineering of vesicle traffic is the manipulation 
of SNARE proteins. SNARE proteins are involved in the fusion of vesicles but also the sorting 
of the different vesicles. Peng et al (2011) reported on the overexpression of several 
SNAREs to investigate the impact on mammalian cell secretory productivity. These authors 
investigated the overexpression of STX2, STX3, SNAP23, SNAP25, VAMP2 and VAMP8 
proteins that are principally involved in traffic between the ER and the Golgi and the Golgi 
and the plasma membrane. It was observed that only the overexpression of SNAP23 and 
VAMP8 increased the secretory productivity of the different cell lines used (HeLa, CHO and 
HEK293). The authors suggested that enhanced secretory productivity was the result of an 
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increase in membrane turnover and dynamics as SNAP23 and VAMP8 are located at the 
secretory vesicle and the plasma membrane. Collectively, such studies suggest that 
engineering of vesicle traffic and formation is a good strategy for increased secretory 
productivity of mammalian host cell lines. The work presented in this thesis is based on the 
manipulation of the SNARE family to improve the secretory capacity of CHO cells. 
 
1.6. The SNARE protein family 
Soluble N-ethylmaleimide-sensible factor attachment protein receptor or SNARE is a family 
of proteins involved in the promotion of vesicle fusion and in determining the specificity of 
the fusion. SNAREs are proteins with a size between 100 to 300 amino acids that can 
functionally be divided in two, the v-SNAREs and the t-SNAREs (Jahn and Scheller 2006). 
The v-SNAREs for vesicle-SNARE are present on the surface of the vesicle and the t-SNAREs 
for target-SNARE are present on the surface of the targeted compartment to which the 
vesicle will fuse. Recognition of a v-SNARE, a tail-anchored SNARE containing a single 
SNARE motif, with a t-SNARE, composed of two or three polypeptides, generates a complex 
termed a trans-SNARE (or SNAREpin) composed of a four SNARE motif organised as a 
twisted parallel four helical bundle (Figure 1.5A). The action of the four-motif facilitates the 
fusion of the two opposed membranes. Table 1.2 reports the 36 SNAREs known in 
mammalian cells (Bonifacino and Glick 2004; Hong 2005). All the family members present 
at least one SNARE motif that is evolutionary conserved. SNARE proteins can also be 
classified structurally as Q or R type which is a more accurate definition because it takes in 
account homotypic fusion. During the formation of trans-SNARE complex, the four helixes 
form an interaction surface of 16 layers. The central layer, defined as the layer 0, has a 
hydrophobic interaction between 3 arginine residues (Q) and one glutamine residue (R) 
(Figure 1.5B). According to what residue of the SNARE participates in the central layer of 
the bundle, SNARE proteins are qualified as Q or R-SNARE (Figure 1.5C). Q-SNAREs can be 
subdivided into 3 types Qa, Qb and Qc. A particular subfamily of SNARE, the SNAP25 family, 
is classified as Qbc due to the presence of a Qb and Qc motif. Proteins are classified as Qb 
and Qc depending on the homology of their SNARE motif to the N-term (Qb) or C-term 










Table 1.2. Known members of the SNARE family in mammalian cells (Hong 2005). 
 
PM: plasma membrane; Go: Golgi apparatus; cis- Go: cis-Golgi compartments; trans-Go: trans-Golgi 
compartments; TGN: trans-Golgi network; End: endosomes; EE: early endosomes; LE: late 
endosomes; RE: recycling endosomes; Ly: Lysosomes; ER: endoplasmic reticulum; IC: ER-Golgi 
intermediate compartments; SV: synaptic vesicles. 
Compared to the well preserved SNARE motif, the N-terminal region of the different 
SNAREs are very diverse (Figure 1.6). Qa SNAREs, also called syntaxins, possess a three 
helical motif in their N-terminal region. Qb and Qc SNAREs doŶ͛t haǀe a specific motif at 
their N-terminal region. On the other hand, most of the R-SNAREs have a profilin-like fold 
also referred as a longin domain in their N-terminal region (Daste et al, 2015). The presence 
and function of the different N-terminal regions of the SNAREs are not fully understood. It 
is suggested that they are necessary for the interaction with regulators such as the 
Sec1/Munc18 (SM) family or with tethering factors. Some reports have demonstrated that 
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the N-terminal region is not essential for fusion events (Wang et al, 2001). Most of the 
SNAREs also contain a transmembrane domain connected to the SNARE motif by a linker. 
The SNAP25 family miss the transmembrane domain so the anchorage to the membrane is 
performed via a post translational modification (Gerst 1999; Jahn and Scheller 2006). 
 
SNAREs are thought to act as follows. A v-SNARE is packed together with cargo proteins 
during the formation of a vesicle so after budding of the vesicle interaction between the v-
SNARE and a t-SNARE is possible for membrane fusion. SNAREs have a potential role in the 
formation of vesicles via the interaction of coat proteins, notably from COPI and II 
complexes (Mossessova, Bickford, and Goldberg 2003; Rein et al. 2002). After the traffic of 
the vesicle to the target compartment, tethering factors are necessary to position and 
gather the vesicle to the exact position of the t-SNARE. The SNAREs spatially close interact 
and form a trans-SNARE complex which is believed to catalyse the fusion of the 
membranes. Once the fusion is performed, the complex becomes a cis-SNARE complex that 
needs to be disassembled and the components recycled foƌ fuƌtheƌ use. IŶteƌǀeŶtioŶ of α-
SNAP and NSF are required for disassembly in an ATP dependent manner. Once recycled, 
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the v-SNARE is relocalised to its original compartment by retrograde transport and t-
SNAREs are reorganised for the next fusion (Jahn and Scheller 2006). 
As outlined above, to mediate their action, SNARE proteins work together with tethering 
factors for the fusion of the membranes. Two classes of tethering factors are able to 
intervene; homodimers containing long stretches of predicted coiled-coil and hetero-
oligomers known as multi-subunit tethering complexes. SM family proteins have also been 
proposed to have a role in the assembly and regulation of SNARE proteins but the 
molecular mechanism remain unclear (Archbold et al. 2014; Gerst 1999). As described 
previously, the most important regulatoƌs of the “NA‘E Đoŵpleǆ aƌe N“F aŶd α-SNAP as 
they disassemble the cis-SNARE complex in an ATP-dependent manner to recycle all the 
SNARE elements. 
The different targets investigated in this study are SNAREs and are described in more detail 
below. They were chosen for their roles in functions thought to be important for secretion 
of proteins and that could potentially improve secretory capacity if manipulated. Some 
targets were chosen not for their function but because they participate in complex with 
other SNAREs and to determine if engineering of a complex rather than one component 
would enhance secretory productivity. Interestingly, a number of the targets selected have 
a role in the autophagosome which has also been identified as a potential target for 
manipulation for the improvement of recombinant protein production. 
1.6.1. Vesicle associated membrane proteins or VAMPs 
1.6.1.1. VAMP3 
All the VAMPs (vesicle associated membrane proteins) are R-SNAREs. VAMP3 or 
cellubrevin, is ubiquitously expressed and was first reported in 1993 as a result of the 
screening of a genomic library (McMahon et al. 1993). VAMP3 is a 100 amino acid long 
protein cleaved by the tetanus toxin light chain. It has been demonstrated that VAMP3 
interacts with the syntaxin4/SNAP23 complex and syntaxin16/Vti1a/syntaxin6 complex 
(Mallard et al. 2002), playing a role in the retrograde transport from the early/recycling 
endosome to the TGN. VAMP3 is known to be localised in early and recycling endosomes 
(Galli et al. 1994; Jovi et al. 2014; McMahon et al. 1993). VAMP3 is preferentially present in 
tubular membranes where it facilitates fusion of recycling endosomes and the Golgi. 
VAMP3 is suggested to regulate the recycling of various proteins such as integrins (Luftman 
et al. 2009; Skalski and Coppolino 2005), transferrin and their receptors from endosomes to 
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the plasma membrane (McMahon et al. 1993) as ǁell as α-granule transport in platelets 
(Feng et al., 2002; Polga´r et al., 2002) and retrograde transport of mannose-6 phosphate 
receptor to the Golgi (Ganley et al., 2008). VAMP3 is also involved in fusion at the plasma 
membrane with different t-SNAREs (syntaxin1/SNAP-25, syntaxin1/SNAP-23 and 
syntaxin4/SNAP-25) (Hu, Hardee, and Minnear 2007). A study in murine C3 cells 
demonstrated that depletion of both VAMP3 and YKT6 caused a complete block in 
secretion suggesting a major role in fusion of secretory carriers (Gordon et al. 2017). 
1.6.1.2. VAMP4 
VAMP4 is a 141 amino acid protein discovered in 1998 (Advani et al. 1998) and is only 
expressed and highly conserved in vertebrates (Zeng et al. 2003). It is known to be part of 
the SNARE complex including STX16, Vti1a and STX6 responsible for retrograde traffic 
between the early/recycling endosome and the TGN (Mallard et al. 2002; Zeng et al. 2003). 
Depletion of VAMP4 results in abolition of anterograde transport of GPI-anchored and 
transmembrane proteins (Hirata et al. 2015) suggesting that VAMP4 is important for 
recycling of critical molecules for post-Golgi anterograde transport. In Hela cells, depletion 
of VAMP4 leads to disruption of the organisation of the Golgi apparatus demonstrating the 
importance of the retrograde transport and the central role of VAMP4 (Okayama et al. 
2012). VAMP4 is predominantly localised at the TGN through a 51 residue section of amino 
acids present in its N-terminus (Zeng et al. 2003) and interaction with SNAP47 (Kuster et al. 
2015).  
VAMP4, by its function in specialised cells, has been reported to be involved in exocytosis 
in PC12-27 cells (Cocucci et al. 2008), release of lytic granules in NK cells (Krzewski et al. 
2011) and maturation of secretory granules in PC12 and atT-20 cells (Shitara et al. 2013). 
Through such reports it is thought that VAMP4 has a central role in regulated exocytosis. 
VAMP4 is also localised at hippocampal synapses and is implicated in asynchronous release 
and spontaneous release in neuronal cell lines (Ramirez and Kavalali 2012). A group 
working on Hela cells reported that overexpression of VAMP4 leads to abolition of the need 
of tethering and regulatory elements (Laufman, Hong, and Lev 2011). VAMP4 also has a 
role in activity-dependent bulk endocytosis of synaptic vesicle (Nicholson-Fish et al. 2015) 
1.6.1.3. VAMP7 
VAMP7, also called tetanus-insensitive VAMP (Ti-VAMP), is a 220 amino acid long protein 
discovered in 1998 (Advani et al. 1998). The N-terminal of VAMP7 is suggested to have a 
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profilin like structure (Hong 2005). VAMP7 is localised to the Golgi apparatus (Chaineau, 
Danglot, and Galli 2009) and is the only SNARE to be localised to the late endosome (Pols et 
al. 2013). VAMP7 interacts with different SNARE complexes; the syntaxin4/SNAP23 
complex which is suggested to mediate fusion of lysosomes with the plasma membrane 
(Rao et al. 2004) and syntaxin17/SNAP29 complex required for the fusion of 
autophagosomes and lysosomes (Takáts et al. 2018). By mediating the fusion of vesicles 
from the Golgi, late endosomes and lysosomes, VAMP7 is involved in several cellular 
functions such as phagocytosis, cell migration, membrane repair, and mitosis (Daste et al. 
2015). VAMP7 also has roles in autophagosome biosynthesis (Moreau and Rubinsztein 
2012), autophagosome-lysosome fusions (Takáts and Juhász 2013) and autophagosomal 
secretion (Fader, Aguilera, and Colombo 2012). VAMP7 may also have a general role in 
exocytosis. It is known to have a role in regulated exocytosis in HeLa cells (Chaineau et al. 
2009) and to be involved in the release of lytic granules in NK cells (Krzewski et al. 2011) 
whereas it has only a minor role in constitutive exocytosis in HSY cells (Oishi et al. 2006). 
VAMP7 contributes to sphingolipid and Golgi homeostasis and is involved in transport of 
GPI-anchored proteins to the plasma membrane (Molino et al. 2015) 
1.6.1.4. VAMP8 
VAMP8, also called endobrevin, is a 100 amino acid long protein that was discovered in 
1998 by Advani et al. (1998). Expression of VAMP8 is ubiquitous but enriched in epithelial 
cells such as kidney, intestine, pancreas and lung cells (Hong 2005). VAMP8 is localised in 
endosomes and was suggested to be involved in fusion between the early and late 
endosome (Wong et al., 1998). Endobrevin interacts with the SNARE complex, 
STX7/Vti1b/STX8, to mediate homotypic fusion of early and late endosomes (Antonin et al, 
2000). VAMP8 also interacts with the STX4/SNAP23 complex in pancreatic acinar cells, 
playing a major role in regulated exocytosis of zymogen granules (Wang et al., 2004). 
Involvement in regulated exocytosis of this complex has also been observed in mast cells 
(Paumet et al. 2000). Wang et al. (2007) have suggested that VAMP8 might play the role of 
an R-SNARE for the entire endocrine system with a critical role in parotid and lacrimal 
acinar cells and other exocrine tissues. Fu et al. (2018) have also reported that VAMP8 
interacts with syntaxin17 and SNAP29, two SNAREs involved in autophagosome fusion with 
the lysosome. By coupling with syntaxin2, VAMP8 is involved in cytokinesis too (Low et al. 
2003). VAMP8 regulates compound exocytosis, a mode of secretion were secretion is 
enhanced by vesicle-to-vesicle fusion at the plasma membrane (Thorn and Gaisano 2012). 
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1.6.2. Syntaxins and synaptosome associated proteins (SNAPs) 
1.6.2.1. Syntaxin7 or STX7 
Syntaxin7 or STX7 was first reported in 1998 (Siew Heng Wong et al, 1998). It is a protein of 
261 amino acids length, primarily linked to the early endosome and widely expressed as 
shown by Northern blot experiments (Siew Heng Wong et al. 1998). Syntaxin7 has also 
been associated with later compartments in the endocytic pathway and suggested to be 
involved in cycles between the plasma membrane and early endosomes (Prekeris et al, 
1999). Due to its function in the endocytic pathway and localisation in early/late 
endosomes and lysosomes, STX7 is suggested to have a function in the formation of late 
endosomes and lysosomes (Nakamura et al. 2000). Syntaxin7 forms a complex with Vti1b, 
syntaxin8 and either VAMP7 or 8 (Pryor et al. 2004), depending on the fusion event 
(homotypic fusion or late endosome-lysosome fusion (Hong 2005)). He and Linder (2009) 
have observed that palmitoylation of STX7 is essential for its compartmentalisation, a lack 
of this PTM results in retention of STX7 at the plasma membrane. STX7 has also been 
reported to be implicated in phagocytosis, notably in the maturation process involving 
STX13 in phagocytic cells (Collins et al. 2002) and tumour necrosis factor exocytosis in 
macrophages (Murray et al. 2005). 
1.6.2.2. Syntaxin17 or STX17 
Discovered in 1998 by Steegmaier et al (1998), syntaxin3 was used as a bait in a two-hybrid 
screen to capture syntaxin17, a 303 amino acid long protein. STX17 is a distant member of 
the mammalian syntaxin family and does not have an equivalent in yeast (Steegmaier et al. 
1998). It is expressed ubiquitously with an abundance in rich smooth ER cell membranes 
such as in steroidogenic cells (Steegmaier et al. 2000). STX17 localisation is dependent on 
the nutrient environment. In nutrient rich situations STX17 is localised to the ER (tubular 
and smooth ER), mitochondria and cytosol, otherwise STX17 is associated with the 
autophagosome (Itakura and Mizushima 2013) and mitochondria associated membranes 
(Hamasaki, Furuta, et al. 2013). Such localisation indicates roles at the mitochondrial and 
autophagosome levels. 
STX7 possess two adjacent hydrophobic domains whereas other syntaxin only have one 
and a C-terminal luminal tail. Both hydrophobic domains are used for membrane anchoring 
but no function has been reported yet for the c-terminal luminal tail (Muppirala, Gupta, 
and Swarup 2011). STX17 activity is regulated in the early secretory pathway by tyrosine 
phosphorylation (Muppirala, Gupta, and Swarup 2012). In rich nutrient conditions, STX17 
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promotes mitochondrial fission by controlling localisation and activity of Drp1. Syntaxin17 
is present on raft-like structures of the ER-mitochondria contact sites (Arasaki et al. 2015). 
Under starvation conditions, STX17 relocalises to mitochondria associated membranes and 
promotes formation of autophagosomes by interacting with ATG14L (Hamasaki, Shibutani, 
and Yoshimori 2013). STX17 plays a role in regulation of ER Ca2+ homeostasis and in 
mitochondrial dynamics by interacting with the protein Rab32. Syntaxin17 plays a role in 
responding to nutrient conditions and coordinates action between the ER, autophagosome 
and mitochondria under unfavourable nutrient conditions (Arasaki et al. 2015). 
Syntaxin17 also plays a role in autophagy and notably in the fusion of the autophagosome 
with the endosomes and lysosomes. For fusion of the autophagosome, synxtaxin17 forms a 
trans-SNARE with SNAP29 and VAMP8 (Hubert et al. 2016). It has been suggested that 
depletion of syntaxin17 can inactivated mTOR, a major negative regulator of autophagy 
(Hegedus et al. 2013). Two reports have reported that this role is conserved through 
evolution (Hegedus et al. 2013). Without STX17, autophagosomes accumulate in the cell 
without degradation due to lack of fusion with lysosomes (Itakura, Kishi-Itakura, and 
Mizushima 2012). 
Syntaxin17 also forms a complex with SNAP29 and VAMP7 to mediate the fusion of 
mitochondrial derived vesicles and endosomes or lysosomes. It is the last eukaryotic 
common ancestor suggesting that management of mitochondrial damage could have been 
one of the first vesicle transport pathways in cells (McLelland et al. 2016). A siRNA screen 
of several SNAREs to identify proteins necessary for constitutive secretion reported that 
STX17 is necessary for secretion (Gordon et al. 2010). STX17 might have roles other than 
membrane fusion, notably in specific cell lines where it has been observed to 
predominantly localise in the nucleus (Q. Zhang et al. 2005).  
1.6.2.3. Syntaxin18 or STX18 
STX18 was first reported in 2000 by Hatsuzawa et al. (2000) as a result of a yeast two-
hǇďƌid sĐƌeeŶ usiŶg α-SNAP as a bait. Syntaxin18 or STX18 is a 335 amino acid long protein 
principally located in the ER and plays a role in transport between the ER and Golgi. STX18 
is involved in membrane traffic between the ER and the Golgi and interacts notably with 
RINT-1 and ZW10 which regulates its functions (Arasaki et al. 2006). STX18 forms a complex 
with Sec20, Use1 and Sec22b, playing a role in recycling traffic (Hong 2005). An siRNA 
screen confirmed that STX18 is essential for retrograde traffic from the Golgi (Gordon et al. 
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2010). This retrograde function is suggested to be essential to maintain the organisation of 
the smooth/rough ER and ER exit sites (Iinuma et al. 2009). Roles in ER mediated 
phagocytosis and Procollagen VII secretion have been reported for STX18 in J774 cells and 
HeLa cells respectively (Hatsuzawa et al. 2006; Nogueira et al. 2014) suggesting interaction 
of STX18 with a wide range of proteins. 
1.6.2.4. SNAP29 
SNAP29 (synaptosome associate protein of 29 kDA) is a 258 amino acids protein discovered 
in 1998 by Steegmaier et al. (1998) widely expressed in different tissues. SNAP29 belongs 
to the SNAP25 family which contains two SNARE motifs and do not possess a C-terminal 
membrane domain anchoring them to membranes (Hong 2005). For membrane anchoring, 
members of the SNAP25 family tend to use palmitoylation but SNAP29 uses instead an 
asparagine-proline-phenylalanine protein binding motif in the N-terminal (Rapaport et al. 
2010). This binding domain gives SNAP29 a great versatility in its interactions with other 
proteins, notably syntaxins (Steegmaier et al. 1998) confirmed in vitro. It has been reported 
that the binding of syntaxins to SNAP29 increases their ability to bind to vesicles associated 
with SNAREs and that the presences of these vesicles also increases the binding of SNAP29 
to syntaxins (Hohenstein and Roche 2001). 
Due to the variety of interactions possible for SNAP29, it has been suggested that the 
protein has numerous functions. SNAP29 has been reported as being localised at the outer 
kinetochore, playing a role in kinetochore assembly and avoiding mis-segregation and/or 
formation of fragmented nuclei (Morelli et al. 2016). Through the formation of the trans-
SNARE, SNAP29/STX17/VAMP8, SNAP29 controls fusion of autophagosomes with 
lysosomes (Itakura et al. 2012; Takáts and Juhász 2013). The association of the trans-SNARE 
is dependent on O-liŶked β-N-acetylglucosaminylation of SNAP29 which prevents 
association of the complex (Guo et al. 2014). SNAP29 might also have a ƌole iŶ platelet α-
granule secretion regulation and thrombus stability in mouse platelets (Williams et al. 
2016). Moreover, SNAP29 has roles in regulation of the secretion of neuronal secretory 
vesicles (Su et al. 2001) and lamellar granules in keratinocytes (Sprecher et al. 2005). The 
role of SNAP29 in endocytic recycling of transferrin and β1-integrin suggests a prominent 
role in endocytic recycling events that have also been observed (Rapaport et al. 2010). 
The multiple roles of SNAP29 suggest that it is a general regulator of SNARE complex 
disassembly and has some function in trans-SNARE recycling post membrane fusion. This is 
probably due to its interactions with most of the syntaxins and its non-specific localisation. 
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This would also explain why so few members of the SNAP25 family are present if SNAP29 
acts as a general participant in trans-SNARE complex (Steegmaier et al. 1998). 
 
1.7. Aims of this study 
For the last few decades, the biopharmaceutical market has expanded rapidly with the 
approval of complex molecules by the regulatory authorities produced from cultured 
mammalian cells, particularly monoclonal antibodies. Mammalian cell hosts are the system 
of choice for the production of monoclonal antibodies due to their capacity to correctly 
fold and assemble the different polypeptides required to generate a full length monoclonal 
antibody (HC and LC) and their ability to undertake human-like PTMs, particularly N-
glycosylation. CHO cells have to date been optimised for secretory recombinant protein 
production via various approaches as outlined in the introduction to this thesis. In 
particular, cell line engineering has been attempted through strategies such as the 
manipulation of cell metabolism, apoptosis engineering and engineering of the secretory 
pathway by manipulating the vesicle traffic and formation. To date few such engineered 
systems have made it to manufacturing processes yet the opportunity remains to enhance 
the CHO chassis via cell engineering. The few studies available in the area of engineering of 
vesicle trafficking have suggested that the approach can be successful and overcome 
existing bottlenecks in CHO cells. The overall goal of this project was to investigate the 
increase of the production of secreted recombinant protein yields from CHO cells by 
engineering of the secretory pathway. The approach selected was the manipulation of 
proteins belonging to the SNARE family involved in vesicle traffic and formation. The 
outcome of this strategy was evaluated in two different environments, industry and 




CHAPTER 2: Materials and Methods 
 
2.1. DNA manipulation and cloning 
2.1.1. DNA plasmid sources 
Plasmids pMRXIP-SNAP29, pMRXIP-STX18, pMRXIP-STX7 and pMRXIP-STX17 were 
outsourced from Addgene where they were deposited by Noboru Mizushima (Addgene 
plasmid # 45923, # 45918, # 45921 and # 45909). Plasmids pEGFP-VAMP8, pEGFP-VAMP7, 
pEGFP-VAMP4, pEGFP-VAMP3 were deposited by Thierry Galli (Addgene plasmid # 42311, 
# ϰϮϯϭϲ, # ϰϮϯϭϯ aŶd # ϰϮϯϭϬͿ. The plasŵid pĐDNA™ϯ.ϭ/HǇgƌo(+) was sourced from 
Thermo Fisher Scientific. 
2.1.2. Polymerase chain reaction for fragment amplification 
Polymerase Chain Reaction (PCR) experiments were carried out using a Phusion High-
Fidelity DNA polymerase (Thermo Fisher Scientific, UK). Typically, the PCR mix was 4 µL of 5 
x Phusion HF buffer, 0.4 µL of 10 mM dNTPs (Invitrogen, USA), 0.8 µL of both forward and 
reverse primers at 100 µM, less than 100 ng/µL of cDNA or 20 ng/µL plasmid, 0.2 µL 
polymerase and nuclease-free water (Thermo Fisher Scientific, UK) for a final volume of 20 
µL. The primers were designed using SnapGene software (GSL Biotech LLC, USA) and the 
Oligo Analysis Tool (Eurofins, UK). The amplification cycle started with an initial 
deŶatuƌatioŶ at ϵϴ˚C foƌ ϯϬ seĐ followed by ϯϬ oƌ ϯϱ ĐǇĐles of ϵϴ˚C foƌ ϭϬ seĐ, ϱϴ to ϲϮ˚C 
foƌ ϯϬ seĐ ;depeŶdiŶg oŶ the ŵeltiŶg teŵpeƌatuƌe ;TŵͿ of the pƌiŵeƌsͿ, ϳϮ˚C foƌ ϯϬ seĐ foƌ 
each 1 kb of the desiƌed fƌagŵeŶt leŶgth. The fiŶal step ǁas a fiŶal eǆteŶsioŶ ĐǇĐle at ϳϮ˚C 
for 7 min. All the different primer sets used in this work are detailed in Appendix 1. 
2.1.3. Enzymatic digest of plasmid DNA 
All restriction enzyme digests ǁeƌe doŶe usiŶg FastDigest™ enzymes (Thermo Fisher 
“ĐieŶtifiĐ, UKͿ uŶless speĐified. The ŵaŶufaĐtuƌeƌ͛s ƌeĐoŵŵeŶdatioŶs ǁeƌe folloǁed foƌ 
the diffeƌeŶt ĐoŶditioŶs. GeŶeƌallǇ, ϭ µL of eŶzǇŵe ǁas used to digest ϭ µg of DNA at ϯϳ˚C 
for 30 min in a reaction volume of 20 µL. 
2.1.4. Agarose gel electrophoresis for DNA observation and analysis 
Agarose gels were composed of 1 x TAE buffer (50 x TAE buffer; 2 M Tris, 50 mM EDTA, 20 
mM acetic acid) containing 0.5 to 2% agarose. Agarose was dissolved by microwaving the 
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solution. After cooling down the mixture, 3 µL/50 mL gel of ethidium bromide (Invitrogen, 
USA) was added and the gel was casted into an electrophoresis tank. Once solidified, 1 x 
TAE buffer was used as electrophoresis buffer. When necessary, a loading dye was added 
to the DNA mixture (Promega, USA) (FastDigest buffer already includes a loading dye). A 
DNA ladder (Promega, UK) was loaded alongside the samples to help determine the sizes of 
the DNA fragments. Routinely, agarose gel electrophoresis was performed at 80 V for one 
hour. For visualization of the DNA fragments, the gel was exposed under UV light using a G 
Box (Syngene, UK). 
2.1.5. DNA purification 
After extraction from an agarose gel, DNA fragments were purified using the Wizard® SV 
Gel and PCR Clean-Up System (Promega, USA). The manufactuƌeƌ͛s pƌotoĐol ǁas folloǁed 
and the last elution step was performed using 50 µL of nuclease-free water. The DNA 
solution obtained was quantified using a nanodrop ND 1000 spectrophotometer 
(NanoDrop technologies, USA). 
2.1.6. Ligation of DNA fragments 
To ligate 2 digested DNA fragments with compatible ends, T4 ligase (Promega, USA) was 
used folloǁiŶg the ŵaŶufaĐtuƌeƌ͛s specifications. Typically, the quantity of backbone 
(acceptor fragment) and insert (donor fragment) was calculated using a ratio of 1:3 
(backbone to insert ratio) and 100 ng of backbone with the following equation: ݊݃ ݋݂ ܾܾܽܿ݇݋݊݁ ×  ܾ݇ ݏ��݁ ݋݂ �݊ݏ݁ݎݐ ܾ݇ ݏ��݁ ݋݂ ܾܾܽܿ݇݋݊݁ ×  ݉݋݈ܽݎ ݎܽݐ�݋ = ݊݃ ݋݂ �݊ݏ݁ݎݐ 
The reactional volume was 10 µL incubated oveƌŶight at ϰ˚C. 
2.1.7. Generation of DH5α Escherichia coli competent cells  
A DHϱα E. coli strain was prepared for calcium chloride transformation. An isolated colony 
was picked from an overnight petri dish culture in Lysogeny Broth (LB) media with agar (1% 
w/v of peptone, 0.5% w/v of yeast extract, 1% w/v of NaCl, and 1.5% w/v of agar) and used 
to inoculate 5 mL of LB media (1% w/v of peptone, 0.5% w/v of yeast extract, 1% w/v of 
NaClͿ. The staƌteƌ Đultuƌe ǁas iŶĐuďated oǀeƌŶight at ϯϳ˚C, ϭϱϬ ƌpŵ aŶd used to iŶoĐulate 2 
x 50 mL of Super Optimal Broth (SOB) media (2% w/v of peptone, 0.5% w/v of yeast extract, 
0.1% w/v of NaCl, 2.5 mM KCl, 10 mM MgCl2) in 250 mL Erlenmeyer flasks the next day. The 
cultures were grown at ϯϳ˚C, ϭϱϬ ƌpŵ uŶtil ƌeaĐhiŶg aŶ aďsoƌďaŶĐe AϲϬϬ of 0.4-0.6. 
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Cultures were then transferred to chilled 50 mL tubes and harvested at 3000 g for 15 min 
at ϰ˚C. The pellets ǁeƌe ƌesuspeŶded iŶ ϭϬ ŵL iĐe-cold 100 mM CaCl2 previously filter-
sterilized and incubated on ice for 30 min. After a second spin at 4000 g foƌ ϭϱ ŵiŶ at ϰ˚C, 
the pellets were gently resuspended into 2 mL ice-cold CaCl2, pooled together and 1 mL 
sterile 80% glycerol was added to the cells. Cells were dispensed as 100 µL aliquots in 
cryotubes and flash-frozen on dry ice. Once flash-frozen the aliquots were kept at -ϴϬ˚C.  
2.1.8. Transformation of DNA into competent cells 
An aliquot of ĐoŵpeteŶt DHϱα Đells ǁas thaǁed on ice. 3 µL of plasmid or 10 µL of ligation 
mix was added to cells then incubated for ϯϬ ŵiŶ oŶ iĐe. A heat shoĐk at ϰϮ˚C foƌ ϵϬ seĐ 
was performed to transform the cells. After 2 min recovery on ice, 900 µL of LB media was 
added to the ĐoŵpeteŶt Đells aŶd the Đells ǁeƌe iŶĐuďated foƌ aŶ houƌ at ϯϳ˚C, ϭϴϬ ƌpŵ. At 
the end of the incubation step, 100 µL of competent cells was spread on a LB media agar 
plate containing the appropriate selection marker (ampicillin at 100 µg/mL or kanamycin at 
ϱϬ µg/ŵLͿ. The plates ǁeƌe plaĐed at ϯϳ˚C oǀeƌŶight. 
2.1.9. Plasmid DNA amplification 
Depending on the quantity of DNA needed, two scales of plasmid DNA amplification were 
used; QIAprep Spin Miniprep kit and HiSpeed Plasmid Maxi kit (Qiagen, UK). Depending on 
the desired scale, 5 mL in a 50 mL tube or 250 mL in a 1 L Erlenmeyer flask of LB media 
containing selection antibiotics was inoculated with a colony containing the desired 
plasŵid. Cultuƌes ǁeƌe iŶĐuďated oǀeƌŶight at ϯϳ˚C, ϭϱϬ ƌpŵ. The next day the cells were 
harvested at 3000 g for 20 min and the pellets were processed using the appropriate kit. 
For quantification, a nanodrop ND 1000 was used. 
2.1.10. DNA sequencing 
All sequencing was outsourced to Genewiz UK Ltd. The DNA samples were sent as 10 µL 
aliquots at 100 ng/µL. 
2.1.11. Plasmid linearization and DNA precipitation 
2.1.11.1. University of Kent procedure 
FspI enzyme (New England Bioloabs, USA) was used to linearize the plasmid, the ratio used 
was 1 µL of enzyme for 10 µg of DNA. The mixture was incubated oveƌŶight at ϯϳ˚C. To 




The different precipitation steps were performed in a laminar flow hood to avoid 
contamination. After linearization, the DNA was precipitated with 0.1 volume of 3 M 
sodium acetate pH 5.2 and 2.5 volume 95% ethanol chilled at -ϮϬ˚C. The mix was 
centrifuged at 17000 g foƌ ϯϬ ŵiŶ at ϰ˚C. The supeƌŶataŶt ǁas disĐaƌded aŶd ϭ ǀolume of 
70% ethanol chilled at -ϮϬ˚C added. A seĐoŶd ĐeŶtrifugation at 17000 g foƌ ϱ ŵiŶ at ϰ˚C ǁas 
performed. Decanted pellet was left to air-dry. Finally, the pellet was resuspended in 50 µL 
of sterile-filtered TE buffer (HiSpeed Plasmid Maxi kit (Qiagen, UK)) and left overnight at 
room temperature. A small volume was then used (2 µL) for quantification. 
2.1.11.2. Fujifilm Diosynth Biotechnologies procedure 
NheI enzyme (New England Bioloabs, USA) was used to linearize the plasmid, the ratio used 
was 1 µL of enzyme for 10 µg of DNA. The mixture was incubated overnight at ϯϳ˚C. To 
check the full linearization of the plasmid a small volume (1 µL) was analysed by agarose gel 
electrophoresis. 
The different precipitation steps were performed in a laminar flow hood to avoid 
contamination. The linearized DNA was transferred to a 2 mL tube and 0.1 volumes of 3 M, 
pH 5.2 sodium acetate (Sigma Aldrich, USA) was added. The DNA was precipitated by 
adding 2.5 volumes of ice-cold 95% ethanol. To improve the precipitation, the tube was 
incubated 1 hour at -ϴϬ˚C. The pƌeĐipitated DNA ǁas ĐeŶtƌifuged at top speed foƌ ϯϬ ŵiŶ at 
ϰ˚C aŶd the supeƌŶataŶt disĐaƌded. OŶe ǀoluŵe of ϳϬ% iĐe-cold ethanol was added to wash 
the pellet aŶd aŶotheƌ ĐeŶtƌifugatioŶ at top speed foƌ ϭϬ ŵiŶ at ϰ˚C peƌfoƌŵed. The 
supernatant was discarded again and the pellet was left to air dry. To resolubilize the 
pellet, 55 µL of water (Sigma Aldrich, USA) was added and the tube was incubated 
oǀeƌŶight at ϯϳ˚C. The Ŷeǆt daǇ ϱ µL was used for quantification using a Qubit 4 
fluorometer (Invitrogen, USA) following the ŵaŶufaĐtuƌeƌ͛s pƌotoĐol. 
 
2.2. Cell culture 
2.2.1. Suspension cell lines 
2.2.1.1. CHO-S cells 
The CHO-S cell line was a serum-free cell line originated from the laboratory of Professor 
Nicole Borth. CHO-S cells were routinely seeded at 0.2 x 106 viable cells/mL in 20 mL of CD-
CHO media (Life Technologies, USA) containing 8 mM L-glutamine (Sigma Aldrich, USA) in a 
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125 mL Erlenmeyer flask (Corning, USA). Cells were manually gassed. Flasks were incubated 
in a HT multitron standard incubator (Infors, CHͿ at ϯϳ˚C, ϭϰϬ ƌpŵ. WheŶ CO2 monitoring 
was essential, cells were inoculated in 125 mL Erlenmeyer flasks with vented caps (Corning, 
U“AͿ aŶd iŶĐuďated iŶ a Neǁ BƌuŶsǁiĐk™ “ϰϭi iŶĐuďatoƌ ;EppeŶdoƌf, U“AͿ at ϯϳ˚C, ϭϰϬ ƌpŵ 
and 5% CO2. Stably transfected CHO-S cells were cultivated under the same conditions as 
the host cell line except with the addition of selection agent in the media, Hygromycin B at 
750 µg/mL (Thermo Fisher Scientific, USA) or Puromycin at 7.5 µg/mL (Sigma Aldrich, USA). 
Tube spin vessels were also used with a working volume of 10 mL in 50 mL conical bottom 
tubes (Sarstedt, DE) or 50 mL conical bottom tubes with vented cap (Corning, USA) when 
ŶeĐessaƌǇ aŶd iŶĐuďated at ϯϳ˚C, ϮϰϬ ƌpŵ, ϱ% CO2. Cells were passaged every 3-4 days. 
2.2.1.2. Clone 27 (Fujifilm Diosynth Biotechnologies) CHO cells 
Clone 27 is a CHO-DG44 derived cell line used as a host at Fujifilm Diosynth. Clone 27 was 
routinely seeded at 0.2 x 106 viable cells/mL in 30 mL of CD-DG44 media (Life Technologies, 
USA) containing 8 mM L-glutamine (Thermo Fisher Scientific, USA)) and 0.18% (v/v) 
pluronic F-68 (Thermo Fisher Scientific, USA) in a 125 mL Erlenmeyer flask with vented caps 
(Corning, USA). Flasks were incubated in a Certomat CT Plus incubator (Sartorius, DE) at 
ϯϳ˚C, ϭϮϱ ƌpŵ, ϱ% CO2 and 80% humidity. Cells were passaged every 3 days. 
Stably transfected Clone 27 cells were cultivated in FDB-MAP (SAFC, USA) containing 8 mM 
L-glutamine and a selection pressure, Methotrexate (MTX) at 175 nM (Sigma aldrich, USA) 
or Puromycin at 10 µg/mL (Sigma Aldrich, USA). Stably transfected Clone 27 cell lines were 
maintained every 3-4 days. Tube spin vessel were also used with a working volume of 10 
mL in 50 mL spin tubes bioreactor with vented caps (TPP, CH) and incubated in a Certomat 
CT Plus incubator ;“aƌtoƌius, DEͿ at ϯϳ˚C, ϮϬϬ ƌpŵ, ϱ% CO2 and 80% humidity. 
2.2.2. Adherent cell lines 
2.2.2.1. Flp-In ™ CHO Đells 
Flp-IŶ™ CHO Đells aƌe adheƌeŶt Đells ĐoŵŵeƌĐiallǇ aǀailaďle fƌoŵ Theƌŵo Fisheƌ “ĐieŶtifiĐ. 
The cells were maintained in DMEM media (Thermo Fisher Scientific, USA) complemented 
with 10% (v/v) Foetal Bovine Serum (Gibco, USA). Five mL of media was inoculated in T25 
tissue culture flasks (Sarstedt, DE) and incubated in a MCO-200 Sanyo incubator (Sanyo, JP) 




2.2.3. Cell maintenance 
2.2.3.1. Suspension cells 
Culture viability and cell concentration were determined by processing a sample (0.6 to 1 
mL) of the culture with a Vi-CELL cell counter (Beckman Coulter, USA). The cell suspension 
was diluted at the desired level in pre-warmed media and returned as soon as possible in 
the incubator under the conditions described in 2.2.1. 
2.2.3.2. Adherent cells 
Adherent cells were observed under a microscope to determine the level of confluency. 
When confluency reached 90-100%, media was removed and cells were washed with PBS. 
One mL of pre warmed 0.25% trypsin-EDTA (Thermo Fisher Scientific, USA) was added to 
the cells and the flask returned to the incubator for 5 min. After incubation, cells were 
dislodged by pipetting and 4 mL of pre warmed media was added to stop trypsin action. A 
few drops of the dislodged cell mixture were used to inoculate fresh media. If a precise cell 
number was required, a cell count was performed using a Vi-CELL before dilution to the 
desired concentration. 
2.2.4. Antibiotic kill curve 
2.2.4.1. University of Kent procedure 
Kill curves were performed with different concentrations of hygromycin B (0, 100, 250, 500, 
750 and 1000 µg/mL) and puromycin (0, 1, 2.5, 5, 7.5 and 10 µg/mL) with the CHO-S cell 
line. The cells were grown in 6-well plates at 1 x 105 viable cell/mL in a volume of 2 mL of 
CD-CHO media with 8 mM L-glutamine and the desired antibiotic concentration. Time 
points were taken at day 2, 4 and 7 for cell concentration and culture viability using a Vi-
CELL instrument. The working concentrations arrived at from those experiments were 750 
µg/ŵL foƌ hǇgƌoŵǇĐiŶ B aŶd ϳ.ϱ µg/ŵL foƌ puƌoŵǇĐiŶ. Plates ǁeƌe iŶĐuďated at ϯϳ˚C, ϱ% 
CO2. 
2.2.4.2. Fujifilm Diosynth Biotechnologies procedure 
A kill curve was performed for puromycin (7.5, 10 and 15 µg/mL) with mpDG44/ADA 7 cell 
line. Cells were inoculated at 2 x 105 viable cells in 1 mL of FDB-MAP media containing 8 
mM L-glutamine and the desired puromycin concentration in a 24 well plate. Plates were 
iŶĐuďated at ϯϳ˚C, ϭϬ% CO2 and 80% humidity. Culture viability and cell concentration were 
recorded after 5 days incubation using a Vi-CELL cell counter. 
51 
 
2.2.5. Stably expressing cell line generation 
2.2.5.1. University of Kent procedure 
After a culture viability check, 1 x 107 viable cells were pelleted at 200 g for 5 min and 
resuspended in 0.7 mL of CD-CHO with 8 mM L-glutamine, 20 µg of linearized DNA was 
added to the cells and the mixture was poured into a Gene Pulser® cuvette (Biorad, USA). 
Cells ǁeƌe eleĐtƌopoƌated usiŶg a GeŶe Pulseƌ XĐell™ EleĐtƌopoƌatioŶ sǇsteŵ ;Bioƌad, U“AͿ 
with the following parameters; 300 V, 900 µF and 4 mm cuvettes. Electroporated cells were 
resuspended into 18 mL of media in a T75 tissue culture flask (Sarstedt, DE). Cuvettes were 
ƌiŶsed ǁith ϭ.Ϯ ŵL of ŵedia. Afteƌ aŶ oǀeƌŶight iŶĐuďatioŶ at ϯϳ˚C, ϱ% CO2, the selection 
pressure agent was added to obtain the desired concentration in a final volume of 25 mL.  
2.2.5.2. Fujifilm Diosynth Biotechnologies procedure 
After a culture viability check, 5 x 106 viable cells were centrifuged at 180 g for 10 min and 
resuspended in 100 µL of SF buffer provided in the SF Cell line 4D-NuĐleofeĐtoƌ™ X Kit L 
(Lonza, CH). The cells were placed into the nucleocuvettes and 8 µg of linearized DNA was 
added. The cells were electroporated using program FF-137 (parameters not 
communicated) of the 4D-NuĐleofeĐtoƌ™ “Ǉsteŵ ;LoŶza, CHͿ. Post-nucleofection, 400 µL of 
pre-warmed FDB-MAP containing 1 x HT supplement (Thermo Fisher Scientific, USA) and 8 
mM L-glutamine were added into the cuvettes and they were inĐuďated at ϯϳ˚C foƌ ϭϱ ŵiŶ. 
After incubation, 20 mL of pre-warmed FDB-MAP containing 1 x HT supplement and 8 mM 
L-glutamine in a T75 flask were inoculated with the transfected cells. The flasks were 
iŶĐuďated at ϯϳ˚C, ϭϬ% CO2 overnight. Next day, cells were centrifuged for 10 min at 180 g 
and the media was replaced by FDB-MAP media containing and 8 mM L-glutamine and the 
selection pressure agent (175 nM MTX or 7.5 µg/mL puromycin). Flasks were placed in the 
incubator for a recovery period of 2-3 weeks. 
2.2.6. Transient transfection experiments 
2.2.6.1. University of Kent procedures 
2.2.6.1.1. Lipofectamine 2000  
Lipofectamine 2000 (Invitrogen, USA) was used to transfect Flp-In cells. First, 500 µL of 
growth media in a 24-well plate were inoculated with 6 x 104 viable cells. The next day, 0.8 
µg of DNA was diluted in 50uL Opti-MEM™ ;Theƌŵo Fisheƌ “ĐieŶtifiĐ, U“AͿ aŶd geŶtlǇ 
mixed while 2 µL of lipofectamine was added to 50 µL of Opti-MEM and incubated for 5 
minutes at room temperature. After incubation, the diluted DNA and lipofectamine were 
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mixed gently together and incubated for 20 minutes at room temperature. To finish, 100 µL 
of the complexes were added to eaĐh ǁell aŶd the Đells iŶĐuďated at ϯϳ˚C, ϱ% CO2 for 72 
hours. 
2.2.6.1.2. Novachoice 
Prior to transfection, the desired vessels and media were inoculated at 1 x 106 viable 
cells/mL in 96-DWP or 0.5 x 106cells/mL in spin tubes. 1 µg/mL DNA was added to 0.1 times 
the total volume of media followed by 1 µL of Novachoice (Roche, CH) reagent and 0.5 µL 
of booster for every millilitre of media used. After a 20-min incubation step at room 
temperature, the mix was added to the freshly inoculated culture and the cells were 
incubated at desired parameters depending on the vessel used. 
2.2.6.1.3. Electroporation 
The protocol was similar to the stable cell line generation (see section 2.2.5.1) except the 
DNA concentration used was 40 µg (non-linearized) instead of 20 µg and the absence of 
selection pressure. 
2.2.6.2. Fujifilm Diosynth Biotechnologies procedures 
2.2.6.2.1. Novachoice 
Prior to transfection, 10.8 mL of CD-DG44 media with 8 mM L-glutamine and 0.18% 
pluronic F-68 was inoculated at 1 x 106 viable cells/mL in spin tubes. 1 µg/mL DNA was 
added to 1.2 mL of CD-DG44 media with 8 mM L-glutamine followed by 12 µL of 
Novachoice (Roche, CH) reagent and 6 µL of booster before a 20-min incubation step at 
room temperature. After incubation, the mix was added to the freshly inoculated culture 
aŶd the Đells ǁeƌe iŶĐuďated at ϯϳ˚C, ϱ% CO2, 200 rpm for the amount of time needed. 
2.2.6.2.2. Electroporation 
The protocol was similar to the stable cell line generation (see section 2.2.5.2) except for 
the DNA concentration used (8 or 16 µg DNA) and the absence of selection pressure. 
2.2.7. Limiting dilution cloning 
Before starting, 96-well plates were filled with 100 µL of the adequate media except for the 
ǁell Aϭ aŶd stoƌed at ϯϳ˚C. The daǇ folloǁiŶg staďle tƌaŶsfeĐtioŶ, Đells ǁeƌe diluted to Ϯ ǆ 
104 viable cells/mL and 200 µL was placed into the well A1 of a 96-well plate. A series of 1:2 
dilutions were undertaken through the column A of the plate. At the last well 100 µL was 
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discarded to have the same volume across the whole plate. With a multichannel pipette, 
100 µL was added to the first column to give a total volume of 200 µL/well. Using 100 µL 
from the first column, a 1:2 dilution was performed in the second column and carried 
through the whole plate with the removal of 100 µL in the last column. The final volume of 
each well was made to 200 µL with pre-warmed media. After inoculating the plates, they 
were incubated for 2-3 weeks at ϯϳ˚C, ϱ% CO2. Wells were constantly checked by 
microscopy to detect the formation of single colonies in wells. When the confluency was 
sufficient (around 70%) and monoclonality confirmed, wells containing single colonies were 
expanded into 24-well plates, 6-well plates, T-25 flasks, T-75 flasks and then spin tubes or 
125 mL Erlenmeyer flasks. Figure 2.1 is a graphical explanation of the dilution across the 96 
well plate. 
 
2.2.8. Cell line revival after cryopreservation 
2.2.8.1. University of Kent procedure 
A cryovial was thaw gently in the water bath. The content of the vial was then transferred 
to a 50 mL tube and 40 mL of pre warmed CD-CHO media containing 8 mM L-glutamine 
was added drop by drop. Cells were centrifuged at 200 g for 5 min. The pellet was 
resuspended in 20 mL of fresh media and transferred to a 125 mL Erlenmeyer flask that 
was then iŶĐuďated at ϯϳ˚C, ϭϰϬ ƌpŵ. 
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2.2.8.2. Fujifilm Diosynth Biotechnologies procedure 
A cryovial was thaw gently in the water bath. The content of the vial was resuspended in 20 
mL of pre warmed CD-DG44 media containing 8 mM L-glutamine and 0.18% pluronic F-68 
added drop by drop. A cell concentration and culture viability count was performed. Cells 
were diluted to a concentration of 0.2 x 106 viable Đells/ŵL aŶd iŶĐuďated at ϯϳ˚C, ϭϮϱ ƌpŵ, 
5% CO2 and 80% humidity. 
2.2.9. Cryopreservation of cell lines 
2.2.9.1. University of Kent procedure 
After verification of the viability of the culture using a Vi-CELL instrument, 1 x 107 viable 
cells were centrifuged at 200 g for 5 min. The cells were resuspended in 1 mL of CD-CHO 
media containing 8 mM L-glutamine and 7.5% (v/v) DMSO (Sigma Aldrich, USA) and 
tƌaŶsfeƌƌed to a CƌǇoTuďe™ ǀial ;NuŶĐ, U“AͿ. Vials ǁeƌe kept oǀeƌŶight at -ϴϬ˚C iŶ a 
Nalgene Mr Frosty before being transferred into liquid nitrogen storage. 
2.2.9.2. Fujifilm Diosynth Biotechnologies procedure 
After verification of the culture viability using a Vi-CELL device, 1 x 107 viable cells were 
centrifuged at 180 g for 10 min. The cells were resuspended in 1.5 mL of FDB-MAP media 
containing 10% (v/v) DMSO (Sigma Aldrich, USA)) and transferred to a cryovial. Vials were 
kept overnight at -ϴϬ˚C iŶ a NalgeŶe Mƌ FƌostǇ ďefoƌe ďeiŶg tƌaŶsfeƌƌed iŶto liƋuid ŶitƌogeŶ 
storage. 
2.2.10. Mini-pool cell line generation procedure 
After electroporation and addition of the selection pressure, 96-well plates were inoculated 
at ϱϬϬϬ Đells/ǁell. The plates ǁeƌe iŶĐuďated at ϯϳ˚C, ϭϬ% CO2 for 3 weeks. After 3 weeks, 
the confluency and monoclonality of the wells were evaluated by eye or using a Cell 
Metric® CLD plate reader (Solentim, UK) and 48 wells were selected. The content of the 
selected wells (200 µL) was transferred to a 24-well plate, and 800 µL of FDB-MAP 
containing 8 mM L-glutamine and 175 nM MTX added aŶd iŶĐuďated at ϯϳ˚C, ϭϬ% CO2. 
After 5 days of growth, 200 µL of supernatant was sampled from each well to quantify the 
antibody concentration using the Octet instrument (see section 2.3.6). This quantification 
was used to rank the mini-pools and select 8 mini-pools to progress in T25 flasks containing 
5 mL media and then in spin tubes containing 10 mL of media. The spin tubes were 
iŶĐuďated at ϯϳ˚C, ϮϬϬ ƌpŵ, ϱ% CO2 and 80% humidity. 
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2.2.11. Fed-batch over grow or FOG cultures 
250 mL flasks with vented caps were inoculated at 0.2 x 106 viable cells/mL in 60 mL FDB-
MAP media containing 8 mM L-glutaŵiŶe. The flasks ǁeƌe iŶĐuďated at ϯϳ˚C, ϭϮϱ ƌpŵ, ϴϬ% 
humidity and 5% CO2. During the FOG the following parameters were monitored: cell 
concentration, culture viability, concentration of glucose, glutamine, glutamate, lactate and 
ammonium. Cell concentration and culture viability were monitored daily from day 2 using 
a Vi-CELL cell counter. Metabolite levels were evaluated daily from day 3 using a YSI 2950 
metabolic analyser (YSI, USA). Every other day from day 4, 1 mL of culture was sampled, 
centrifuged 5 min at 1400 g and both pellet and supernatant were kept at -ϮϬ˚C. ‘egaƌdiŶg 
the feed ƌegiŵe, the Đultuƌes ǁas fed fƌoŵ daǇ Ϯ ǁith Ϯ% ;ǀ/ǀͿ HǇCloŶe™ Cell Boost ϳA ;GE 
healthĐaƌe, U“AͿ aŶd Ϭ.Ϯ% ;ǀ/ǀͿ HǇCloŶe™ Cell Boost 7B (GE healthcare, USA), 0.5% (v/v) 
200 mM L-glutamine when the glutamine concentration was below 0.22 g/L. Glucose 
(Sigma Aldrich, USA) was added when the concentration dropped under 3 g/L. The volume 
of glucose added to the culture was calculated using the following formula: 
�݈ݑܿ݋ݏ݁ ݂݁݁݀ ݒ݋݈ݑ݉݁ ሺ݉�ሻ = ሺ4 − ܿݑݎݎ݁݊ݐ ݈݃ݑܿ݋ݏ݁ ܿ݋݊ܿ݁݊ݐݎܽݐ�݋݊ሺ݃/�ሻሻݏݐ݋ܿ݇ ݈݃ݑܿ݋ݏ݁ ܿ݋݊ܿ݁݊ݐݎܽݐ�݋݊ ሺ݃/�ሻ × ݏݐܽݎݐ�݊݃ݒ݋݈ݑ݉݁ ሺ݉�ሻ 
FOG experiments were stopped after 14 days of culture or when the viability of the culture 
dropped under 70%. 
2.2.12. Tissue culture in 96 Deep Well Plates (DWP) 
Deep well plate culture system was used to screen at a small scale numerous conditions in 
an environment mimicking flask culture. The deep well plate system is composed of 2 
distinct parts, the single use 96-DWP plate and the reusable lid. The lid was composed of a 
stainless steel lid, blue microfiber filter inlay, green ePTFE filter inlay and a silicone seal to 
maintain the culture aerated and sterile as represented in Figure 2.2B. Lids were 
assembled, autoclave and dried before use. 96 deep well plates were inoculated at the 
desired cell concentration before the lid was placed on top and clamped into position. 




2.3. Protein analysis 
2.3.1. Total protein extraction from cell pellets 
A known number of cells (generally between 1 and 2 x 106 viable cells/mL) was centrifuged 
at 1500 g for 5 min and the supernatant discarded. For each 1 x 106 cell pellet, 100 µL of 
extraction buffer (20 mM Hepes pH 7.2, 100 mM NaCl, 1% Triton X-ϭϬϬ, ϭϬ ŵM β-
glycerophosphate, 1mM Na3VO4, ϱϬ ŵM NaF aŶd a taďlet of ĐOŵplete™ ŵiŶi EDTA-free 
Protease Inhibitor cocktail (Roche, CH) for every 10 mL of buffer) was added to the cells. 
After incubation for 30 min on ice, the extract was centrifuged at 17000 g for 5 minutes in 
order to pellet all the cell debris. The protein extract was kept at -20˚C oƌ -ϴϬ˚C foƌ longer 
periods. 
2.3.2. SDS-PAGE 
2.3.2.1. Sample preparation procedure 
To prepare the samples, 5 x sample buffer (10% (v/v) glycerol, 120 mM Tris-HCl pH 6.8, 2% 
;ǁ/ǀͿ “D“, feǁ gƌaiŶs of ďƌoŵopheŶol ďleu, feǁ gƌaiŶs of pǇƌoŶiŶ G aŶd ϰ% ;ǀ/ǀͿ β-
mercaptoethanol if reducing buffer) was added to the desired amount of protein lysate 
diluted in distilled water to a 1 x final buffer concentration. Samples were vortex 






2.3.2.2. Gel preparation and electrophoresis 
Sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE) were composed of two phases, 
the stack (5% acrylamide; 5% (v/v) acrylamide/Bis solution 37.5:1 (Biorad, USA), 125 mM 
Tris-HCl pH 6.8, 1% (w/v) SDS, 1% (w/v) Ammonium persulfate, 0.1% TEMED) and the 
separating phase between 8 and 12% acrylamide (8-12% (v/v) acrylamide/Bis solution 
37.5:1 (Biorad, USA), 375 mM Tris-HCl pH 8.8, 1% (w/v) SDS, 1% (w/v) ammonium 
persulfate, 0.06% TEMED) set in a Novex cassette (Life Technologies, USA). After loading of 
the samples on the gels, electrophoresis were performed in running buffer (200 mM 
glycine, 25 mM Tris-HCl, 0.1% (w/v) SDS, pH 8.8) at 100 V for 30 min and then at 150 V until 
desired migration. 
2.3.3. Western blot analysis 
After SDS-PAGE, the polyacrylamide gel was inserted in between 2 sheets of 3 mm CHR 
Whatman paper (GE healthcare, USA) in direct contact with an Amersham Protran 0.45 NC 
nitrocellulose membrane (GE healthcare, USA). The stack was inserted in a cassette fitting 
in a transfer tank. Transfer of the proteins from the gel to the nitrocellulose membrane was 
performed in transfer buffer (100 mM glycine, 12.5 mM Tris-HCl, 0.1% (w/v) SDS, 20% (v/v) 
ŵethaŶolͿ at ϰ˚C foƌ ϭ houƌ at ϳϱϬ ŵA. Non-specific interactions were blocked by 
incubating the membrane in a 5% (w/v) solution of marvel milk for 30 min. Two washes 
with 0.1% TBST buffer (150 mM NaCl, 2.5 mM KCl, 25 mM Tris-HCl, 0.1% (v/v) tween20, pH 
7.6) were performed before incubating the membrane with a solution containing the 
primary antibody of choice (diluted antibody, 150 mM NaCl, 2.5 mM KCl, 25 mM Tris-HCl, 
Ϭ.ϭ% ;ǀ/ǀͿ tǁeeŶϮϬ, pHϳ.ϲ, ϯ% ;ǁ/ǀͿ ďoǀiŶe seƌuŵ alďuŵiŶ ;“igŵa AldƌiĐh, U“AͿͿ at ϰ˚C 
overnight on a rocking table. All sources and dilutions for the antibodies used in this project 
are reported in Table 2.1. The following day, the membrane was washed 4 times with 0.1% 
TBST for 10 min with agitation. Once the washes were finished, the membrane was 
incubated for 1 hour at room temperature with a 5% (w/v) marvel milk solution containing 
a secondary antibody coupled to Horseradish peroxidase. Four new washes with 0.1% TBST 
for 10 minutes were then performed. To detect signal, the membrane was incubated for 1 
ŵiŶ ǁith Ϯ ŵL of PieƌĐe™ ECL suďstƌate ;Theƌŵo Fisheƌ “ĐieŶtifiĐ, U“AͿ ďefoƌe eǆposiŶg it 
to an Amersham Hyperfilm ECL film (GE Healthcare, USA) and developing using a Optimax 








Densitometry using ImageJ (NIH, USA) was undertaken to evaluate target protein 
expression in cell lines. After western blot analysis, signals obtained for protein of interest 
ǁeƌe aŶalǇsed aŶd Đoŵpaƌed to the house keepiŶg pƌoteiŶ β-actin which was used to 
normalise the level of signal and define the relative level of expression of the protein of 
interest in each sample. 
2.3.5. Flow cytometry 
Fluorescent profiles were recorded using a BD FACSJazz flow cytometer. For analysis, 2 x 
106 viable cells were harvested at 200 g for 5 min and resuspended in 1 x phosphate 
buffered saline buffer before processing on the flow cytometer. Cell line profiles were 
obtained by recording of 10000 events (cells). All the results were analysed using the BD 
FACS Software. 
2.3.6. Bradford assay 
To determine the protein concentration of samples, 1 mL of Bradford reagent (120 mM 
Coomassie Blue G250, 15% (v/v) ethanol, 8.5% (v/v) phosphoric acid) was added to 50 µL of 
sample (diluted or not). The mixture was incubated 10 min at room temperature before 
using a calibrated spectrophotometer to determine the absorbance at 595 nm. A standard 
curve of known bovine serum albumin amounts was used to determine the concentration 
of unknown protein samples. 
2.3.7. Octet measurements 
Protein samples were centrifuged at 1400 g for 5 min and 200 µL of sample (diluted or not) 
was placed into a 96-well plate. The columns 11 and 12 were reserved for media (used 
during the experiment) and the regeneration buffer (10 mM glycine pH 1) respectively. 
Before measurement, the Dip aŶd ‘ead ™ PƌoteiŶ A ďioseŶsoƌs ;PALL FoƌtéBio, USA) were 
Name Type Dilution target coupled specie origin
Anti-GFP Primary 1:5000 GFP / mouse CRUK
Anti-β-aĐtin Primary 1:5000 β-aĐtiŶ / mouse Sigma
Anti-α-tuďulin Primary 1:5000 α-tuďuliŶ / mouse Sigma
Anti-SNAP29 Primary 1:1000 SNAP29 / mouse Santa Cruz Biotechnologies
Anti-STX18 Primary 1:1000 STX18 / mouse Santa Cruz Biotechnologies
Anti-STX7 Primary 1:1000 STX7 / mouse Santa Cruz Biotechnologies
Anti-Heavy chain Primairy 1:10000 HuŵaŶ IgG ;γ-ĐhaiŶ speĐifiĐͿ / rabbit Sigma
Anti-rabbit Secondary 1:1000 Rabbit IgG Horseradish peroxidase goat Sigma
Anti-mouse Secondary 1:1000 Mouse IgG Horseradish peroxidase goat Sigma
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soaked in media for 10 minutes. Titre measurements were done using a Octet® QKe system 
and the results analysed using the Octet Qke system analysis (version 9.0) with a 5PL 
unweighted curve fitting curve.  
2.3.8. Cellometer analysis 
The cellometer vision CBA commercialised by Nexcelom bioscience is an imager used to 
determine cell density and viability but also carry out fluorescence measurements. This 
device had been used to measure GFP levels in cell sample and obtained transfection 
efficiency data. To do so, 20 µL of cell culture was inserted in one chamber of a SD100 slide. 
This slide was then inserted into the cellometer for GFP measurement. 
 
2.4. Microscopy techniques 
2.4.1. Coverslip treatment with poly-L-lysine 
Round glass coverslips were inserted in a 24-well plate and covered with 0.01% poly-L-
Lysine w/v in sterile water (Sigma Aldrich, USA). After a 20 min incubation at room 
temperature, wells containing the coverslip were rinsed 3 times with sterile water and air 
dried before use. 
2.4.2. Cell culture for microscopy 
For microscopic studies, the culture of cells was required to be in a specific manner. The 
concentration of cells should be low to avoid cells growing over each other, but also not 
too low so as to have cells to observe and have a representative view. As such, cells were 
inoculated at 4 x 105 viable Đells/ŵL foƌ Ϯ daǇs at ϯϳ˚C aŶd ϱ% CO2. 
2.4.3. Coverslip preparation 
After growing the cells on coverslips, the culture media was aspirated and a PBS wash was 
performed. The cells were fixed by incubating 1 mL of pre-warmed 4% (w/v) 
paraformaldehyde diluted in PBS solution for 20 min at room temperature. Following 
incubation, the paraformaldehyde solution was discarded and 3 PBS solution washes were 
undertaken. The coverslips were then mounted on slides using 10 µL 10% 
phenylenediamine w/v (Sigma Aldrich, USA) diluted in Mowiol 4-88 (Harco, UK) and left 
oǀeƌŶight at ϰ˚C to dƌǇ iŶ the daƌk. The Ŷeǆt daǇ, the edges of the Đoǀeƌslips ǁeƌe sealed 
using nail varnish to prevent drying and oxidation. 
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2.5. Statistical analysis 
Two statistical tests were used in this study, one way ANOVA and a student t-test. When 
comparing more than 2 means, one way ANOVA was performed followed by a post-hoc 
Tukey analysis with a confidence interval of 95% considered as significant. The means 
sharing a letter do not have a statistical difference. For comparison of two means, a 




CHAPTER 3: Molecular Cloning of Target SNARE 




As outlined in the introduction section of this thesis, in the biopharma industry mammalian 
cells (e.g. HEK, VERO, and NS0) are commonly used for the production of biotherapeutic 
recombinant proteins, however one cell line predominates, the Chinese hamster ovary 
(CHO) cell line. CHO cell lines are the workhorse of industry for the production of 
biotherapeutic proteins with over 30% of approved products produced in CHO derived cell 
lines (Walsh 2014). Since their first isolation and description in 1956 (Puck 1958), CHO cells 
have been continuously studied and optimised for protein production (specifically 
production of post-translationally modified proteins at a commercial scale for use in 
humans) over the years (Wurm 2004) to give specific productivities (the amount of protein 
made per cell) of up to 90 pg/cell/day and viable cell concentrations of 10 x 106 cells/mL 
and beyond for extended periods of time in fed-batch culture mode. Cell culture process 
and media optimisation have been part of the reason for the improvements in cell growth, 
increased viable cell numbers and increased cell specific productivity and culture yields 
(referred to as titre) but will not be discussed in detail here. Cell line engineering has, for 
the last 20 or more years, been an important consideration and approach for the 
improvement of CHO cells with regard to all the different major attributes studied for 
improvement. These include manipulation of the glycosylation pattern (Amann et al. 2018), 
cell metabolism (Pereira, Kildegaard, and Andersen 2018) and apoptosis engineering (Lee 
et al. 2009). The work described in this thesis is focused on the engineering of the secretory 
pathway of the cell, a pathway that encompasses co-translational polypeptide synthesis 
into the ER, folding, assembly, post-translational modification and secretion of secreted 
proteins. 
Several approaches have been reported on the manipulation of the secretory pathway in 
CHO cells with the aim of enhancing its protein folding, assembly and secretory capacity, 
such as; (i) the amelioration of the translocation of the polypeptide into the ER through 
manipulation of the peptide signal sequence (Kober et al. 2013) and (ii) signal recognition 
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particle (SRP) elements (Le Fourn et al. 2014), (iii) overexpression of chaperones within the 
ER (Borth et al. 2005; Chung et al. 2004), (iv) engineering of the unfolded protein response 
(UPR, Tigges and Fussenegger 2006) and (v) engineering of vesicle trafficking and formation 
(Peng et al. 2011; Peng and Fussenegger 2009). This last strategy, engineering of vesicle 
trafficking and formation, is probably the least explored of these different areas and was 
the main approach investigated in this project. With regard to vesicle formation and 
targeting, the SNARE family is a potential target area for manipulation with members of 
this family being involved in vesicle sorting and formation. Moreover, studies have 
successfully reported the manipulations of a small number of SNARE proteins in CHO cells 
to deliver an increase in recombinant protein production (Peng, Guetg, Tigges, et al. 2010; 
Peng and Fussenegger 2009). 
To study the effect(s) of manipulation of a gene of interest (and hence the functional 
protein), two approaches have been widely used over the years; overexpressing or 
knocking down/out of the gene of interest (Fischer et al. 2015). Genomic knockout is used 
to delete the effect of disadvantageous genes or to determine the impact of unknown gene 
function using a range of techniques mainly involving designer nucleases such as 
CRISPR/cas9 (Grav et al. 2015). Knockdown approaches can also be used (e.g. siRNAs) 
where gene silencing may be lethal. On the other hand, overexpression is used to increase 
the beneficial effect of an existing gene, change the balance of gene expression, alleviate 
potential bottlenecks or to introduce the effect of an ectopic gene. With specific regard to 
the SNARE proteins, these have essential roles in vesicle trafficking and fusion so an 
overexpression strategy was used in this study. 
This chapter is focused on describing all the experiments undertaken to obtain monoclonal 
CHO cell populations overexpressing specific SNARE proteins. Firstly, all the processes for 
the generation of mammalian expression vectors for the SNARE proteins fused with an 
eGFP tag are described. Expression analysis was then carried out for the proteins of interest 
before proceeding to the generation of stably expressing CHO cell lines. Once the 
expression of the protein of interest in the different cell lines was confirmed, monoclonal 
populations were derived from the stably expressing cell lines. To finish, monoclonal 
populations were selected with regards to target SNARE protein expression and the 
stability of the expression in the cell lines. The overall result was the generation of CHO-S 
monoclonal cell lines stably expressing SNARE proteins for further characterisation and 
application to recombinant protein production.  
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3.2. Generation of mammalian expression vectors for the expression 
of the SNARE genes of interest 
3.2.1. VAMP expressing vectors 
From a survey of the literature (Aoyagi et al. 2016; Cocucci et al. 2008; Mallard et al. 2002; 
Nozawa et al. 2017; Oishi et al. 2006; Peng et al. 2011; Tran, Zeng, and Hong 2007), 4 VAMP 
proteins, VAMP3, VAMP4, VAMP7 and VAMP8, were judged to potentially have a 
significant impact on the capacity/efficiency of the secretory pathway (see section 1.6 and 
3.5). For the different selected VAMP proteins, plasmids containing the Human encoding 
gene were obtained from Addgene; pEGFP-VAMP3 (plasmid #42310), pEGFP-VAMP4 
(plasmid #42313), pEGFP-VAMP7 (plasmid #42316) and pEGFP-VAMP8 (plasmid #42311), 
having been deposited in the collection by Thierry Galli. The different genes were all 
provided in the pEGFP-C3 plasmid which is a mammalian expression vector using neomycin 
or G418 as a selection marker. The different genes were fused to an eGFP gene to express a 
fused protein with an eGFP tag in the N-terminal position. As neomycin or G418 can result 
in poor selection with the CHO-S host cell line used in this study and can result in unstable 
integration (data not shown), it was decided to subclone the eGFP-VAMP fusions into a 
new mammalian expression vector, the commercially available pcDNA3.1/Hygro(+) vector 
which has a hygromycin B selection gene for the selection of stably expressing cells. 
To generate the pcDNA3.1Hygro/VAMP3 construct, the coding sequence for VAMP3 fused 
to an eGFP tag was digested from the original pEGFP-VAMP3 using XbaI and NheI 
restriction enzymes. After digestion, two bands were obtained at the respective size of 
1173 bp and 3920 bp as determined by agarose gel electrophoresis analysis (Figure 3.1A). 
The lower band containing the fragment of interest was excised from the gel and purified 
before being ligated into the pcDNA3.1/Hygro(+) backbone previously digested with XbaI 
and NheI. Ligation was successful using a 3:1 ratio (insert:vector) and several colonies 
obtained were used to extract DNA after cultivation overnight at 37oC in 5 mL LB media 
with 100 µg/mL ampicillin. From analytical digestion with XbaI and NheI, two fragments at 
1173 bp and 5501 bp were expected for successful ligations, one colony showed the 
required DNA pattern (Figure 3.1B). The region containing VAMP3 and the eGFP gene was 
then sequenced to check for any anomalies in the sequence, such as point mutations, and 
was found to be correct. 
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The pcDNA3.1Hygro/VAMP4 construct was generated by digesting the sequence containing 
the fused protein from pEGFP-VAMP4 using BamHI and NheI restriction enzymes. Two 
bands were obtained at the respective size of 1198 bp and 3932 bp by agarose gel 
electrophoresis analysis (Figure 3.1C). The smaller band, containing the gene of interest, 
was extracted from the agarose gel, purified and ligated into the pcDNA3.1/Hygro(+) vector 
previously digested with BamHI and NheI. Ligation was successful using a 3:1 ratio (insert: 
vector) and several of the resulting colonies were used to extract DNA after growth 
overnight at 37oC in 5 mL LB media with 100 µg/mL ampicillin. One colony showed the 
required DNA pattern as determined by agarose gel electrophoresis analysis, with two 
bands expected at 1198 bp and 5563 bp after analytical digestion with BamHI and NheI 
(Figure 3.1D). The region containing VAMP4 and the eGFP gene was confirmed as correct 






The pcDNA3.1Hygro/VAMP7 construct was created in a similar manner to the 
pcDNA3.1Hygro/VAMP4 construct in that the original pEGFP-VAMP7 construct was 
digested using BamHI and NheI restriction enzymes generating two fragments of 3932 bp 
and 1437 bp in size. The smaller band carrying the region of interest was excised, purified 
and ligated into the pcDNA3.1/Hygro(+) vector co-digested with the same restriction 
enzymes. Ligation was successful using a 3:1 ratio (insert: vector) and several colonies 
obtained were used to extract DNA after cultivation overnight at 37oC in 5 mL LB media 
with 100 µg/mL ampicillin. When performing a test digest with HindIII and SmaI, two 
fragments of 1828 bp and 5172 bp were anticipated for a successful ligation. One colony 
showed the desired pattern after digestion (Figure 3.2A). To confirm the success of the 
ligation, the region containing VAMP7 and the eGFP gene was sequenced. 
The generation of the pcDNA3.1Hygro/VAMP8 construct was more technical due to the 
potential presence of methylation at the XbaI site used for digestion. To prevent the 
potential methylation, the bacterial strain used for transformation and DNA amplification 
ǁas ĐhaŶged fƌoŵ a DHϱα E. coli strain to a SCS110 E. coli strain. The SCS110 strain is 
lacking the genes dam (DNA adenine methylase) and dcm (DNA cytosine 
methyltransferase), two essential genes for DNA methylation in E. coli. Once demethylated 
pEGFP-VAMP8 was obtained, digestion was performed using NheI and XbaI restriction 
enzymes. Two fragments of 1166 bp and 3920 bp were observed after agarose gel 
electrophoresis analysis (Figure 3.2B). The smaller, required fragment was extracted, 
purified and ligated with the pcDNA3.1/Hygro backbone digested with the XbaI and NheI 
restriction enzymes. Ligation was successful using a 3:1 ratio (insert: vector) and several 
colonies obtained were used to extract DNA after cultivation overnight at 37oC in 5 mL LB 
media with 100 µg/mL ampicillin. When performing a test digest with the SmaI restriction 
enzyme, two fragments of 1309 bp and 5358 bp were expected. One colony demonstrated 
the banding pattern indicative of successful ligation (Figure 3.2C). To confirm the success of 





To be able to distinguish any effect upon transfection of the constructs into CHO-S host 
cells specific to the vector or the eGFP tag (i.e. not due to the presence of the target SNARE 
gene but due to other sequences in the vector), a control pcDNA3.1Hygro/GFP construct 
was generated. To achieve this, eGFP was excised from a donor vector (a gift from Tulshi 
Patel) using HindIII and BamHI restriction enzymes to result in the release of a 738 bp band 
containing the eGFP gene and 5505 bp band from the remainder of the vector. The 
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fragment containing the eGFP gene was excised, purified and ligated into the 
pcDNA3.1/Hygro(+) backbone digested with the same enzymes. Ligation was successful 
using a 3:1 ratio (insert: vector) and several colonies obtained were used to extract DNA 
after cultivation overnight at 37oC in 5 mL LB media with 100 µg/mL ampicillin. An 
analytical digest on a successful clone using BamHI and HindIII restriction enzymes was 
performed, resulting in the generation of two bands at 738 bp and 5579 bp of size as 
expected (Figure 3.3A). Sequencing of the eGFP region was also undertaken to confirm the 
presence of the correct nucleotide sequence. 
Once all the described vectors were generated, the plasmids were amplified by growth of 
tƌaŶsfoƌŵed DHϱα ĐoŵpeteŶt E.coli cells and then 250 mL of LB media containing 100 
µg/mL ampicillin were inoculated for each constructs and large stocks of DNA generated 
using the HiSpeed Plasmid Maxi kit in preparation for future experiments. Appendix 2 
presents the different vector maps for each of the newly generated plasmids which are 
summarised in Table 3.1. 
Table 3.1. List of vectors described in Chapter 3. 
 
3.2.2. Syntaxin (STX) and SNAP expressing vectors 
As described for the VAMP proteins in section 3.2.1, a literature research was performed to 
identify appropriate genes/proteins to target and 3 syntaxin and one SNAP proteins were 
selected as candidates for the project, STX7, STX17, STX18 and SNAP29 (Arasaki et al. 2015; 
Gordon et al. 2010; Ward et al. 2000)(see section 1.6 and 3.5). Plasmids containing the 
human sequence of the selected four genes were procured from Addgene, pMRXIP-STX7 
(plasmid #45921), pMRXIP-STX17 (plasmid #45909), pMRXIP-STX18 (plasmid #45918) and 
pMRXIP-SNAP29 (plasmid #45923), these being deposited in the collection by Noboru 
Mizushima. All the genes of interest were fused with an N-terminal eGFP gene to give a 
fused protein with a eGFP tag in the N-terminal position. The different plasmids obtained 
Name Backbone Gene of interest Tag
restriction sites used for 
cloning
Mammalian selection Origin
pcDNA3.1/Hygro(+) / / / / Hygromycin B Thermo Fisher
pEGFP-VAMP3 pEGFP-C3 VAMP3 N-term fused eGFP XbaI/NheI Hygromycin B Addgene, plasmid #42310
pEGFP-VAMP4 pEGFP-C3 VAMP4 N-term fused eGFP BamHI/NheI Hygromycin B Addgene, plasmid #42313
pEGFP-VAMP7 pEGFP-C3 VAMP7 N-term fused eGFP BamHI/NheI Hygromycin B Addgene, plasmid #42316
pEGFP-VAMP8 pEGFP-C3 VAMP8 N-term fused eGFP XbaI/NheI Hygromycin B Addgene, plasmid #42311
pcDNA3.1Hygro/VAMP3 pcDNA3.1/Hygro(+) VAMP3 N-term fused eGFP XbaI/NheI Hygromycin B This work
pcDNA3.1Hygro/VAMP4 pcDNA3.1/Hygro(+) VAMP4 N-term fused eGFP BamHI/NheI Hygromycin B This work
pcDNA3.1Hygro/VAMP7 pcDNA3.1/Hygro(+) VAMP7 N-term fused eGFP BamHI/NheI Hygromycin B This work
pcDNA3.1Hygro/VAMP8 pcDNA3.1/Hygro(+) VAMP8 N-term fused eGFP XbaI/NheI Hygromycin B This work
pcDNA3.1Hygro/GFP pcDNA3.1/Hygro(+) eGFP HindIII/BamHI Hygromycin B This work
pMRXIP-STX7 pMRXIP GFP-Ci2 STX7 N-term fused eGFP / Puromycin Addgene, plasmid #45921
pMRXIP-STX17 pMRXIP GFP-Ci2 STX17 N-term fused eGFP / Puromycin Addgene, plasmid #45909
pMRXIP-STX18 pMRXIP GFP-Ci2 STX18 N-term fused eGFP / Puromycin Addgene, plasmid #45918
pMRXIP-SNAP29 pMRXIP GFP-Ci2 SNAP29 N-term fused eGFP / Puromycin Addgene, plasmid #45923
pMRXIP-GFP pMRXIP GFP-Ci2 eGFP BamHI Puromycin This work
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from Addgene were not modified and used as provided. The pMRXIP GFP-Ci2 backbone 
plasmid into which these gene sequences had been cloned is a mammalian expression 
vector with a puromycin selection marker. Having a different selection marker from the 
VAMP expressing vector was convenient to allow the potential generation of STX/SNAP and 
VAMP co-expressing stable cell lines.  
Nonetheless, it was necessary to generate a control vector to determine any effect of the 
backbone or the eGFP tag in subsequent experiments on the CHO cell. To do so, a vector 
only expressing eGFP, pMRXIP-GFP, was generated in this backbone by removing the gene 
coding for STX17 in the pMRXIP-STX17 plasmid. To do this, pMRXIP-STX17 was digested 
using the BamHI restriction enzyme and two bands at 918 bp and 6815 bp were obtained. 
The larger band was extracted (Figure 3.3B), purified and re-ligated to itself to generate 
pMRXIP-GFP. After successful ligation, several colonies were used to extract DNA after 
cultivation overnight at 37oC in 5 mL LB media with 100 µg/mL ampicillin. After analytical 
digestion with BamHI, a unique fragment at 6815 bp was expected. One colony showed the 




Subsequent to the generation of the control vector, the constructs were bulked up by 
inoculation of 250 mL of LB media with 100 µg/mL ampicillin with DHϱα tƌaŶsfoƌŵed Đells. 
DNA was extracted and purified from the culture using the HiSpeed Plasmid Maxi kit for 
later use.  
 
3.3. Generation of stably expressing CHO-S cell lines 
3.3.1. Initial confirmation of expression of the eGFP tag of the fused proteins 
To simplify the study and detection of the different proteins of interest, vectors expressing 
fused proteins with eGFP at the N-terminal had been generated. eGFP is a fluorescent 
protein of 26.9 kDa widely used in biology. It has the advantage of its visualization being 
non-invasive making it a powerful tool for observation in vivo. Despite this, some 
precautions need to be considered in using this as a tag to follow expression of the tagged 
protein of interest (in this case the STXs and VAMPs). eGFP, like every other protein, needs 
to be properly folded to maintain its fluorescence activity. The fusion with membrane 
proteins having high structural restraints and the presence of a linker could possibly cause 
the misfolding of the eGFP tag. Further, the presence of eGFP alone does not confirm the 
presence of the target gene as it is possible that the eGFP could be cleaved from the target 
protein which is then degraded whilst the eGFP remains. It was therefore necessary to 
confirm the presence of both the eGFP and the fusion protein at the appropriate size 
before undertaking studies with such constructs. 
To determine if the fused proteins generated maintained their fluorescent signal, a 
transient transfection of commercially available, adherent CHO Flp-In cells was performed 
with the different vectors generated in section 3.2 above. 24-well tissue culture plates 
were inoculated with CHO Flp-In cells at 1.2 x 105 viable cells/mL and transfected using 
Lipofectamine 2000 (see protocol 2.2.6.1.1) and 0.8 µg DNA. After 72 h of incubation, cells 
were observed using a Leica MZFL III microscope and a Leica CD300F camera to detect the 
presence of eGFP expression. Figure 3.4 shows the results obtained from this transient 
transfection experiment. For all the constructs, a fluorescence signal was detected 
demonstrating that the eGFP was present and properly folded. Differences in the intensity 
of fluorescence were observed with a notably low signal with the pcDNA3.1Hygro/VAMP7 
and pMRXIP-STX18 constructs which may suggest low expression of these compared to the 
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other constructs. This experiment successfully showed that the eGFP tag was properly 






3.3.2. Titration of hygromycin B and puromycin to determine the appropriate 
amount that kills the host CHO-S cell in the absence of the selection 
marker for use in stable cell line generation 
In order to generate stably expressing cell lines, selection agent (hygromycin B or 
puromycin depending on the vector) needed to be added at the appropriate concentration 
for successful selection of cells stably expressing the selection marker. The concentration of 
antibiotic to use was determined by generating kill curves. For this, CHO-S cells were 
cultivated in 6 well plates at 1 x 105 viable cells/mL in media containing a specific amount of 
selection agent. Growth and cell viability were then monitored at day 2, 4 and 7 post 
addition of selection agent using a Vi-CELL instrument (see protocol 2.2.4.1). 
Concentrations from 0 to 1000 µg/mL were tested for hygromycin B (Figure 3.5A). No or 
little difference in culture viability was observed for the cells incubated with 0, 100, 250 
and 500 µg/mL hygromycin B until day 4, after which the culture viability reduced except 
for the 100 µg/mL condition. When cells were incubated in the presence of 750 or 1000 
µg/mL hygromycin B, culture viability was reduced below 50% after 4 days and below 10% 
afteƌ ϳ daǇs aŶd Đells iŶĐuďated ǁith ĐoŶĐeŶtƌatioŶ of ϳϱϬ aŶd ϭϬϬϬ µg/ŵL didŶ͛t gƌoǁ. As 
concentrations of 750 and 1000 µg/mL of hygromycin B gave a similar result with regard to 
the observed culture viability and cell concentration after 7 days, the concentration of 750 
µg/mL was chosen as the working concentration for the generation of stable cell lines. 
For determining the appropriate puromycin selection concentration to use, the following 
concentrations were tested; 0, 1, 2.5, 5, 7.5 and 10 µg/mL (Figure 3.5B). No impact on cell 
growth or culture viability was observed for concentrations from 0 to 2.5 µg/mL. The 
culture viability was 49% for 7.5 µg/mL and 14% for 10 µg/mL after 4 days, showing a 
higher impact of 10 µg/mL on culture viability. With regard to the cell growth, only the 
concentrations of 7.5 and 10 µg/mL inhibited cell growth. The effect on culture viability and 
cell growth were judged sufficient at 7.5 µg/mL compared to 10 µg/mL to use as a working 








3.3.3. Stable CHO-S cell line generation and selection 
After determination of an effective concentration of the selective agents (750 µg/mL of 
hygromycin B and 7.5 µg/mL puromycin) and the generation of the different expression 
vectors (see section 3.2), stably eGFP-SNARE expressing CHO-S cell lines were generated. 
CHO-S cells were electroporated ǁith ϮϬ µg of liŶeaƌized DNA usiŶg a GeŶe Pulseƌ XĐell™ 
Electroporation system (protocol 2.2.5.1). The following day, the selection agent was added 
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at the appropriate concentration to apply the necessary selection pressure to generate 
stably expressing cell pools. After 2 weeks of recovery, cell growth and culture viability 
were determined using a Vi-CELL instrument. If appropriate cell numbers and culture 
viability were observed (these being >60% viability and >0.5 x 106 cells/mL), the cells were 
used to inoculate 20 mL of media in a 125 mL Erlenmeyer flask (protocol 2.2.3.1). The 
different cell lines generated are summarised in Appendix 3. 
3.3.4. Analysis of target eGFP-SNARE fusion protein expression in stable CHO-S 
cell pools 
Following the creation of the different stably expressing CHO-S cell pools, further 
investigation needed to be undertaken to confirm the expression of the fusion proteins of 
interest. Indeed, electroporation is a random integration technique where the desired gene 
could be integrated into a silenced region. Moreover, the method used for selection 
(hygromycin B and puromycin) only assures the enrichment of cells stably expressing the 
resistance gene. To confirm expression of the fused proteins, pellets from the stably 
expressing cell pools were extracted for SDS-PAGE and western blot analysis (protocol 
2.3.2). 
Figure 3.6A shows the results obtained after western blot analysis of the different pellets 
extracted from the VAMPs engineered stable CHO-S cell pools. The expected molecular 
weights are 38, 43, 51 and 38 kDa for VAMP3, VAMP4, VAMP7 and VAMP8 fused with 
eGFP. After probing with an anti-GFP antibody, signal was detected for VAMP3, VAMP4 and 
VAMP8 at the expected size (Figure 3.6A). No extra bands were observed confirming the 
integrity of the fused proteins and that the eGFP had not been cleaved from the VAMP 
protein. No signal was obtained for the eGFP-VAMP7 cell pools, even after several repeats 
of the extraction. Several attempts to generate CHO-S/eGFP-VAMP7 cell pools were 
attempted and all were unsuccessful. The reason for this is not known and will be discussed 
later. 
The same analysis was performed for the CHO-S eGFP-STX/SNAP stably expressing cell 
pools, CHO/STX7, CHO/STX17, CHO/STX18, CHO/SNAP29 and CHO/MRXIP-GFP. The 
expected size for the different constructs were 57, 60, 65, 56 and 27 kDa for STX7, STX17, 
STX18, SNAP29 fused with eGFP and the control (pMRXIP-GFP). Western blot analysis 
(Figure 3.6B) with an anti-GFP antibody showed a positive signal at the expected sizes for 
STX7, STX17, SNAP29 and the STX control. Two bands were observed for STX7, a main one 
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at the expected size (57 kDa) and a less intense band of a smaller size directly below the 
main band (Figure 3.6B). The smaller band could correspond to eGFP-STX7 protein lacking a 
particular PTM or be the effect of protease activity trimming one end of the polypeptide 
sequence. STX7 is subjected to several phosphorylations which modifies it molecular 
weight (Achuthan et al. 2008), potentially accounting for the difference in the band sizes 
observed. Western blot analysis of the ectopic expression of the eGFP-STX18 fused protein 
showed a lot of cleavage of the eGFP tag (Figure 3.6C). A signal at the expected size was 
observed (65 kDa) but the tag was predominately removed as shown by the more intense 
band at 27 kDa. This set of experiments confirmed that for most of the targets a fused 
protein containing a correctly folded eGFP was obtained and that the cell pools were 






3.4. Monoclonal CHO-S eGFP-SNARE expressing cell line generation 
3.4.1. Limiting dilution cloning for generation of monoclonal cell lines from the 
CHO-S SNARE engineered cell pools 
Using the stably expressing cell pools generated under section 3.3 above, monoclonal cell 
lines were created. This was achieved using limiting dilution cloning. For each cell pool, a 
series of limiting dilutions were made in 3 x 96-well sterile tissue culture plates in order to 
obtain a sufficient number of monoclonal cell lines. Once the plates were prepared and the 
cells added as described in section 2.2.7, they were incubated at 37oC in a 5% CO2 
atmosphere for 3 weeks while monitoring for out-growth and signs of contamination using 
a bright field microscope. After recovery, the cell lines were characterised via a process 
detailed in figure 3.7. All the stable cell lines generated in section 3.3 were subjected to the 






3.4.2. Monoclonal cell line selection for further study 
From the polyclonal stably expressing cell pools generated earlier in the project, 
monoclonal populations were created using the method described in Figure 3.7. Initially, 12 
clones were selected after recovery and the selection was based on 2 parameters; 
monoclonality (presence of only one cell initially in the well) and confluency (>60%). These 
requirements were evaluated by bright field microscopy. Monoclonal cell lines were named 
with the following pattern; name of the parental cell pool with the addition of a letter A-L 
(e.g. CHO/V4 K for the CHO-S VAMP4 K monoclonal cell line).  
Selected cells were grown in a well of a 24-well plate and then in a well of a 6-well plate 
before the fluorescence was determined using a FACSJazz device. As the different proteins 
of interest were eGFP fused proteins, it was assumed that the level of expression of eGFP 
was correlated to the level of expression of the fusion protein. This assumption was 
undertaken to simplify the selection process. The measurement of eGFP expression using a 
flow cytometer was also helpful in determining if a population was likely to be monoclonal. 
The process of limiting dilution cloning relies on microscopic observation which can be 
error prone. The presence of a single main peak by flow cytometry fluorescence analysis 
would provide further evidence of the likelihood of the monoclonality of the cell 
population.  
Figure 3.8 shows the results obtained for the VAMP expressing monoclonal cell lines using 
the flow cytometer FACSJazz with the 12 clones selected after limiting dilution cloning. 
Generally, for the eGFP-VAMP expressing cell lines, the different monoclonal populations 
had the same profile with a slight shift of population to the right compared to the control 
cells corresponding to an increase in fluorescence that is assumed to be due to eGFP 
expression. For VAMP3 monoclonal populations, only one clone (CHO/V3 J) showed a clear 
increase in fluorescence compared to the control observed as a shift in signal to the right. 
All the other clones had a similar eGFP expression comparable to the host cell line (Figure 
3.8). For VAMP4 and 8, no noticeable difference between the different clonal populations 
was detected, despite a shift to the right in eGFP intensity compared to the control. The 3 
clones with the biggest shift were selected for further study. In all cases for the CHO/V3, 
CHO/V4 and CHO/V8 monoclonal cell lines, only one major peak was observed suggesting 
the presence of one population of engineered cells and hence a monoclonal population. 
Further, whilst different expression of the eGFP-VAMP3 was observed suggesting the CHO-
S cells can tolerate a range of over-expression of this SNARE, only a small increase in 
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expression of the eGFP-VAMP4 and eGFP-VAMP8 was observed and all at approximately 
the same intensity suggesting that the CHO-S cells can only tolerate a small increase in the 
expression of these SNAREs and hence no highly expressing cells survive the selection 
process. 
The monoclonal populations obtained with the eGFP control demonstrated a diverse 
profile of expression across the clones isolated (Figure 3.8). The 3 populations had different 
expression profiles and were much higher in expression than the eGFP-VAMP fusions. A 
second peak was observed in the different control populations suggesting that the 
populations were not monoclonal (Figure 3.8). Even if the smaller peak was minor, this 
subpopulation could eventually outgrow the higher expressing population. Due to the lack 
of choice, these likely polyclonal cell lines were selected as controls but this information 







The same process for selecting clonal cell lines for further study was executed for the 
syntaxin/SNAP expressing cell lines. For the different clonal populations obtained after 
limiting dilution cloning, the profiles of eGFP expression were more varied than observed 
with the VAMPs with relative low, mid and high expressers (compared to the control) 
isolated (Figure 3.9). For the different clones of CHO/STX7, a clear and large shift to the 
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right was noticeable for most clones compared to the control although among those clones 
there was an almost identical fluorescence profile. 3 were selected for expansion and 
further study.  
CHO/STX17 expressing clonal populations had different fluorescence profiles with relative 
low, mid and high expression. This was the preferred outcome after limiting dilution 
cloning providing a diversity of expression across the clones and an ability to select the 
different levels of expression for later study (Figure 3.9). Among the 12 clones expressing 
STX18 selected after limiting dilution cloning, only 3 showed a fluorescence profile with a 
shift to the right confirming eGFP expression. The previous analysis of the STX18 pool 
revealed low expression of eGFP-STX18 and cleavage of the eGFP tag (see Figure 3.6C). The 
monoclonal populations isolated based on eGFP expression were expressing a relative mid 
and high profile of expression but this would need to be characterised further to confirm 
whether the fluorescence signal was due to eGFP only expression or if the full fusion 
protein was expressed. SNAP29 expressing cell lines were observed at relatively low or high 
fluorescence measurements compared to the control. The clones showing low expression 
were not selected. 3 clones among the high expressing profiles were selected and used for 
expansion. The MRXIP-GFP control expressing cell lines surprisingly showed only a small 
shift in the different populations evaluated and all the clones had a comparable profile. 3 
clones were selected for further study 
It was observed that several clones selected for expansion had a broad eGFP signal 
(CHO/STX17 C, CHO/STX17 J, CHO/SNAP29 I) but an absence of two distinct peaks. These 
cell lines could be polyclonal but there was no definitive data to confirm this. Moreover, in 
this project the generation of monoclonal cell lines was not an absolute requirement but 
rather a manner to obtain cell lines with different profiles of SNARE expression for further 









3.4.3. Evaluation of the stability of EGFP-SNARE expression in CHO-S monoclonal 
cell lines over time 
For further analysis of the impact of SNARE over-expression on CHO-S cells, 3 clones were 
selected for each construct and expanded until reaching a shaken culture condition in spin 
tubes. When the different cell lines were adapted to the shaken environment (culture 
viability >90%), profiles of expression were assessed once again using flow cytometry. This 
was to confirm that the expression observed during isolation of the cell lines was 
maintained. Figure 3.10 shows the results obtained from the fluorescence measurement of 
cells cultured in a shaken environment. Surprisingly, most of the VAMP expressing clones 
had lost the expression of eGFP. Only CHO/V4 A and CHO/V3 D had retained eGFP 
expression. CHO/V4 A showed a similar expression profile in the shaken environment to 
that previously observed in the static flask whereas the CHO/V3 D profile had changed. The 
CHO/V3 D profile showed a less pronounced shift to the right compared to static 
conditions. Moreover, it was possible to distinguish 2 populations, one expressing eGFP at 




On-the-other-hand, the STX/SNAP over-expressing clones appeared to have retained eGFP 
expression much better than the VAMP cell lines suggesting that over-expression of the 
STX/SNAP is more tolerated in the CHO-S cell lines and maintained through generations. 
However, for the different CHO-S clones expressing STX7, whereas they showed a very 
similar profile to that observed in the static environment, adaptation to a shaken 
environment appeared to have resulted in a reduction in the relative amount of eGFP 
expression (the shift to the right was less prominent, Figure 3.10). With regard to the cell 
lines expressing STX17, CHO/STX17 K appeared to express less eGFP in shaken 
environment. CHO/STX17 K had a comparable expression level to CHO/STX17 J. The low 
expresser, CHO/STX17 C, appeared to have two distinct populations (two peaks) in the 
shaken environment with no change in the levels of expression. No evident alteration was 
observed for the clones expressing STX18 between the shaken cultured cells and the 
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previous data generated on the static cells. For SNAP29 over-expressers, one of the high 
expressing cell lines (CHO/SNAP29 B) appeared to have lost some eGFP expression 
compared to the other (CHO/SNAP29 A) cell line (Figure 3.10). The profile of eGFP 
expression of CHO/SNAP29 I was broader in the shaken environment and suggested the 
presence of a second peak. No difference was observed when comparing the profiles of the 







The work described in this chapter is focused on the molecular cloning of target eGFP-
SNAREs into appropriate mammalian gene expression vectors with antibiotic selection 
markers. This in order to generate engineered CHO-S cell lines necessary for further study 
around the impact of over-expression of the SNAREs on CHO cell secretory recombinant 
protein production. Thus, the secretory pathway is the main point of interest, and 
particularly vesicle trafficking and formation. The first step in the study was to select 
potential candidate target proteins for manipulation that may be able to impact the 
secretory pathway in order to improve recombinant protein secretion, the overall goal of 
the study. Based on the findings of previous reports into manipulation of some of the 
SNARE family (Peng, Guetg, Abellan, et al. 2010) and work reported by Gordon et al. (2010) 
on the identification of SNAREs necessary for constitutive secretion, the work here was 
focussed upon assessing the impact of SNARE over-expression in CHO cells on recombinant 
protein secretion capacity. 
From a survey of the literature and availability of genetic constructs, a number of potential 
different candidates emerged as targets for SNARE manipulation; VAMP3, VAMP4, VAMP7, 
VAMP8, STX7, STX17, STX18 and SNAP29. A siRNA screen in HeLa (Gordon et al. 2010) 
identified STX17, STX18 and SNAP29 as necessary for constitutive secretion of proteins 
suggesting a potential bottleneck in secretion at the level of these proteins which 
overexpression could alleviate. VAMP8, known to involved in compound exocytosis (Thorn 
and Gaisano 2012), has already been successfully used to increase production of 
recombinant protein in CHO-K1 cells (Peng et al. 2011) and was chosen as a control. VAMP3 
and VAMP4 were selected due to their possible role on the Golgi structure and fusion 
events at the membrane. Indeed, depletion of VAMP4 in HeLa cells affects the structure of 
the Golgi apparatus (Shitara et al. 2013) while VAMP3 is necessary for fusion events at the 
plasma membrane in several trans-SNARE complexes (Hu et al. 2007). STX7 and VAMP7 
were selected due to their involvement in trans-SNARE complexes with other targets such 
as VAMP8 or SNAP29 for further co-expression analysis. Once these targets were selected, 
genetic constructs for their stable expression in mammalian cell lines were generated. At 
the start of this work, the sequences of the candidate genes were only predicted for CHO 
cells in the different databases (http://www.chogenome.org/, as at 2015). All the 
sequences for the genes used were therefore from human. The different sequences for the 
genes are now available (https://www.ensembl.org/Cricetulus_griseus_crigri/Info/Index, as 
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at August 2018). To confirm the high degree of homology between both species for the 
different genes, nucleotide sequence alignments were performed using BLASTn 
bioinformatic tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch). The 
results of the alignment are detailed in Table 3.2. In the particular case of the candidate 
genes, identity of over 80% was observed between Human and Chinese hamster genes. 
Moreover, ectopic expression of human genes in CHO cells is common and has been 
successful (Fischer et al. 2015). Further, the use of the human gene can offer an advantage 
in that this can remove any natural gene expression control elements within the CHO 
sequence that might limit the ability to over-express a given gene sequence. Hence, use of 
human sequences in this project was performed while keeping the information in mind for 
further analysis. 
Table 3.2. Results of nucleotide sequence alignment using BLASTn between the Human and 
the Chinese Hamster candidate genes. 
 
Plasmids with the human genes of interest were initially sourced from Addgene. In all cases 
the target genes were fused to an eGFP gene at the N-terminal for the expression of a 
fusion protein with a fluorescence tag. Here, the different genes of interest were fused to 
eGFP via a tandem repeat (Yu et al. 2015) with no specific sequence used as a linker but 
only a stuffer region providing enough space for proper folding. The presence of a eGFP 
reporter gene is a valuable tool for protein detection and non-invasive visualisation of 
expression in cells (Tsien 1998). However, even though the tag may not interfere with the 
expression of the individual SNAREs, this does not confirm that the tag does not interfere 
with the activity/function of the tagged protein.  
Originally, VAMP candidates were provided inserted in a pEGFP-C1 plasmid backbone with 
a selection based on neomycin or G418 antibiotic resistance. Previous experiments (data 
not shown) in the laboratory had found the generation of stably expressing cell lines using 
this selection to be difficult and unstable cell lines were produced. To solve this issue, the 
different genes of interest were sub-cloned into a commercially available 
gene  CHO gene Ensembl ID CHO genome used identity to human gene (%)
NCBI Reference Sequence ID 
for the hit sequence
E value
VAMP3 ENSCGRT00000002866.1 CriGri_1.0 243/288(84%) NM_004781.3 4.00E-84
VAMP4 ENSCGRT00000024637.1 CriGri_1.0 379/397(95%) NM_003762.4 0
VAMP7 ENSCGRT00000023866.1 CriGri_1.0 614/662(93%) NM_005638.5 0
VAMP8  ENSCGRT00000015951.1 CriGri_1.0 250/285(88%) NM_003761.4 5.00E-96
STX7 ENSCGRT00000018077.1 CriGri_1.0 697/779(89%) NM_001326579.1 0
STX17 ENSCGRT00000024318.1 CriGri_1.0 589/670(88%) NM_017919.2 0
STX18 ENSCGRT00000014508.1 CriGri_1.0 900/1008(89%) NM_016930.3 0
SNAP29 ENSCGRT00000014256.1 CriGri_1.0 528/614(86%) NM_004782.3 0
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pcDNA3.1/Hygro(+) plasmid with a resistance gene for hygromycin B. On-the-other-hand, 
the different syntaxin/SNAP plasmids were provided in another plasmid called pMRXIP 
GFP-CiϮ ĐoŶfeƌƌiŶg a puƌoŵǇĐiŶ ƌesistaŶĐe to the Đells. Those ĐoŶstƌuĐts ǁeƌeŶ͛t ŵodified 
but used as provided. As VAMP and syntaxin/SNAP proteins interact together in vesicle 
formation and trafficking (Hong 2005; Jahn and Scheller 2006), the fact these were under 
different selection agents meant it would be possible to determine any additional effect if 
more than one component of a trans-SNARE complex was expressed. These could also be 
used to determine if a specific component is limiting in the trans-SNARE complex as it is 
suggested that some R-SNAREs and Q-SNAREs might be replaced by other SNAREs (Gordon 
et al. 2010). Control vectors (pcDNA3.1Hygro/GFP and pMRXIP-GFP) were also generated 
to determine any background effect from stable integration of these plasmids and the 
selection process on the CHO cell (Stepanenko and Heng 2017). 
To confirm the expression of the full length fusion proteins with a correctly folded eGFP tag 
from the newly generated vectors, the fluorescent signal as a result of expression of the 
constructs was investigated by transient transfection in adherent CHO Flp-In cells. GFP 
fluorescence is obtained through its fluorophore and its correct folding is required to give 
activity. The fluorescent images taken 72 h after the transient transfection showed that the 
transfected cells were fluorescent, suggesting that the eGFP tag was correctly folded. These 
results agree with the studies where the fusion genes VAMP4, VAMP7, STX17 and STX18 
were originally reported (Itakura et al. 2012; Mallard et al. 2002; Martinez-Arca et al. 2000). 
The differences in signal intensity (notably for STX18 and VAMP7) for the different 
constructs may be explained by several factors. As the transfection approach was the same 
for all constructs, the most probable explanation is that the over-expression of these 
SNAREs is not well tolerated by the cell or that these are turned over rapidly and hence the 
amount of expressed eGFP-fusion protein observed is low in comparison to the other 
constructs. Stable cell line generation subsequently undertaken was also difficult with 
these two constructs, providing further evidence that the over-expression of these fusion 
proteins is not tolerated in CHO cells. 
In order to generate the different stably expressing cell lines, the working concentration for 
the different selection agents was determined. From the results in section 3.3.2, a working 
concentration of 750 µg/mL of hygromycin B and 7.5 µg/mL of puromycin were used. All 
the stably expressing CHO-S SNARE engineered cell lines were generated by 
electroporation (Appendix 3) which results in delivery of the plasmid DNA to the nucleus 
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and random integration of the linearized plasmid into the genome of the host cell. By this 
nature of integration, the genes of interest may be silenced or have low expression levels 
due to positional effects (Davami 2016). To determine the eGFP-SNARE fusion protein 
expression profiles of the different polyclonal pool populations, protein extraction from 
cells and subsequent western blot analysis for the eGFP-SNARE fusion proteins was 
undertaken. After incubation with an anti-GFP antibody, an expression signal for the full 
length fused protein was obtained for all the constructs except for eGFP-VAMP7 and eGFP-
STX18. For cells expressing STX18, two bands were detected at 65 kDa and 27 kDa 
corresponding to the size of the full fusion protein and the eGFP alone. A stronger signal 
was detected for the eGFP than the full protein suggesting a more abundant presence of 
cleaved but properly folded eGFP. This indicates cleavage of the eGFP tag. The cleavage of 
the eGFP tag may be due to the presence of a cleavage motif in the linker sequence. 
Indeed, full size fusion protein and eGFP were detected and in the case of mis/unfolding of 
the fusion protein, both parts of the fusion protein would have been degraded. After 
analysis of the linker region on synlinker (http://synlinker.syncti.org/, National University of 
Singapore), no common cleavage recognition motif was found.  
Regarding eGFP-VAMP7 stably expressing CHO-S cells, no eGFP signal was obtained after 
blotting with an anti-GFP antibody for either the full fusion protein or any fragment 
containing the eGFP. This was unexpected because a fluorescent signal was detected 
during the transient transfection suggesting at least proper folding of the eGFP. Several 
protein extractions and generation of stably expression cell lines were unsuccessful. The 
most likely reasons for this are that either the eGFP-VAMP7 fusion protein (with the human 
VAMP7 sequence) is toxic to the cells and hence cells expressing this do not survive or that 
the protein is rapidly degraded. No further studies were undertaken during this work to 
ascertain if either of these possibilities was correct. 
Overexpressing ectopic proteins can be a burden on the cell and have detrimental effects. 
For example, when heterologous proteins are being translated, overload of the ER capacity 
to fold proteins can trigger the UPR pathway (Chakrabarti, Chen, and Varner 2011). This 
pathway leads to recovery of a normal state or apoptosis. Different levels of ectopic protein 
expression may be needed to observe when the ER capacity is destabilised. One way to 
obtain different levels of expression is the use of promoters with different transcription 
rates. This strategy requires the creation of a different vector for each promoter used. In 
this study, we used instead the property of random integration by electroporation. Indeed 
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after electroporation, cells integrate a different amount of DNA into their genome in 
different locations giving a polyclonal population. Potentially every cell expresses the 
protein of interest at a different level due to integration of different copy number of the 
genes, positional effects, and different translational and protein folding capacities across 
cells. By performing limiting dilution cloning to obtain monoclonal cell lines, cell lines 
derived from a unique cell, it is theoretically possible to obtain cell lines expressing the 
target recombinant fusion protein at different levels. Further, monoclonal populations have 
become a standard in industrial processes in order to obtain a population with 
homogeneous genetic information. 
The monoclonal cell lines were generated through two steps of selection. The first was 
after the recovery step where clones were selected based on clonality and confluency. 
From 3 x 96-well plates initially setup for each construct, 12 clones were selected. The 
second step was a screening of the 12 selected clones for expression of each eGFP-SNARE 
fusion construct based on fluorescence measurements. Flow cytometry was used to 
determine the relative level of expression of the fused protein. This approach does not 
however, allow the investigator to determine if SNARE protein function is impaired by the 
presence of the eGFP tag. 
When analysing the data obtained by flow cytometry, a difference in the shift of the curves 
between the eGFP-VAMP and eGFP-syntaxin/SNAP expressing cell lines was noticeable. The 
different nature of the backbone into which these genes were cloned and expressed from 
may explain the variation observed. For all the proteins of interest, at least 3 clones with 
fluorescent signal above from the host cell lines were obtained, although the magnitude of 
the difference in expression differed between the constructs.  
After selection of the different clones based on the fluorescence by flow cytometry, they 
were expanded from 6 well plates to spin tubes. Normally, the CHO-S cells used were 
cultured in suspension but for the limiting dilution cloning and the expansion period 
folloǁiŶg it, the diffeƌeŶt ĐloŶes speŶt a peƌiod of tiŵe iŶ a statiĐ eŶǀiƌoŶŵeŶt ;≈Ϯ ŵoŶthͿ. 
CHO cells were initially a static cell line and were adapted to suspension culture resulting in 
changes in gene expression (Shridhar et al. 2017). The level of eGFP-SNARE fusion protein 
expression was determined in the cells for selection purposes in a static environment so 
the change to suspension culture could result in a change in the expression profile in the 
different clones. Therefore, in order to determine whether any changes in the level of 
expression of the eGFP were observed, flow cytometry was performed after adaptation of 
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the cells to the shaken environment. Some changes were expected due to the drastic 
change of environment, increasing the risk of loss of the gene of interest. Surprisingly, most 
of the VAMP expressing clones had lost eGFP expression when adapted to the shaken 
environment while the selection pressure was present. Gene position and structure at the 
integration site have a great impact on the stability of integration, but the presence of the 
selection pressure should preserve gene integration. Moreover, Böhm et al. (2004) showed 
that expression of a gene of interest was lost over time (2 months) only when selection 
pressure was absent. On-the-other-hand, the syntaxin/SNAP expressing cell lines profile 
changed much less and the general profile was maintained. The difference between the 
VAMP and syntaxin/SNAP expressing cell lines may be explained by the difference in the 
backbone, or by the very nature of the proteins being expressed. If the over-expression of 
the VAMP proteins is toxic to the cell one would expect over time that those with 
expressing the protein at a low level ǁould ͚out-gƌoǁ͛ those ǁith higher expression levels 
so that with every culture passage the expression observed would be reduced. This could 
be investigated by following the expression of the eGFP-VAMP fusion protein in culture 
over time. 
Another phenomenon was also observed during the second round of flow cytometry on the 
cells growing in suspension. In a few populations there was clear evidence of a polyclonal 
population (presence of two or more distinct peaks) where this had not been observed. In 
all cases, the fluorescent peaks were close together denoting a small difference in the 
fluorescent expression. This may have arisen as a result of the initially selected cell line not 
being monoclonal or during subsequent adaptation and culturing of the cells in suspension 
culture. In order not to reduce the number of cell lines for each target, the potential 
polyclonal populations were not discarded.  
 
3.6. Summary of the main findings from the work in this chapter 
This chapter summarises the processes undertaken for the generation of all the cell lines 
required for the remainder of the project. After focusing on a limited number of targets, 
VAMP3, VAMP4, VAMP7, VAMP8, STX7, STX17, STX18 and SNAP29, picked from literature 
reports, mammalian expression vectors of these fused N-terminally to eGFP were 
generated. The expression of the different fused proteins was checked using fluorescent 
microscopy and western blot analysis after transient transfection. Stably expressing CHO-S 
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cell pools were then generated and subjected to limiting dilution cloning to generate 
monoclonal populations with different levels of eGFP-SNARE fusion protein expression. 
After selection of the different monoclonal populations based on fluorescence levels, only 
the syntaxin/SNAP expressing clones provide adequate expressing monoclonal cell lines. 
The generated cell lines were then characterised further, particularly the ability of these to 
secrete a target recombinant biotherapeutic protein and in relation to the relative levels of 




CHAPTER 4: Assessment of the Impact of Over-
expression of Target SNAREs in CHO-S Cells on the Cell 
and Recombinant Protein Expression 
 
4.1. Introduction 
As described previously in this thesis, cell line engineering processes classically use one of 
two approaches, either the overexpression of a beneficial gene or the repression of a 
detrimental gene. Here, cell line engineering was undertaken via the generation of cell 
pools and clonal lines overexpressing ectopic proteins, VAMPs or syntaxin/SNAP fused to 
an eGFP tag (see Chapter 3). After generation of these engineered cell lines as described in 
Chapter 3, the next step was to determine how the introduced characteristics impacted 
upon the cell lines compared to the parental cell line control. In this regard, a number of 
key parameters can be evaluated with regard to improving recombinant protein production 
from a new host. Three such parameters which are fundamental to recombinant protein 
expression from cell hosts are cell growth and survival (this reflects the rate of growth, the 
biomass that is accumulated and then for how long this is maintained), cell productivity and 
titre (reflecting both cell specific productivity and overall product yield from the culture) 
and the product quality (including correct folding and assembly of polypeptides and post-
translational modifications). Once these 3 parameters have been investigated and 
characterised, the stability of these paraŵeteƌs oǀeƌ tiŵe ;ƌefeƌƌed to as the ͞staďilitǇ of 
the Đell liŶe͟Ϳ aƌe ŵoŶitoƌed to ĐoŶfiƌŵ that a ƌeĐoŵďiŶaŶt cell line does not lose the 
desired characteristics over time (Chen et al. 2012; Li et al. 2016). 
Introduction or the overexpression of a gene into a host cell might have consequences on 
the engineered cell line growth properties and culture durability and viability. Indeed, 
placing a burden on the ER by overexpression of proteins that are directed into the ER can 
activate the UPR (Schröder and Kaufman 2005), which acts to initially try to alleviate the 
burden on the ER by upregulation of chaperones and foldases in the ER whilst 
simultaneously slowing entry of new polypeptides into the ER. If the burden cannot be 
reduced or, in a timely manner, apoptosis is induced (Xu, Bailly-Maitre, and Reed 2005). 
Indeed, in general the overexpression of either endogenous or exogenous genes and 
proteins can lead to a disturbance of the homeostasis of the cell, a perceived cell stress and 
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impaired cell growth and performance with regard to recombinant protein production. 
Moreover, expression of ectopic proteins can be toxic to the cells and hence produce 
undesired effects on growth and culture viability leading to cell death. On-the-other-hand, 
overexpression of proteins involved in proliferation such as cyclin-dependent kinase like 3 
(Jaluria et al. 2007) or vasolin containing protein (Doolan et al. 2010) can result in the 
manifestation of desired characteristics.  
In order to assess the impact of cell engineering on growth rate and cell doubling time, 
experiments can be performed to generate data that allows the plotting of the viable cell 
concentration through time on a log scale to determine the different growth phases of 
culture (exponential, stationary and decline phase). The curves obtained can be used to 
extrapolate the growth rate during the exponential phase of growth using the following 
equation µ = ���� × ଵ� or X=X0.eµt 
where X0 is the initial cell concentration, µ is the growth rate and t is time. 
Productivity or titre are terms used to describe the concentration of recombinant protein 
of interest produced. The culture yield or titre can be calculated as a concentration (e.g. 
often mg/mL or g/L of the target protein of interest) or a specific productivity (pg/cell/day 
of product of interest). Specific productivity is a more precise measurement than titre or 
culture yield, giving the average quantity of product produced per cell over time. It is 
calculated by plotting the change in integral viable cell concentration (IVC) against the 
change in product concentration over time and using the following equation 
�ሺݐሻ = ݍ݌ሺݐሻ × ∫ �ሺݐሻ݀ݐ��଴  
where C(t) is the product concentration, qp(t) is specific productivity over a specified time 
period and ∫ �ሺݐሻ݀ݐ��଴  is the integral viable cell concentration across the specified time 
period. 
This chapter describes the characterisation of those cell lines generated in Chapter 3 and 
any impact of the over-expression of the proteins of interest on cell growth and secreted 
recombinant protein productivity. After the limiting dilution and selection process, 
experiments were undertaken to confirm the correct ectopic expression of the fused 
molecule in the different cell lines. Once correct expression was confirmed, the effect of 
100 
 
the overexpression on the cell lines with regard to growth was assessed at different scales 
(shake flasks and spin tubes). Any impact on secretory productivity of model recombinant 
biotherapeutic proteins was then assessed under different conditions and with different 
recombinant model proteins. The end result is the characterisation of monoclonal cell lines 
expressing eGFP-SNARE fused protein of interest with defined cell growth profiles and 
productivity assessments under different conditions and scales. Comparison between 
different scales was also performed to determine reproducibility of prediction. 
 
4.2. Characterisation of different selected syntaxin/SNAP expressing 
cell lines 
After limiting dilution cloning of the engineered cell pools, 2 or 3 clones for each 
syntaxin/SNAP construct were obtained. Investigations were then undertaken to confirm 
expression of the intact fusion protein and an active fluorescent tag in the stably 
transfected pools (see section 3.3) and on the monoclonal cell lines. 
4.2.1. Microscopy studies confirm the presence of a correctly processed eGFP tag 
in the different eGFP-syntaxin/SNAP fusion protein engineered CHO-S cells 
To determine the presence and correct folding of the eGFP tag in the eGFP-syntaxin/SNAP 
engineered CHO-S cells, fluorescence microscopy was performed to detect the eGFP 
fluorescence signal within the cells. For the different cell lines, cells were immobilised on 
coverslips after poly-L-lysine treatment (see 2.4.1). The cells were then observed using a 
LS620 microscope (Etaluma, USA) and fluorescent images collected. Figure 4.1 shows 
representative images collected for the engineered cell lines. All the eGFP-SNARE cell lines, 
except the CHO/MRXIP-GFP H cell line, contained a fluorescence signal confirming the 
presence of correctly folded eGFP tag (Figure 4.1). Differences in fluorescence intensity 
were observed between the different cell lines, notably between the different cell lines 
expressing the same protein of interest. For example, CHO/SNAP29 A had a stronger signal 
compared to CHO/SNAP29 B whilst no fluorescence signal above background was observed 
in the CHO/MRXIP-GFP H cell line. This result did not follow the expression profile as would 
be predicted from the previously undertaken flow cytometry analysis (see section 3.4.3) 
and likely reflects changes in the relative expression profiles since the flow cytometry 
analysis. Further, the flow cytometry analysis profile represents that from 10000 cells 
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whilst the microscopy analysis shows relative expression across a small number of cells. 
Regardless, this experiment successfully confirmed that the majority of the generated 
monoclonal cell lines had correct processing of the eGFP tag and a diversity in fluorescent 
intensity (and hence presumably of the fusion protein and syntaxin) as expected from the 
selection of cell lines with different profiles by flow cytometry after the limiting dilution 







4.2.2. Western blot relative expression analysis of the eGFP-syntaxin/SNAP fused 
protein in the different CHO-S engineered monoclonal populations 
Until this point, the CHO-S eGFP-syntaxin/SNAP engineered monoclonal cell lines had been 
selected based upon their fluorescence signal intensity from the eGFP moiety of the fused 
protein and not on the expression of the intact fused protein. Indeed, to facilitate selection 
it was assumed that the level of fluorescence was correlated to the expression of the fused 
protein. Although previous experiments had shown the expression of intact proteins in the 
stably expressing CHO-S engineered pools (see section 3.3.4), the expression profile and 
potential for fragmentation or cleavage of the eGFP from the fusion protein in the different 
monoclonal population could be different due to the selection and expansion procedure 
following limiting dilution cloning. 
For every eGFP-syntaxin engineered CHO-S monoclonal cell line, total protein was 
extracted from a set number of viable cells and detection of the overexpressed eGFP-
syntaxin fusion protein was assessed by western blot analysis using an anti-GFP antibody. 
Indicative resulting signals detected are shown in Figure 4.2A. A signal at the expected size 
was detected for all the different engineered cell lines except for CHO/STX18 H and 
CHO/STX18 C. The expected band sizes were 57, 60, 65 and 56 kDa for the STX7, STX17, 
STX18 and SNAP29 fused protein with eGFP. Low signal was detected for CHO/STX18 F 
even after a long exposition times (30 min) (Figure 4.2A). A similar experiment was then 
undertaken with the different eGFP-STX18 expressing cell lines using an antibody specific 
for STX18. Figure 4.2B confirmed that endogenous STX18 could be detected in all of the 
CHO-S engineered and host cells lines but that no expression of the exogenous eGFP-STX18 
protein was detectable in the CHO/STX18 H cell line whilst for the CHO/STX18 F cell line 
there was a strong positive signal at the expected size (65 kDa). No data was obtained for 
CHO/STX18 C, the cell line was lost before the experiment so no material was available. 
Thus, this data shows that except for the CHO/STX18 H and C cell lines, there was a signal 
at the expected size of the eGFP-syntaxin/SNAP fusion protein confirming expression of the 




In order to try and ascertain the relative difference in expression between individual clones 
of the eGFP-syntaxin/SNAP fusion protein, densitometry analysis was undertaken (Figure 
4.3) based on the signal obtained in Figure 4.2A to rank the expression between the 
different clones. Indeed, one of the goals of generating monoclonal population was to 
obtain cell lines with different profiles of expression. After normalizing the signal intensity 
fƌoŵ the ǁesteƌŶ ďlot eǆpeƌiŵeŶt ǁith the eǆpƌessioŶ of the house keepiŶg geŶe β-actin, it 
was determined that CHO/STX17 J had a higher level of expression than CHO/STX17 K 
(around 1.2 times more). CHO/SNAP29 B was expressing 2.5 times less than CHO/SNAP29 
A, 0.52 compared to 1.32. For STX7 expressing cell lines, CHO/STX7 C (0.86) was expressing 
less than CHO/STX7 A and B (1.08 and 1.05). The difference of expression between 




4.2.3. Analysis of growth profiles during batch culture of the different eGFP-
syntaxin/SNAP CHO-S engineered cell lines 
After confirming the expression of the full length eGFP-syntaxin fusion protein and the 
correct folding of the eGFP tag in the different CHO-S engineered cell lines, the different 
monoclonal cell lines were further characterised with respect to growth characteristics. The 
viable cell concentration and culture viability were therefore monitored during batch 
culture to determine if there was any effect of the overexpression of the target proteins on 
cell growth compared to the host cell line. Experiments were also performed in shake flasks 
and spin tubes to determine if a change of scale or vessel in further experiments would 
impact upon the cell growth characteristics. 
4.2.3.1. Growth assessment of SNARE engineered CHO-S cells in shake flasks 
Cell lines were grown in 125 mL Erlenmeyer flasks with a vented cap and the cultures were 
initially inoculated at a concentration of 0.2 x 106 viable cells/mL with a viability >95% from 
an exponentially growing culture. The viable cell concentration and culture viability were 
then monitored daily using a Vi-CELL instrument. All cell lines were analysed with triplicate 
Đultuƌes ďeiŶg setup. Cells ǁeƌe iŶĐuďated at ϯϳ˚C, ϱ% CO2 and with shaking at 140 rpm. 
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The media used for the experiment was different for the engineered syntaxin/SNAP cell 
lines (CD-CHO + 8 mM L-glutamine + 7.5 µg/mL puromycin) compared to the host cell line 
(CD-CHO + 8 mM L-glutamine) in that the selection agents was maintained in the 
engineered cell lines. 
Figure 4.4 shows the growth curve for the appropriate controls, the initial CHO-S non-
engineered host cell line and two CHO-S eGFP expressing cell lines designated CHO/MRXIP-
GFP L and H. These cell lines were expressing eGFP only from the same vector backbone 
and selection as the syntaxin engineered CHO-S cell lines. The CHO/MRXIP-GFP L eGFP 
expressing cell line and the original CHO-S host cell line showed a similar exponential phase 
growth profile whereas the CHO/MRXIP-GFP H control appeared to potentially have a 
faster growth rate during exponential phase and reached a peak viable cell concentration 
at 6.73 x 106 cells/mL. The growth phase for the CHO/MRXIP-GFP H cell line was also longer 
compared to the other cell lines. Despite the visual differences in the growth profiles 
described (Figure 4.4), there was no significant difference in the growth profiles as 
determined by one way ANOVA analysis of the means of the viable cell numbers at the 
different time points except on days 6 and 8, which showed a difference between the CHO-
MRXIP-GFP H cell line and the other two.  
The culture viability of the CHO/MRXIP-GFP L cell line started to decrease from day 4 under 
the batch culture conditions, falling below 10% on day 11 (Figure 4.4). CHO/MRXIP-GFP H 
showed a drop in culture viability only from day 7, but the reduction was more abrupt and 
the culture had a viability <10% by day 10 compared to the other CHO/MRXIP-GFP cell line. 
The non-engineered host cell line culture viability decreased from day 5 with the culture 
viability falling below 10% by day 10, although the culture was continued until day 13 to be 
able to compare this with the other cell lines. No statistical difference in the culture 
viability between the cell lines was discerned in the first 4 days of culture. As no statistical 
difference was found between the non-engineered host cell line and those engineered to 
express eGFP alone, it was decided to compare the growth results of the different 
engineered eGFP-syntaxin monoclonal population to the host cell line and CHO/MRXIP-GFP 
H. This would allow comparison to the original host cell and to cells which had been 
engineered to have the additional transcriptional and translational burden of eGFP 







After establishing the growth characteristics of the control cell lines, the profiles of the 
eGFP-syntaxin/SNAP engineered cells were compared to these. When comparing the STX7 
expressing cell lines with the controls, there was no consistent pattern between the 
different eGFP-STX7 cell lines and the control with regard to cell growth (Figure 4.5). Up 
until day 4 the growth profiles were similar, however at this point they diverged from each 
other. CHO/STX7 A had a longer exponential phase than the host cell line and CHO/STX7 C, 
and the duration of its exponential phase was similar to CHO/STX7 B and the CHO/MRXIP-
GFP H ĐoŶtƌol although it didŶ͛t oďtaiŶ as high ǀiaďle Đell ĐoŶĐeŶtƌatioŶ ;ϯ.ϵϳ ǆ ϭϬ6 
cells/mL). The CHO/STX7 C exponential phase was shorter compared to the other cell lines 
and the maximum viable cell concentration reached, 1.70 x 106 cells/mL, was the lowest of 
all cell lines in this comparison. Among the STX7 expressing cell lines, CHO/STX7 B had the 
longest exponential phase and reached the highest viable cell concentration of 6.47 x 106 
cells/mL on day 7. The STX7 expressing cell lines were all terminated at day 10 when the 
culture viability dropped below 10%. No statistical difference between the different STX7 
engineered cell lines and the host cell line was observed when comparing the viable cell 
concentrations across the culture. It was clear from the error bars that even within 
triplicate cultures there was variability. 
When the culture viability of STX7 expressing cells was considered, the culture viability of 
the CHO/STX7 C cell line declined first, beginning at day 3 (Figure 4.5). CHO/STX7 A had an 
almost identical culture viability profile as the host cell line with a decline in viability at day 
4 until day 10. The CHO/STX7 B cultures showed an unusual profile with an initial drop in 
viability at the start of the experiment until day 2, whereupon its viability increased until 
day 5, after which the culture viability then decreased until the end of the experiment at 
day 10. Statistical analysis showed that across the 5 first days of culture there was no 
statistical difference in the culture viabilities, however after this there were statistical 






When the growth profiles of the cell lines engineered to express eGFP-STX17 were 
considered, a significant difference in growth was demonstrated compared to the control 
CHO/MRXIP-GFP H cell line (Figure 4.6). Both of the eGFP-STX17 cell lines had a slower 
growth rate, and reached lower maximum viable cell concentrations than the eGFP 
expressing control cell line. When compared to the non-engineered host cell line, 
CHO/STX17 J and K cell lines obtained similar cell concentrations (2.53 x 106, 3.05 x 106 and 
2.49 x 106 viable cells/mL for the host cell line, CHO/STX17 K and CHO/STX17 J respectively) 
but their growth profile was slower (see Figure 4.6). The CHO/STX17 K and J cell lines 
followed a similar exponential phase of growth until day 6 at which point the growth 
profiles diverged. At this point the viable cell concentration of the CHO/STX17 J cell line 
began to decline whilst the viable cell number of the CHO/STX17 K cell line was maintained 
and was statistically different from day 10 to 12. 
When comparing the culture viabilities of the different eGFP-STX17 cell lines (Figure 4.6), a 
decrease in culture viability for CHO/STX17 K was observed at day 1 before an increase 
until day 5. From day 6, the viability of CHO/STX17 K culture reduced slowly until day 13 
with this culture lasting longer than the other cell lines. Viability of the CHO/STX17 J 
cultures started to decline from day 6 in line with that observed for the host cell line, but at 
a slower rate. The CHO/MRXIP-GFP H culture viabilities began to decline later than the 
other cell lines (day 7) but at a faster rate. The monitoring of the growth profiles of the 
STX17 engineered cell lines under batch culture conditions demonstrated that the 
CHO/STX17 K cultures maintained higher cell concentrations and maintained higher culture 






Figure 4.7 shows the growth curve profiles for the cell lines expressing STX18 alongside the 
different controls. The first 4 days of exponential growth were more-or-less identical across 
the different cell lines, although the engineered cell lines expressing STX18 achieved higher 
viable cell concentrations than the host cell line, but not the GFP expressing control cell 
line. CHO/STX18 H cultures had a shorter exponential phase and attained lower cell 
concentrations on average, 5.43 x 106 cells/mL, compared to CHO/STX18 F, C and 
CHO/MRXIP-GFP H cultures. The CHO/STX18 C cultures attained similar viable cell 
concentrations to the control CHO/MRXIP-GFP H cultures, whilst CHO/STX18 F cultures 
reached higher viable cell concentrations (8.16 x 106 compared to 6.73 x 106 and 5.57 x 106 
for CHO/MRXIP-GFP H and CHO/STX18 F respectively). The duration of the batch cultures 
was similar for the three STX18 expressing cell lines, showing a decrease in viable cell 
concentrations from day 7 for CHO/STX18 C and F cultures and day 8 for CHO/STX18 H 
cultures. When the culture viability was compared across the different STX18 expressing 
cell lines (Figure 4.7), the 3 clones had almost identical profiles with a rapid decline in 






Figure 4.8 shows the growth curves for CHO/SNAP29 A and B engineered cell lines, 
including the control cell lines, the original CHO-S and eGFP expressing CHO/MRXIP-GFP H 
cell line. CHO/SNAP29 B cultures showed slower growth compared to the other cell lines 
but reached higher viable cell concentrations than the host cell line. CHO/SNAP29 B 
cultures also had a longer exponential phase (until day 9) than the other cell lines, being 3 
days longer than CHO/MRXIP-GFP H and CHO/SNAP29 A cultures. From day 9, 
CHO/SNAP29 B cultures maintained superior viable cell concentrations compared to the 
other cell lines while showing a slow decrease in viable cell concentration with time. The 
CHO/SNAP29 A culture growth curves were similar to the control CHO/MRXIP-GFP H 
profiles with an exponential phase until day 6 and a decline phase starting at day 8. 
CHO/SNAP29 A cultures achieved similar viable cell concentrations compared to the control 
CHO/MRXIP-GFP H cultures (5.75 x 106 cells/mL compared to 6.73 x 106 cells/mL). 
When comparing the culture viabilities of the cell lines as shown in Figure 4.8, it was 
observed that the CHO/SNAP29 A culture viabilities decreased from day 3, slowly at first 
and more drastically from day 6. CHO/SNAP29 B culture viabilities started to decline at the 
same time as the control CHO/MRXIP-GFP H culture viability at day 6. However, whereas 
CHO/MRXIP-GFP H culture viability dropped suddenly, CHO/SNAP29 B culture viability 
reduced slowly over time until day 13 and was still 19.6% at day 13 when the culture was 
terminated. 
Whereas the growth profiles of the majority of the engineered cell lines did not show any 
significant difference with the host and control cell lines, the CHO/SNAP29 B and 
CHO/STX17 K engineered cell lines demonstrated the ability to maintain viable cell 
concentrations at a higher amount longer than the other cell lines with an observed slow 






4.2.3.2. Growth assessment of SNARE engineered CHO-S cells in spin tubes 
Batch culture growth profiles of a number of the syntaxin/SNAP engineered cells were also 
generated when grown in spin tubes. The aim of this experiment was to investigate if there 
was any impact of change of scale on the cell growth and culture viability of the cell lines to 
be further studied. Spin tubes and Erlenmeyer flasks are different in their geometry so the 
shaking pattern and gas intake are different. Cells were grown in a 10 mL culture volume 
and inoculated at 0.2 x 106 viable cells/mL with an initial viability >95%. Spin tubes with 
ǀeŶted Đap ǁeƌe used aŶd Đells ǁeƌe iŶĐuďated at ϯϳ˚C, with shaking at 220 rpm and in a 
5% CO2 atmosphere. Cell numbers and culture viability were monitored everyday 
throughout cultures using a Vi-CELL instrument. 
Figure 4.9 shows the results obtained using spin tubes for culturing the cell lines 
CHO/STX18 F, CHO/STX17 K, CHO/SNAP29 B, the eGFP control CHO/MRXIP-GFP H and the 
original CHO-S host cell line. CHO/SNAP29 B, CHO/MRXIP-GFP H and the host cell line had 
similar growth rates under these conditions, whilst CHO/STX18 F cultures had a faster 
growth rate and CHO/STX17 K had a slower growth profile. CHO/STX18 H cultures reached 
a maximal viable cell concentration of 14.3 x 106 cells/mL at day 5 of culture under these 
conditions. The exponential phase lasted until day 5 for the different cell lines before they 
entered a stationary phase or decline phase (CHO/STX18 F). Interestingly, a lag phase was 
observed for the different cell lines in the first 24 h, this might be due to the fact cells were 
subculture in 125 mL Erlenmeyer flasks prior the experiment. 
Figure 4.9 reveals the different culture viability measurements across the batch culture. All 
the cell lines showed a decrease in culture viability from day 5, some more rapidly than 
others (CHO/STX18 H). It was also observed that CHO/STX17 K cultures maintained lower 
culture viability compared to the other cell lines across days 2-5 of culture (viability around 
90%). CHO/SNAP29 B and CHO/MRXIP-GFP H cell lines maintained higher levels of culture 






4.3. Characterisation of the impact of engineering over-expression of 
syntaxins and SNAP in CHO-S cells on recombinant protein 
productivity 
After characterisation of the growth profiles of the different eGFP-syntaxin/SNAP over-
expressing generated cell lines, transient transfection experiments were undertaken to 
determine if there was any effect of overexpression of the candidate SNAREs on secreted 
recombinant protein production. Transient transfection is a rapid technique to express 
recombinant material from a cell line (Geisse 2009). The advantages compared to stably 
expressing cell lines are that the method is rapid and can generate material in a few days 
and can be easy to optimise at small scale. The disadvantage is that the recombinant DNA is 
quickly lost from cells as cells grow and divide and that the number of copies of DNA 
introduced into each cell can be very variable. For the purposes of the studies here, two 
model commercial recombinant proteins were used, Adalimumab and Etanercept. 
Adalimumab (trade name Humira) is an IgG1 molecule acting as a TNF-inhibitor used to 
treat inflammatory type arthritis (Burmester et al. 2013). Etanercept (trade name Enbrel) is 
a fused protein of the TNF receptor and the constant heavy chain fragment of an IgG1. As 
for Adalimumab, Etanercept is also used to treat inflammatory type of arthritis (Scott 
2014). The adalimumab plasmid, pAdalimumab, used in this study was previously 
geŶeƌated ďǇ LiŶas Taŵošaitis aŶd the EtaŶeƌĐept plasŵid, pEtanercept, by James Budge. 
4.3.1. Rapid screening of the eGFP-syntaxin/SNAP engineered CHO-S monoclonal 
populations for any impact on the secretory productivity of a recombinant 
protein at small scale 
Transient transfection in 96-DWPs was performed to determine if the overexpression of 
the syntaxin proteins had any effect on the secretory productivity of the cells. 96-DWPs are 
a vessel used for rapid screening of large amounts of different conditions in small volumes. 
The control cell lines (CHO-S, CHO/MRXIP-GFP H) and the engineered cell lines 
(CHO/MRXIP-GFP L, CHO/SNAP29 A, CHO/SNAP29 B, CHO/STX17 J, CHO/STX17 K, 
CHO/STX18 C, CHO/STX18 F, CHO/STX18 H, CHO/STX7 A, CHO/STX7 B and CHO/STX7 C) 
were transiently transfected with 1 µg/mL DNA of Adalumimab or Etanercept plasmid using 
the NovaCHOice reagent. Due to the low volume in the wells (300 µL), 2 plates were 
incubated in parallel for each condition; one to generate material for recombinant protein 
analysis and one dedicated to profiling of cell concentrations and culture viabilities. Cells 
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ǁeƌe iŶĐuďated at ϯϳ˚C, ϱ% CO2, in a 90% humidity atmosphere with shaking at 375 rpm. 
Cell pellets and supernatant were harvested 5 days after transfection for analysis. 
4.3.1.1. Determination of the expression of the recombinant protein Etanercept 
Figure 4.10 shows western blots analysis of Etanercept amounts in day 5 supernatants after 
probing with an anti-heavy chain antibody the amount of material generated across the 
different cell lines investigated. Samples were analysed under non-reduced conditions and 
normalised by loading the same volume of supernatant. Several bands were observed 
(Figure 4.10) and correspond to alternative forms of the recombinant protein produced. 
Under non-reducing conditions, disulphide bonds are preserved so only the full size 
molecule should be recognised (upper band, Figure 4.10). However, whilst the full, intact 
molecule was observed, a band corresponding to half size was also detected that 
corresponds to half-molecule forms (one unit of heavy chain and one unit of TNF receptor) 
and heavy chain fragments present in the media after breaking of the disulphide bonds. 
Indeed, release into the media by dying cells of enzymes with thioredoxin like activity is 
known to cause reduction of recombinant product (Koterba, Borgschulte, and Laird 2012; 
Trexler-Schmidt et al. 2010). On the blot, the upper band detected around 250 kDa 
represents the intact product and the lower band represents the signal from detection of 
half molecule (association of heavy chain fused to the TNF receptor fragment).  
When the relative amounts of product were assessed by western blot across the different 
cell lines, compared to the controls, a more intense band was obtained for the analysis of 
the supernatant material of the replicates from the CHO/STX17 J and CHO/STX17 K cell 
lines (Figure 4.10). The CHO/STX17 J banding was stronger than that from the CHO/STX17 K 
cultures. When investigating the STX18 expressing clones, CHO/STX18 F and H cell lines 
showed a stronger Etanercept banding compared to the controls whereas the analysis of 
material from the STX18 C engineered cell line showed no observable difference in banding 
intensity compared to the control. CHO/STX18 C and CHO/STX18 H cell lines demonstrated 
no expression of eGFP-SNARE target, hence the difference of signal between the cell lines 
was probably due to the cell line performance. The amount of Etanercept from the STX18 F 
cell line was higher than that from the STX18 H cell line as indicated by the stronger 
banding pattern. 
The data presented in Figure 4.10 for the relative amount of Etanercept in the culture 
supernatant from the CHO/SNAP29 A cell line was striking in that lack of a signal for the full 
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length molecule whereas for material from the CHO/SNAP29 B cell line there was a strong 
band present which was more intense than that from the controls. For analysis of material 
from the STX7 expressing cell lines (Figure 4.10), CHO/STX7 C and B appeared to have 
weaker expression than the controls. On-the-other-hand, supernatant material from the 
CHO/STX7 A cell line appeared to give a slightly stronger intensity band than the controls 
for 2 of the replicate cultures while one had a similar intensity to the controls. 
 
Whilst western blotting is a powerful technique for confirming the presence of a specific 
protein and the relative amounts between samples, it is only a semi-quantitative method at 
best. A more quantitative measurement of the amount of Etanercept in supernatant 
samples was therefore also undertaken using a commercially available Octet instrument 
and appropriate probes and standards to determine concentrations in the supernatants. 
Octet measurements were therefore undertaken on the different samples to determine 
their product concentration. Due to the low volumes from the 96 DWPs available, only one 
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measurement of each biological replicate was undertaken (no technical triplicate). Figure 
4.11 summarises the Etanercept product titres obtained on day 5 supernatants after 
transient transfection of the different controls and syntaxin engineered cell lines. The host 
cell line and the two CHO/MRXIP-GFP control clones had a similar concentration of 
Etanecept present in the supernatant samples. The supernatant samples from the 
CHO/STX7 B and CHO/STX7 C cultures had similar amounts of Etanercept present to the 
controls whilst that from the SNAP29 A cell line was very variable across the 3 cultures 
(Figure 4.11). The remaining syntaxin/SNAP engineered cultures all showed an increase in 
Etanercept amounts in the supernatant compared to the control cultures. Two cell lines 
had higher Etanercept concentrations than the others or the controls, CHO/STX17 J and 
CHO/STX18 F with concentrations of 9.94 and 8.91 µg/mL respectively. The other cell lines, 
CHO/STX17 K, CHO/STX18 C, CHO/STX18 H, CHO/SNAP29 B and CHO/STX7 A yielded similar 
concentrations of Etanercept, all superior to the controls. As described above, the samples 
from the CHO/SNAP29 A cultures showed a huge variability in measurement. Specific 
productivity was not calculated due to the low number of data points. 
 
Figure 4.12 shows the viable cell concentration at day 5 of batch culture after transfection 
for the different engineered cells and controls. CHO/STX17 J, CHO/STX18 H and CHO/STX7 
A cell lines had low viable cell concentrations after 5 days of culture compared to the other 
cell lines and controls. CHO/MRXIP-GFP controls had higher viable cell concentrations 5 
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days post-transfection than the initial host cell line and all other cell lines. CHO/SNAP29 A 
and B cultures had similar viable cell concentrations after 5 days, higher than the host cell 
line. The CHO/STX17 K cultures had a much higher viable cell number compared to CHO/ 
STX17 J (7.59.106 and 1.37.106 cells/mL respectively) on day 5 of the culture. CHO/STX18 C 
and CHO/STX18 F cultures had a similar viable cell concentration to the host cell line 5 days 
post-transfection whereas CHO/STX18 H cultures had a reduced viable cell concentration. 
Each clone of CHO/STX7 had a different viable cell concentration 5 days post-transfection 
during batch culture. CHO/STX7 C had a similar viable cell number to the host cell line while 
the CHO/STX7 B viable cell concentration was higher than that of the host. CHO/STX7 A 
cultures had a low viable cell concentration compared to the host cell line. No link between 
titre and viable cell line concentration was observed. Indeed, CHO/MRXIP-GFP H and L did 
not have a higher titre than that from other cell lines despite having higher viable cell 
concentrations on day 5 whereas CHO/STX17 J, CHO/STX18 H and CHO/STX7 A with lower 
viable cell concentrations had higher Etanercept titre. 
Two profiles were noted for culture viability across the cell lines investigated (Figure 4.12), 
cell lines having a viability >80% after 5 days or having a viability between 50 and 70%. The 
host cell line and the empty vector controls had culture viabilities over 80%, as did 
CHO/SNAP29 B, CHO/STX17 K, CHO/STX18 C and CHO/STX18 F cultures. Cell lines 
CHO/STX17 J, CHO/STX18 H and CHO/STX7 A had a much lower viable cell concentration at 






4.3.1.2. Determination of the expression of the recombinant protein Adalimumab 
As for the Etanercept analysis, Figure 4.13 shows western blot analysis for the transient 
experiment in DWPs for secreted Adalimumab production from the control and different 
syntaxin/SNAP engineered cell lines. As for the results for the Etanercept analysis, samples 
were analysed under non-reduced conditions and normalised by using identical volumes. 
The upper band observed corresponds to the full IgG molecule (250 kDa), the middle band 
corresponds to half molecule (>150 kDa) and the lower band corresponds to heavy chain 
(>100 kDa) (Figure 4.13). A more intense signal was obtained for the different replicates of 
CHO/STX17 J and CHO/STX17 K cell line supernatants compared to the controls and 
samples from the CHO/STX17 J cell line replicates had a stronger signal than CHO/STX17 K. 
For STX18 expressing cell lines, CHO/STX18 F and CHO/STX18 H had stronger band 
intensities for the IgG expression than the controls while the samples from the CHO/STX18 
C cell line had a similar band intensity. Analysis of samples from the CHO/SNAP29 B cell line 
had a strong band intensity compared to the controls whereas samples from the 
CHO/SNAP29 A cell line had a weaker signal compared to the controls (Figure 4.13). 
Samples from CHO/STX7 A and B had similar band intensities as the controls suggesting 
that the amount of IgG expressed was similar whilst samples from the transient 





Figure 4.14 shows the Octet analysis measurement on the different supernatants on day 5 
after transient transfection with pAdalimumab to determine IgG concentration. The host 
cell line and CHO/MRXIP-GFP H and L cell lines had a similar IgG titre after 5 days. The 
CHO/STX18 H cell line yielded the highest average titre of 8.1 µg/mL of Adalimumab 
although there was high variability between the replicate samples. The CHO/STX18 F, 
CHO/STX17 J and CHO/SNAP29 B engineered cell lines all yielded a similar concentration of 
IgG product as determined by the Octet analysis to that of the CHO/STX18 H cell line 
without as much variability across the replicate samples. The titre of the cell lines 
expressing STX7 were more-or-less identical and not significantly different from the 
controls as was the IgG yield from the CHO/SNAP29 A, CHO/STX17 K and CHO/STX18 C cell 




When the viable cell number 5 days post-transfection of the Adalimumab plasmid into the 
different cell lines was investigated, a similar pattern to that observed in the transient DWP 
experiment for Etanercept was observed (Figure 4.15). On day 5, the CHO/MRXIP-GFP H 
and L cell lines had the highest viable cell concentrations whereas CHO/STX17 J, 
CHO/STX18 H and CHO/STX7 A cell lines had low viable cell concentrations at day 5 
compared to the other cell lines (Figure 4.15). The host cell line had a comparable viable 
cell concentration to the CHO/SNAP29 A, CHO/STX18 C and CHO/STX7 B cell lines. Cell lines 
CHO/SNAP29 B and CHO/STX17 K had similar viable cell concentrations but these were 
statistically lower than the control CHO/MRXIP-GFP cell lines. The viable cell concentration 
in CHO/SNAP29 B cell line cultures was higher than that of the CHO/SNAP29 A cell line 
whilst CHO/STX17 K had a considerable difference in viable concentration compared to the 
CHO/STX17 J cell line. Cell lines expressing STX7 also had different viable cell 
concentrations on day 5 after transfection for each clone, with CHO/STX7 B having the 
highest and CHO/STX7 A the lowest (Figure 4.15). 
Culture viability was also monitored at day 5 of the culture after transient transfection and 
culture viabilities are reported in Figure 4.15. The two different groups or trends observed 
for the previous transient transfection with pEtanercept with regard to culture viability 
were once again observed. The two groups were split into those with cultures with a 
viability of approximately 80% such as the controls (host cell line, CHO/MRXIP-GFP H and L) 
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and cell lines with a culture viability around 50%. Except for cell line CHO/STX18 C, it was 




4.3.2. Investigating the impact of syntaxin/SNAP engineering of CHO-S cells on 
secretory productivity under fed-batch culture conditions 
The previous work described in the above sections assessed the impact of SNARE 
engineering of CHO cells on the secretory productivity of two model biotherapeutic 
proteins under batch culture conditions. A common procedure to increase product titre 
and cell growth is to implement a feed strategy in the process (Xie, Zhou, and Robinson 
2003), turning the process into a fed batch culture. Through the culture, cells will consume 
different metabolites present in the media at different rates and produce by-products such 
as lactate and ammonium that are toxic to the cells (Hassell, Gleave, and Butler 1991; Lao 
and Toth 1997). Feeding strategies are specifically design to supply the cells with fresh 
metabolites that are reduced or depleted from the media and maintain high levels of 
carbon source in order to ensure cells obtain the highest possible maximum viable cell 
concentration in the shortest possible time and then to maintain the cells in a stationary 
phase whilst production of the target biotherapeutic protein is achieved. The choice of the 
feed and the feeding strategy vary depending on the cell line and media used. In the case of 
the work here, a commercially available efficient feed B was used because it is 
recommended by the manufacturer when the principal media is CD-CHO. The fed batch 
experiments undertaken here were completed using spin tubes which are vessels with a 
typical working volume of 10 mL, providing more material for analysis than the 96 DWPs. 
Cultures were initially inoculated at 0.5 x 106 viable cells/mL with a viability >95%. Transient 
transfection was then undertaken with 1 µg/mL DNA using NovaCHOice reagent with either 
the pEtanercept or pAdalimumab expression plasmids to allow transient expression of the 
target molecules. The starting volume of the culture was 10 mL in spin tubes with two 
sampling points, day 3 and 5 post-transfection. After sampling on day 3, 15% v/v Efficient 
feed B ǁas added to Đultuƌes as a feed stƌategǇ. Cultuƌes ǁeƌe iŶĐuďated at ϯϳ˚C ǁith 
shaking at 240 rpm and 5% CO2 was supplemented manually. 
4.3.2.1. Fed-batch analysis of Adalumimab expression from syntaxin/SNAP engineered 
CHO-S cells 
Western blot analysis on day 5 post-transfection supernatant samples allowed an initial 
qualitative assessment of relative product yields from the different cell lines investigated 
(Figure 4.16). There was a small visual difference between the banding intensity, and hence 
expression, of the IgG molecule from the host cell line and from the CHO/MRXIP-GFP H cell 
129 
 
lines that had a more intense band (Figure 4.16). The banding pattern, and hence IgG 
expression, from the CHO/STX17 J samples were more intense than the controls and 
CHO/STX17 K and STX18 F whilst those from the CHO/STX17 K cell line were also more 
intense than those from the controls. For samples from the CHO/STX18 F cell line, the band 
intensity was much more similar to that from the CHO/MRXIP-GFP H samples. The 
expression, as determined by western blot, from the CHO/SNAP29 B cell line was higher 
than the controls and the CHO/SNAP29 A cell line. The expression from the other cell lines 
showed no consistent patterns between replicates and cell lines (Figure 4.16).  
 
The western blot analysis in figure 4.16 suggested that under fed-batch conditions some of 
the cell lines yielded higher IgG concentrations than the control samples and therefore a 
more quantitative analysis was undertaken. Figure 4.17 presents Octet analysis of 
supernatant samples from day 3 and 5 for the transient production of Adalimumab under 
the described fed-batch conditions. The CHO/STX17 J cell line, with a final concentration at 
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day 5 of 3.04 µg/mL (5-fold more than the host cell line), had the highest concentration of 
IgG in agreement with the western blot data. The supernatants from cell lines CHO/STX17 
K, CHO/STX7 B and CHO/STX18 F also had a significantly higher concentration of IgG 
compared to the host cell line whereas the cell lines CHO/MRXIP-GFP H, CHO/SNAP29 A 
and B had a similar titre to the controls (Figure 4.17). The titre profiles between the 
different cells lines at day 5 were reflective of those at day 3 and there was not a large 
increase in titre between day 3 and 5, suggesting that most of the expression of the 
recombinant product happened in the first 3 days. Compared to the experiment carried in 
96 DWPs (see section 4.2.3), the range of titres obtained were reduced. 
 
When the viable cell concentrations form the fed-batch cultures were analysed (Figure 
4.18), different profiles were obvious. The host cell line and CHO/STX17 J cell line viable cell 
number declined during across the whole culture period. Cell lines CHO/STX18 F and 
CHO/SNAP29 B initially showed a decline in viable cell numbers before increasing between 
day 3 and 5. Some cell lines had a constant increase in viable cell number across the 
experiment such as CHO/STX7 B, CHO/MRXIP-GFP H and CHO/STX17 K. Cell lines 
CHO/SNAP29 A and CHO/STX7 C cultures had a small increase in viable cell number at day 3 
before decreasing in viable cell concentration. With regard to monitoring culture viability 
(Figure 4.18), all the cell lines had a decreased in viability at day 3 compared to the initial 
viability at the start of the experiment. The decrease in viability was more prominent for 
the SNAP29 B cell line than the other cell lines. From day 3 (feed day), culture viability 
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either recovered or did not (Figure 4.18) in individual cell lines. During the culture it was 




The cell specific productivity was also calculated for the different cell lines for the 
production of Adalimumab and the results are displayed in Figure 4.19. The CHO/STX17 J 
cell line had the highest specific productivity at 1.32 pg/cell/day of Adalumimab. All the 
other cell lines had specific productivity between 0.01 to 0.49 pg/cell/day but were not 
statistically higher than that of the control cell lines. Some cell lines displayed a high 
variability for their specific productivity value between replicate cultures than others, 
notably the host cell line. Clumping observed of the host cell line during the experiment 
might explain this as determination of viable cell numbers is more difficult when the cells 
are clumped. Indeed, calculation of specific production relies on determining viable cell 
concentration values and having non homogenous mixtures (notably with the presence of 
cells clumps) will result in the calculation of incorrect viable cell numbers and hence 
specific productivities. 
 
4.3.2.2. Fed-batch analysis of Etanercept expression from syntaxin/SNAP engineered 
CHO-S cells  
As for the model IgG used to asses impact on secretory productivity of the engineered 
syntaxin/SNAP CHO-S cells, the expression of the model Fc-TNFR fusion protein was also 
assessed under fed-batch culture conditions. Figure 4.20 reports the relative expression of 
as determined by western blot analysis on non-reduced supernatant samples at day 5 post-
transfection from transient production of Etanercept. The intensity of the bands observed 
after incubation of the membrane with anti-heavy chain showed similar expression levels 
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from the host cell line and the CHO/MRXIP-GFP H control cell line. The expression from the 
CHO/SNAP29 A cell line was similar to the control while that from the CHO/SNAP29 B cell 
line was lower than the controls (Figure 4.20). The expression from the CHO/STX7 C and B 
cell lines was also similar to that observed from the controls. Analysis of samples from the 
CHO/STX17 J cell line suggested that expression was higher for at least two biological 
replicates as indicated by a more intense band. Analysis of CHO/STX18 F samples suggested 
that there might be a small increase in the expression of Etanercept compared to the 
controls but this was not the case for the CHO/STX17 K cell line where the band intensity 
was less than that for the controls. 
 
In addition to the qualitative analysis of samples by western blot, more quantitative Octet 
based analysis was also undertaken and the results are reported in Figure 4.21. From this 
analysis the CHO/MRXIP-GFP H, CHO/SNAP29 B and particularly CHO/STX17 K cell lines 
showed a decrease in product titre froŵ daǇ ϯ to daǇ ϱ. This ǁasŶ͛t oďseƌǀed iŶ the 
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experiment using Adalumimab plasmid (see section 4.2.5.1). A possible explanation, 
especially for CHO/STX17 K could be the mixing of the sample days during analysis as this 
decrease was not obvious from the western analysis. Cell line CHO/STX17 J had the highest 
titre at day 5 of 4.16 µg/mL whilst cell lines CHO/SNAP29 A, CHO/STX18 F, CHO/STX17 K, 
CHO/STX7 B and CHO/STX7 C expressed more-or-less the same amount of Etanercept as 
the host cell line. For the majority of the cell lines, it was observed that the difference in 
titre between day 3 and day 5 was small, implying that the majority of the recombinant 
protein production had been completed before day 3 and that the feeding on day 3 did not 
positively impact on the production of the Etanercept material. This may also reflect the 
transient nature of the expression whereby the plasmid is diluted out from cells as they 
divide such that expression can be rapidly lost as the cells grow and divide. 
 
Figure 4.22 reports the viable cell concentration and culture viability recorded on days 3 
and 5 of the transient transfection experiment. The host cell line showed a decrease in 
viable cell concentration from day 0 to day 5 while the CHO/MRXIP-GFP H control showed 
an increase in viable cell concentration during the experiment (Figure 4.22). Several cell 
lines showed little change in their viable cell concentration during the experiment, 
including CHO/STX7 C, CHO/SNAP29 A, CHO/STX18 F. Cell lines CHO/SNAP29 B, CHO/STX17 
K and CHO/STX7 B had a decrease in viable cell concentration from day 0 to day 3 before 
increasing between days 3 and 5.  
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When comparing the culture viability of the different cell lines during the transient 
expression of the recombinant protein Etanercept (Figure 4.22), all cell lines had a decrease 
in culture viability from day 0 to day 3. CHO/SNAP29 B was the cell line with the greatest 
decrease with a culture viability <30% at day 3. Only two cell lines, CHO/STX17 J and the 
host cell line showed a decrease in culture viability across the whole experiment while the 
other cell lines showed an increase in culture viability from day 3 to 5. CHO/MRXIP-GFP H 






The calculated specific productivity for the transient experiment for the production of 
Etanercept for the different cell lines is reported in Figure 4.23. Three cell lines appeared to 
have a negative specific productivity or qp in this experiment, which is clearly not possible 
and reflects the fact that the product titre decreased between day 3 and day 5 while the 
viable cell concentration was increasing. The highest specific productivity was from the 
CHO/STX17 J cell line for the transient production of Etanercept at 5.9 pg/cell/day. 
 
4.3.3. Larger scale transient expression of Etanercept and Adalimumab from the 
syntaxin/SNAP engineered CHO-S cells 
A larger scale transient experiment was performed to allow monitoring of the culture 
through a longer period of time (more sampling points) and study the impact on 
productivity of the syntaxin/SNAP engineered cell lines. Using larger volumes and 13 
different cell lines required transfection of larger numbers of cells. The method of 
transfection used for this transient transfection was electroporation instead of NovaCHOice 
reagent. Compared to NovaCHOice, electroporation is a method able to transfect 
effectively and easily a higher number of cells (Kim and Eberwine 2010). The change of 
scale and method of transfection allowed an investigation into any impact on the 
productivity of the method and scale. 
Cell lines were electroporated with 40 µg DNA of pEtanercept or pAdalimumab using 1 x 
107 viable cells in order to inoculate 125 mL Erlenmeyer flasks with vented caps at 0.3 x 106 
viable cells/mL in 20 mL of CD-CHO supplemented with 8 mM L-glutamine. Cells were 
138 
 
iŶĐuďated at ϯϳ˚C, ϱ% CO2 and 140 rpm. Cell growth and culture viability were monitored 
every 2 days from day 2 using a Vi-CELL instrument. Alongside the Erlenmeyer flasks, 96-
DWPs were inoculated with the same electroporated cell lines. Two DWPs were inoculated 
for each recombinant protein, one sampled at day 2 and the other at day 4. The goal was to 
confirm the capability of 96 DWPs to mimic the results obtained at the larger scale. 
4.3.3.1. Larger scale transient expression of Etanercept from the syntaxin/SNAP 
engineered CHO-S cells 
4.3.3.1.1. Impact on secreted Etanercept productivity of syntaxin/SNAP engineering of 
CHO-S cells 
Western blot analyses on supernatant samples harvested at day 8 of batch culture are 
reported in Figure 4.24. Samples were analysed under non-reducing conditions and 
normalised by loading equal volumes. Controls showed the same banding intensity (host 
cell line, CHO/MRXIP-GFP H and L) indicative of similar expression of Etanercept. The 
CHO/SNAP29 B cell line had higher expression than CHO/SNAP29 A and the controls as 
shown by a more intense band whilst expression from the CHO/SNAP29 A cell line was 
lower than for the controls. The expression from the CHO/STX7 C and B and CHO/STX18 H 
cell lines was similar to the controls. On-the-other-hand, the CHO/STX18 F cell line 
appeared to have mainly half-molecule product in the supernatant, suggesting degradation 
in the supernatant or secretion of only half-molecule. Expression from the CHO/STX17 J cell 





Figure 4.25 summarises the Etanercept titre measured in supernatant samples by Octet for 
each sampling day when transiently expressing Etanercept. The cell line yielding the highest 
concentration at day 8 was CHO/SNAP29 B at 5.38 µg/mL, 1.6 times more than the host cell 
lines or CHO/MRXIP-GFP H cell line. The cell line CHO/STX17 J also gave a similar yield at 
day 8 as the CHO/SNAP29 B cell line. All the other cell lines yielded very similar 




Figure 4.26 reports viable cell number and culture viability data across the batch culture 
and transient expression of pEtanercept. The viable cell concentration trend was similar for 
the different cell lines except for the untransfected control and CHO/STX18 H cell line. The 
cell lines showed no or little growth until day 2, suggesting a lag phase and from there the 
viable cell number increased until day 6 before plateauing or decreasing. The untransfected 
control had a more rapid and exponential growth without any lag phase reaching a 
maximal viable cell concentration on day 4 of 7.51 x 106 cells/mL. No plateau was observed 
for the untransfected control and viable cell concentration decreased continuously from 
day 4 to 8. Even with a delay in growth compared to the untransfected control, the 
CHO/STX18 F cell line reached the highest viable cell concentration of 8.45 x 106 cells/mL 
on day 6. Most of the cell lines achieved comparable viable cell concentrations on day 6. 
Cell line CHO/STX18 H was the only one to show a decrease in viable cell concentration 
from the beginning of the experiment.  
The culture viability profile was similar also for all the transfected cells (Figure 4.26) except 
the untransfected control. Culture viability was decreased at day 2 from where it started to 
recover until day 6. At day 6 the culture viability dropped until day 8. CHO/STX18 H had the 
biggest decrease in viability at day 2 but recovered rapidly. The untransfected control had 
no drop in culture viability until day 4 where upon viability reduced rapidly. It was observed 
that some of the cell lines maintained higher culture viabilities than others at day 8, notably 






Figure 4.27 reports the cell specific productivity of the different cell lines for the transient 
production of Etanercept. CHO/STX17 J had the highest cell specific productivity of 0.25 
pg/cell/day. Whilst CHO/SNAP29 B yielded the highest overall titre at day 8 of culture, its 
specific productivity was not different from the host cell line and the different controls. 
 
4.3.3.1.2. Evaluation of the performance of the different syntaxin/SNAP engineered 
CHO-S cell lines at two different scales, 96-DWP and 125 mL Erlenmeyer flasks, 
for scalability purposes 
Figure 4.28 shows the comparison of Etanercept product titre at day 2 and 4 as determined 
by Octet analysis between the two culturing systems, 96-DWPs and shaking Erlenmeyer 
flask batch cultures. For the statistical analysis, a t-test was used instead of one way Anova 
analysis because Anova analysis is designed for analysis of multiple components whereas a 
t-test is more relevant for comparison of one mean against another. After statistical 
analysis between the conditions at day 2 and 4, no significant difference was found in the 
titres between the culture systems for the majority of the cell lines except for that from cell 
lines CHO/SNAP29 A and B at day 4 and CHO/STX18 F, CHO/SNAP29 B and CHO/MRXIP-GFP 
L at day 2. Even when statistical difference was confirmed, the difference between the two 




4.3.3.2. Larger scale transient expression of Adalimumab from the syntaxin/SNAP 
engineered CHO-S cells 
4.3.3.2.1. Impact on secreted adalimumab productivity of syntaxin/SNAP engineering of 
CHO-S cells 
Western blot analysis of supernatant samples from day 8 of batch culture after transient 
transfection with pAdalimumab of the different syntaxin/SNAP engineered CHO-S cell lines 
(Figure 4.29) demonstrated that the host cell line and the different empty vector controls 
had a similar level of Adalimumab expression. The CHO/SNAP29 B sample had a more 
intense band than samples from the CHO/SNAP29 A cell line and the controls, indicative of 
higher expression. The band intensity from the CHO/SNAP29 A samples suggest that the 
level of expression from this cell line is reduced compared to the host cell line and 
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CHO/MRXIP-GFP control cell lines. The expression from the CHO/STX17 K cell line was 
higher than the controls as indicated by a more intense band, whereas the expression from 
the CHO/STX17 J cell line was similar to the controls. The CHO/STX7 C samples had two 
biological replicates with a band intensity higher than the controls whereas the last 
replicate had an intensity similar to the controls. The CHO/STX7 B cell line yield similar 
expression profiles to the controls. Finally, the CHO/STX18 H cell line had lower expression 
of Adalimumab than the controls whereas two of the CHO/STX18 F cell line generally had 




More quantitative Adalimumab product titres across the different days of the batch culture 
transient expression with pAdalimumab are reported in Figure 4.30. The cell line with the 
highest product titre at day 8 was CHO/STX17 K at 3.18 µg/mL. The host cell line and the 
empty vectors had similar product titres with no statistical difference between them. The 
cell lines CHO/STX7 B and CHO/STX7 C also yielded a similar amount of Adalimumab. The 
cell line CHO/STX17 K expressed considerably more Adalimumab than the CHO/STX17 J cell 
line (2.5 times more) whilst the CHO/STX18 F cell line expressed 2.6 times more than the 
CHO/STX18 H cell line and the CHO/SNAP29 B cell line 2.2 times more than the 
CHO/SNAP29 A cell line. The CHO/SNAP29 B, CHO/STX18 F and CHO/ STX17 J cell lines 
yielded a higher Adalimumab titre than the host cell line which was statistically different 
(Figure 4.30). 
 
Figure 4.31 reports growth data of the cell lines during the batch culture transient 
Adalimumab expression experiment. The cell growth profiles appear similar for the 
different transfected cell lines except for the untransfected cell line. A lag phase was 
observed between day 0 and day 2 with no growth or decrease in viable cell concentration. 
After day 2, all the cell lines went into exponential cell growth until day 6. At day 6 the 
viable cell numbers plateaued except for the CHO/STX18 F cell line that decreased in viable 
cell number. The CHO/STX18 F cell line obtained the highest viable cell concentration at 
7.86 x 106 cells/mL on day 6. This was more than the untransfected control that had a 
maximum viable cell concentration of 6.41 x 106 cells/mL on day 6.  
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The culture viability profiles of the transient experiment are also reported in Figure 4.31. All 
the transfected cell lines showed a drop in culture viability at day 2 compared to day 0 but 
recovered from there until day 6. At day 6 the culture viability plateaued or declined. This 
was different for the host cell lines that showed recovery and maintenance of culture 
viability from day 2 until the end of the experiment. Some of the transfected cell lines, such 
as CHO/SNAP29 B and CHO/STX17 K, maintained high viability until the last day of the 
experiment with a culture viability around 93%. The untransfected control showed no 
reduction in culture viability at day 2 but this started to decrease slowly from day 4 before 






Figure 4.32 reports the specific productivity measurements for the different cell lines when 
transiently expressing the model molecule, Adalimumab. Not all the data points were used 
to calculate the specific productivity, with only the data from day 4 to 8. Some cell lines had 
a low titre of the product of interest at day 2 and the measurements were below the limit 
of detection when using the Octet instrument. These points were therefore not included in 
the calculation of specific productivity for all the cell lines. The highest specific productivity 
achieved was 0.14 pg/cell/day by the CHO/STX17 K cell line. The cell lines CHO/STX7 B, 
CHO/STX7 C, CHO/STX17 J were also statistically superior to the host cell line (Figure 4.32). 
 
4.3.3.2.2. Evaluation of the performance of the different syntaxin/SNAP engineered 
CHO-S cell lines at two different scales, 96-DWP and 125 mL Erlenmeyer flasks, 
for scalability purposes 
CoŵpaƌisoŶ of the tǁo ŵethods of Đultuƌe ǁasŶ͛t possiďle foƌ Adalimumab expression 
from the syntaxin/SNAP CHO-S engineered cell lines. Indeed, no detectable expression 
could be determined for DWP samples at day 2 or day 4 for most of the cell lines. Only 3 
cell lines gave detectable expression, CHO/STX17 K, CHO/STX17 J and CHO/SNAP29 B at 
day 4. To perform technical triplicates, the samples needed to be diluted and this resulted 
in the sample concentration being below the limit of detection of the instrument explaining 
the lack of data for the early points at day 2. Where comparisons were possible, the data 





This chapter is focused on the characterisation of the different monoclonal syntaxin/SNAP 
engineered CHO-S cell populations generated and described in Chapter 3. The investigated 
cell lines overexpressing SNARE-eGFP fused proteins were analysed with respect to how 
the engineering, and level or amount of over-expression, impacted upon the growth 
properties of the cells and/or the secretory capacity of the cell using model recombinant 
proteins. To assess any impact on secretory capacity, transient transfection experiments 
were performed and any impact on cell growth or secretory productivity assessed.  
After the selection of the different monoclonal populations in Chapter 3 and their 
adaptation to suspension environment, cells were cryopreserved for further use. When the 
cells were revived for the studies described in this chapter, some cell lines never recovered 
or were lost at different stages due to adaptation problems. No noticeable trend was 
observed with regard to a particular effect of overexpression of specific targets of interest 
that related to non-recovery from cryopreservation or death of the culture after recovery 
over time. The CHO/SNAP29 I cell line did not recover from cryopreservation whilst the cell 
lines CHO/STX17 C and CHO/STX18 C did initially recover from cryopreservation but were 
subsequently lost during subculture. 
To confirm proper folding of the eGFP tag in the different monoclonal cell lines, microscopy 
analysis was performed. The different cell lines demonstrated fluorescent expression at 
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different levels, except for the CHO/MRXIP-GFP H cell line, indicative of varying eGFP and 
hence syntaxin/SNAP expression. The intensity differences by microscopy observation 
related to the flow cytometry profiles of the monoclonal cell lines; cells with low 
fluorescence intensity as determined by fluorescence microscopy analysis had a smaller 
shift in their fluorescence intensity compared to control samples as determined by flow 
cytometry analysis. Surprisingly, no fluorescence could be detected in the CHO/MRXIP-GFP 
H cell line by microscopy whereas analysis on the parental cell line (microscopy, western 
blot analysis and flow cytometry) suggested the presence of a properly folded eGFP 
protein. As the cell lines were prepared in a similar manner, the most probable reason for 
absence of fluorescence is a rapid turnover in the cells so the amount of fluorescence 
observed was low and not detectable under the conditions this experiment was 
undertaken.  
The different clonal populations obtained after limiting dilution cloning had all been 
exposed to a stressful selection process. Previous data showed that the parental cell lines 
were not all expressing predominantly the intact fusion protein such as CHO/STX18 (see 
section 3.3.4). Western blot analysis using an anti-GFP antibody on cell lysates was 
therefore performed to determine the relative level of expression of the fused protein for 
each cell line. Except for cell lines expressing STX18, detection of a signal for the intact 
fusion protein was at the expected size. For cell lines expressing STX18, only CHO/STX18 F 
had a weak signal after long exposure of the membrane to film (30 min) when using the 
anti-GFP antibody. Western blot analysis with a specific antibody for the detection of STX18 
was then performed for STX18 expressing cell lines. Low or an absence of signal could be an 
indication of degradation of the fusion protein or cleavage of the eGFP tag. A Fluorescent 
signal was observed by flow cytometry and fluorescence microscopy analysis so cleavage of 
the eGFP tag could be a viable explanation as to why the full length product was not 
observed. When analysing samples with the anti-STX18 antibody, the CHO/STX18 F cell line 
samples contained two bands as expected, one for the full size fusion protein around 65 
kDa and one representing the endogenous STX18 expression of the protein. A stronger 
signal for the endogenous protein in CHO/STX18 H compared to the controls would have 
suggested a cleavage between the eGFP and the syntaxin but still overexpression of the 
protein of interest. Here, the most plausible explanation is cleavage of the eGFP and 
degradation of the syntaxin part, leaving a free functional eGFP tag responsible for the 
signal in the microscopy and flow cytometry experiments. No analysis was performed on 
151 
 
the CHO/STX18 C cell line because it perished during subculture and no successful revival 
was achieved. 
Further analysis on western blot data was undertaken using densitometry and the free 
software ImageJ. Densitometry is a technique to measure band signal intensity and 
compare the relative intensity of different bands. Due to the use of anti-β-actin antibody in 
parallel with the anti-GFP aŶtiďodǇ, deteĐtioŶ of leǀels of β-aĐtiŶ ǁas possiďle. β-actin is a 
house keeping gene that is assumed to be expressed to the same extent across cells from 
the same parental host cell line (i.e. is inǀaƌiaŶtͿ. The sigŶal foƌ β-actin was used as 
normaliser to compare the relative level of expression of the fused proteins across the 
different cell lines. It was then possible to quantify the differences in expression, for 
example CHO/STX17 J expressed 1.2 times more of STX17-eGFP fused protein than 
CHO/STX17 K. These results generally correlated with the flow cytometry results and the 
fluorescence microscopy observations. 
After confirming the relative level of expression of the specific SNARE-eGFP fusion proteins 
in each selected cell line and confirmation of the expression of an intact fusion protein with 
a correctly processed eGFP tag, growth profiles under batch-culture conditions were 
generated to determine if the overexpression of the different ectopic proteins had any 
effect on the growth of the cells. Indeed, overexpression of proteins in cells generates an 
additional burden on the cell. Moreover, when overexpression is chosen for the study of a 
protein function, strong promoters are typically used, potentially saturating the cellular 
capacity with the production of one protein (Xia et al. 2006). This can be detrimental to the 
cell and activate stress pathways in response such as the unfolded protein response (UPR). 
On the other hand, overexpression of proteins involved in controlling cell proliferation can 
also enhance culture viability and cell growth (Doolan et al. 2010; Jaluria et al. 2007). 
When comparing the growth of the host cell line and the eGFP expressing only controls 
CHO/MRXIP-GFP H and L, no statistical difference was generally observed. Nonetheless, 
whilst CHO/SMRXIP-GFP L had an almost identical growth profile to the host cell line, the 
CHO/MRXIP-GFP H cell line appeared to have a faster growth rate and reached higher 
viable cell concentrations. This probably reflects biological diversity within the host cell 
population that becomes apparent when the host cell line is cloned. Nevertheless, this data 
suggests that the introduction of the backbone alone expressing eGFP and a resistance 
gene for puromycin did not confer any dis/advantage on cell growth. 
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The analysis of the growth and culture viability profiles of the control and syntaxin/SNAP 
engineered cell lines showed no significant impact of the ectopic expression of the fusion 
protein on growth. However, the culture viability and duration of culture was impacted in 
some of the engineered cell lines compared to the controls with extended periods of 
growth or stationary phase. The cell lines with lower over-expression of STX17, CHO/STX17 
K, and SNAP29, CHO/SNAP29 B, were positively impacted with regard to the duration of 
cell growth but not high expression cell lines. STX17 and SNAP29 are proteins involved in 
autophagy and notably the formation of the autophagosome and fusion with the lysosome 
(Burgo et al. 2012; Guo et al. 2014; Hegedus et al. 2013; Kumar et al. 2018; Morelli et al. 
2014). The autophagosome is a double-membrane vesicle, encapsulating unwanted 
molecules such as protein aggregates, damaged mitochondria, and no longer required 
proteins, that will fuse with a lysosome for degradation of the content (Shibutani and 
Yoshimori 2014). Autophagy is triggered by stress such as energy deprivation or nutrient 
starvation (He and Klionsky 2009) which are generally experienced by the cell during batch 
culture late in the culture. By potentially influencing the formation and maturation of the 
autophagosome, over-expression of STX17 and SNAP29 might well improve the 
degradation and turnover of proteins and thus allow amino acids to be liberated to 
maintain protein synthesis and support other metabolic pathways, hence allowing the cell 
lines to maintain higher culture viability levels for longer periods. In support of this, other 
reports have shown that engineering of the autophagosome can lead to prolonged culture 
times (Lee et al. 2013; Lee and Lee 2012). 
After analysing the impact of the ectopic over-expression of the different eGFP-
syntaxin/SNAP fusion proteins of interest on growth profiles, transient transfection was 
performed to determine the effect on the transient secretory productivity of the cell lines. 
Any effects on secretory productivity were studied using two models proteins, Adalimumab 
and Etanercept. IgG molecules were chosen as model proteins because they are relevant in 
an industrial context with therapeutic antibodies representing around 25% of approved 
molecules by the FDA (Walsh 2014). 
The first transient transfection experiment was undertaken using a 96-DWP culturing 
approach and NovaCHOice transfection reagent. DWPs are a convenient platform for the 
rapid screening of multiple cell lines and conditions. The western blot analysis confirmed 
the cells could transiently produce the model recombinant proteins. Western blot is only a 
semi-quantitative method but relative comparisons were possible between the different 
153 
 
cell lines, especially when samples are processed in the same way. It was possible to detect 
an increase in secretory productivity from the cell lines CHO/SNAP29 B, CHO/STX17 J and 
CHO/STX18 F compared to the control and host cell lines for both model proteins. The 
results were then confirmed by a more quantitative method using an Octet instrument that 
allowed the determination of the actual concentration of the target molecule in the 
supernatant.  
Cell line CHO/STX17 K also showed an increase in productivity but to a smaller extent than 
STX17 J. The CHO/STX17 J cell line was shown to express more fusion protein than the 
CHO/STX17 K cell line and the impact on productivity might therefore be proportional to 
the over-expression of STX17-eGP protein. This was the opposite for the SNAP29 
expressing cell lines. Indeed, CHO/SNAP29 B that expressed lower levels of fusion protein 
than CHO/SNAP29 A was more productive. In this case, high levels of SNAP29 might be 
toxic for the cell or have an antagonist effect on productivity explaining the difference 
between the clonal populations. No obvious relationship between growth and productivity 
was observed in that experiment.  
The impact of the over-expression of ectopic eGFP-SNAREs on productivity was also studied 
under fed-batch culture conditions. Fed-batch cultures are a process where the culture 
media is supplemented during culture to replace depleted components and consists of 
carbon sources (usually glucose for CHO cells), vitamins, amino acids and other 
metabolites. Initial assessment of relative product titres was undertaken using western blot 
analysis with anti-heavy chain antibody. When the expressed molecule of interest was 
Adalimumab, a stronger band signal for the product IgG from cell lines CHO/STX18 F, 
CHO/STX17 K, CHO/STX17 J and CHO/SNAP29 B was observed, suggesting higher 
expression of the model molecule compared to the controls. CHO/STX17 J gave the 
strongest signal, in agreement with the batch culture experiments. When the preliminary 
results were compared to the quantitative results obtained by Octet analysis, they agreed. 
Indeed, CHO/STX17 J produced the highest titre of model protein at 3.04 µg/mL at day 5. 
CHO/SNAP29 B, CHO/STX17 K and CHO/STX18 F also obtained statistically higher titre than 
the host cell line. When comparing those results with the batch experiment in 96-DWPs, 
the trend was similar. Higher expression was obtained for the cell lines CHO/STX17 K, J 
CHO/STX18 F and CHO/SNAP29 B suggesting that either the scale up or the change in 
culture conditions had no impact when expressing Adalimumab. On-the-other-hand, in the 
transient transfection experiment for expression of Etanercept, the preliminary results 
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obtained by western blot analysis of the supernatant at day 5 suggested that only 
CHO/STX17 J seemed to have a positive effect on titre. This did not relate to the findings in 
the previous experiment (see section 3.2.4) where higher concentrations were obtained 
also for CHO/STX17 K, CHO/STX18 F and CHO/SNAP29 B in batch cultures. 
The viable cell concentration and culture viability was also monitored at day 3 and 5 for 
both fed-batch experiments. One noticeable observation was the slow growth of the 
different cell lines under these conditions. Most cell lines had only at most doubled, 
reaching concentrations below 1 x 106 viable cells/mL. This was surprising when compared 
to the growth profiles in spin tubes under batch conditions where cells concentrations at 
day 5 were >5 x 106 cells/mL. The transfection protocol might explain a delay in growth due 
to the stress applied to the cells but a similar protocol was applied to the 96-DWP 
experiment where some cell lines reached high viable cell concentrations (> 8 x 106 
cells/mL for CHO/MRXIP-GFP H and L). Another possible parameter that might influence 
these results was the use of spin tubes without vented caps. The spin tubes were gassed 
manually at the beginning of the experiment and at day 3, whereas vented caps help to 
maintain a constant supply of oxygen and CO2 to control pH in the culture over time. 
Moreover, cells were inoculated at a high starting concentration (0.5 x 106 cells/mL) which 
may have impacted on the growth. When monitoring culture viability, the same trend was 
observed across the different conditions tested. The culture viability was decreased at day 
3 and then recovered at day 5. This was possibly the effect of the transfection on day 0 and 
then the addition of the efficient feed B on day 3. 
There was also a difference observed in the titre obtained between the 96-DWP 
experiment and the spin tube fed-batch experiment. Whilst both used the same 
transfection protocol, the titre was two times higher from the 96-DWP experiment. The 
low viable cell concentration and poor growth in the spin tube experiment is a likely 
explanation for the difference in titre between the experiments. Another explanation could 
be the loss of expression, as the majority of the product was shown to be generated in the 
first 3 days of culture, before the feeding. Indeed, transient transfection is not a method 
designed to support prolonged expression over time such as stably cell line generation.  
A larger scale batch culture transient expression experiment was also undertaken in 125 mL 
Erlenmeyer flasks to determine the reproducibility of results when scaling up the process. 
In this case the method of transient transfection was different, electroporation was used. 
The resulting analysis of the amount of Etanercept product in the cell culture supernatants 
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by western blot analysis of day 8 samples suggested higher expression of Etanercept in 
CHO/STX17 J and CHO/SNAP29 B confirmed by quantitative Octet measurements. Those 
results were in line with the other experiment in different scales when expressing 
Etanercept, cell lines overexpressing STX17 and SNAP29 at specific levels conferred an 
increase in recombinant protein production. It was also observed that the cell line 
CHO/STX18 F supernatant from day 8 gave an intense signal but for a sized product that 
corresponded to only half of the molecule. CHO/STX18 F achieved low culture viability at 
day 8 when expressing Etanercept while achieving high viable cell concentration. Release of 
the intracellular content of numerous cells affects product degradation notably by 
unleashing enzymes with thioredoxin-like activity into the media. Those enzymes reduce 
the disulphide bonds and only the half-molecule of the product of interest remains.  
When producing Adalimumab, an intense signal was observed for CHO/SNAP29 B and for 
CHO/STX17 K but not J. In the case of production of Adalimumab, titre measurement only 
correlated with the preliminary results of CHO/STX17 K whereas CHO/SNAP29 B had similar 
titre to the controls. For the Adalimumab producing cell lines, CHO/STX17 K had the best 
specific productivity but in a similar range to CHO/STX7 C, which demonstrated neither an 
overexpression of recombinant product in the western blot experiments or a statistical 
difference in the octet measurement compared to the controls, whereas CHO/SNAP29 B 
had a similar specific productivity to the controls (host cell lines and eGFP expressing cell 
lines). 
Growth profiles of the different cell lines were similar in both experiments, first a lag phase 
followed by an exponential phase until day 6 and then a stationary/decline phase. The 
untransfected cell line did not show any lag phase in both experiments indicating that the 
lag phase was probably a consequence of the electroporation. This was also associated by a 
reduction of viability at day 2 in all the electroporated cell lines compared to the 
untransfected control. The effect on cell line culture viability on the transfected cell lines 
was different across both experiments so it was not possible to determine if overexpression 
of the targets of interest influence electroporation recovery.  
When the results from the different transient expression studies were compared (Table 
4.1), it was observed that 3 cell lines had a constant positive increase in productivity over 
the control cell lines, these being cell line CHO/STX17 J, CHO/SNAP29 B and in to a smaller 
extent, CHO/STX18 F. While the CHO/STX17 J cell line did not have an extended longevity 
of culture as the CHO/STX17 K cell line, it had enhanced productivity under different 
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conditions and to a greater extent than the CHO/STX17 J cell line compared to the controls. 
The CHO/STX17 J cell line had a higher expression of the STX17-eGFP fusion protein 
compared to the CHO/STX17 K cell line, suggesting that the magnitude of expression was 
linked to the impact on productivity. STX17 plays a role in autophagy by facilitating the 
generation of autophagosomes (Hubert et al. 2016; Itakura and Mizushima 2013) but also 
plays a role in traffic between the smooth ER and ERGIC/Golgi compartment (Muppirala et 
al. 2011). Positive increase in titre in batch and fed-batch experiments suggests that not 
only the action of STX7 on autophagosomes is involved but also its function in the traffic 
between the smooth ER and ERGIC/Golgi. 
The CHO/SNAP29 B cell line also had enhanced secretory recombinant protein production 
compared to the controls and prolonged culture viability. This effect was observed in the 
different batch experiments but not as such in the fed-batch transient expression 
experiment. During fed-batch, feed is added to the culture to compensate for the 
deprivation of nutrients in the media. Autophagy is triggered by nutrient deprivation (Glick, 
Barth, and Macleod 2010) and SNAP29 is involved in fusion between the autophagosome 
and the lysosome. Hence, when the cells are not deprived of nutrients they do not form 
autophagosomes so there is less need for maturation of the autophagosome and fusion 
with the lysosome. This could be an explanation as to why the effect on productivity of 
CHO/SNAP29 B was limited in fed-batch experiments and more pronounced under batch 
conditions. Moreover, it was possible to observe a difference between the CHO/SNAP29 A 
and B cell lines, suggesting that the level of expression of SNAP29 plays a role in 











Table 4.1. Summary of the results of the different experiments for the characterisation of the monoclonal populations. 
Relative levels of expression of the eGFP fused proteins of different monoclonal cell lines is represented by (*) ((*) low, (**) medium and (***) high) based on the western 
blot and densitometry analyses realised in section 4.2.2. Regarding the effect on titre or specific productivity, (/) indicates no change compared to the host cell line, (+) 
indicates statistically higher titre/specific productivity of the recombinant protein compared to the host cell line, (++) indicates statistically higher titre/specific productivity 
compared to the host cell line and empty vector controls (CHO/MRXIP-GFP H/L) and (-) indicates a lower titre than the host cell line.
Cell line














































CHO/MRXIP-GFP H / no difference No difference / - / / / / / / / /
CHO/MRXIP-GFP L / no difference No difference / / / / / /
CHO/STX7 A *** no difference No difference + /
CHO/STX7 B ** no difference No difference / / / / / / / / / /
CHO/STX7 C * no difference No difference / / / / + / / / / +
CHO/STX17 J ** no difference No difference ++ ++ + + ++ / / / ++ /
CHO/STX17 K * no difference
Extended culture 
time and increased 
viability
+ / / / + ++ / / / +
CHO/STX18 C Not detected no difference No difference / /
CHO/STX18 H Not detected no difference No difference + / / / / /
CHO/STX18 F * no difference No difference ++ / / + + + / / ++ /
CHO/SNAP29 A *** no difference No difference / / / / / / / / / /
CHO/SNAP29 B * no difference
Extended culture 
time and increased 
viability
+ - + + + + / / / /
Effect on Titre
Etanercept AdalimumabEffect on growth





The STX18 expressing cell lines did not show any impact on the cell growth, however it is 
important to note that only the cell line CHO/STX18 F expressed a full-length fused protein. 
On different occasions, cell line CHO/STX18 F showed significantly higher product 
concentration than the host cell line (see section 4.3.3.2, 4.3.2.1 and 4.3.1). STX18 is a 
protein involved in the organisation of the different subdomains of the ER (Iinuma et al. 
2009) and the retrograde traffic between the ER and the Golgi (Hatsuzawa et al. 2000). By 
overexpressing STX18, cells may gain the ability to extend their ER capacity which could 
lead to improved secretory productivity. Indeed, an increase in ER content had been 
documented as an approach to improve recombinant protein production (Tigges and 
Fussenegger 2006). By overexpressing STX18, cells might be able to expand their ER for 
improved ER capacity, this inherently leading to improvement in productivity. The 
enhancement of secretory product amounts from the CHO/STX18 F cell line compared to 
the control was less than the increase observed with STX17 or SNAP29 expressing cell lines 
and this might reflect the low expression of the eGFP-STX18 fusion protein in the cell line. 
Finally, where enhancement of product yields was observed from an engineered cell line 
compared to the controls the effect was demonstrated for both Etanercept and 
Adalimumab, suggesting that the increase in secretory productivity is not related to the 
nature of the product. However, further investigations need to be performed to confirm 
this because even if the two model molecules are structurally different, they share a lot in 
common around the IgG1 constant heavy chain constant domains. 
 
4.5. Conclusions 
In this chapter, the different syntaxin/SNAP engineered CHO-S cell monoclonal populations 
overexpressing eGFP fused SNAREs were characterised with respect to their growth profiles 
and recombinant protein secretory capacity compared to control cell lines. The key findings 
of the work in this chapter is that the over-expression of a number of the SNAREs appeared 
to enhance recombinant protein secretory product yields and the extent of this increase 
was possibly defined by the extent of over-expression of the eGFP-syntaxin/SNAP protein. 
In particular, overexpression of STX17, STX18 and SNAP29 positively altered the 
productivity of the model recombinant proteins investigated compared to the host cell line. 
Further, investigation showed that the level of expression was associated with the 
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improvement observed and higher titres were obtained with cell lines overexpressing 
relatively higher amounts of eGFP-STX17 and lower amounts of eGFP-SNAP29. After 
demonstrating the possible titre improvement by the overexpression of key SNARE 
proteins at the laboratory scale, these proof-of-concept studies and targets were evaluated 





CHAPTER 5: Industrial Scale Investigation and 
Validation of SNARE Engineering of CHO Cells on 
Secretory Recombinant Protein Production 
 
5.1. Introduction 
In the previous chapter (Chapter 4), CHO-S cells genetically engineered with a number of 
different syntaxin/SNAPs were shown to yield increased production of secreted 
recombinant protein compared to the original host cell line. Of the four SNARE targets 
investigated in detail (STX7, 17, 18 and SNAP29), STX17 and SNAP29 when over-expressed 
in CHO-S cells resulted in longer viable cell culture times under batch culture conditions 
and increased secretory recombinant protein productivity depending on the levels of 
expression of these SNARE. In this chapter, these two SNAREs were to be investigated in 
terms of the impact of their over-expression in an industrial host cell line and the effect in 
the industrial environment determined. Indeed, cell line engineering and the impact of this 
can be cell line dependent such as the overproduction of XBP1 (Tigges and Fussenegger 
2006), while other approaches may be applied to a range of cell lines with similar effects 
(Jaluria et al. 2007; Peng et al. 2011). In this chapter, work was undertaken at Fujifilm 
Diosynth Biotechnologies (FDB) to assess the impact on the secretion of recombinant 
proteins of manipulation of SNARE proteins using a CHO-DG44 cell line and FDB 
methodology at their facilities.  
FDB is a contract manufacturing company offering cell line development services and 
manufacturing for recombinant protein production. FDB has developed a CHO-DG44 
derived cell line kŶoǁŶ as ͞CloŶe Ϯϳ͟ foƌ secretory recombinant protein production 
commercially. The CHO-DG44 host was generated in 1981 by Uƌlauď͛s teaŵ by two 
mutagenesis steps to obtain a DHFR deficient cell line (Urlaub et al. 1983). The 
dihydrofolate reductase enzyme (DHFR) is responsible for the conversion of dihydrofolate 
into tetrahydrofolate, an important intermediate for the synthesis of purines and amino 
acids (Chen et al. 1984). Methotrexate (MTX) is a competitive inhibitor of DHFR (Goodsell 
1999; Rajagopalan et al. 2002) and one manner to overcome its effects is by overexpressing 
DHFR. The DHFR/MTX combination has since been used as a metabolic selection system 
involving the transfection of a plasmid containing a dhfr gene and addition of MTX to the 
media. The host Clone 27 cell line was used to investigate the impact of syntaxin cell 
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engineering. A direct comparison of the impacts of syntaxin/SNAP engineering between the 
CHO-S cell line and the CHO-DG44 cell line which share a common ancestor could be seen 
as limited, but several reports have shown heterogeneity in-between and between 
different host cell lines derived from CHO cells (Kim et al. 2011; Lewis et al. 2013). Derouazi 
et al. (2006) also demonstrated the heterogeneity of monoclonal populations derived from 
the same parental cell line. It is therefore necessary to undertake appropriate experiments 
to unravel any cell line dependent effect of engineering the targets of interest. 
This chapter is focused on determining if the findings described in Chapter 4 investigating 
transient expression of target biotherapeutic proteins are transferable to a different host 
CHO cell line in an industrial environment stably expressing the target biotherapeutic under 
fed-batch conditions. Initially, new genetic constructions in the pAVE vector system used at 
FDB are described. Following generation of the different vectors of interest, the process for 
mini-pool generation is described and the different selection steps documented. In parallel, 
transient transfection experiments were undertaken to analyse the impact of different 
promoters and the fusion of an eGFP tag to the syntaxin/SNAP proteins. A further co-
transfection strategy was also used to generate stably expressing cell lines using vectors 
generated in Chapter 3. Once stably expressing syntaxin/SNAP and target recombinant 
protein cell lines were obtained, a fed-batch over grow method was used to determine any 
effect on the industrial relevant cell lines engineered with SNARE proteins on the 
production of recombinant protein. Finally, expression of the fused eGFP-syntaxin/SNAP 
proteins was evaluated in the stably expressing cell lines and levels of endogenous SNARE 
were compared between the industrial host, Clone 27, and the cell line used in the 
academic lab, CHO-S.  
 
5.2. Generation of vectors for the engineering of syntaxin/SNAP and 
expression of model recombinant proteins in the FDB CHO-DG44 
host cell line 
For the different experiments that were undertaken at FDB, the eGFP-STX7, 17, 18 and 
SNAP29 fusions were selected as targets to engineer based upon the proof-of-concept 
work described in Chapter 4. The engineering of the CHO-S host with eGFP-STX17 and -
SNAP29 gave interesting results in the proof-of-concept academic lab studies (see Chapter 
4), whilst engineering of STX7 and STX18 was undertaken to determine if the observed 
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effect in CHO-S cells could be transferred to another industrial host grown under 
industrially relevant conditions. Fujifilm Diosynth Biotechnologies have developed a CHO-
DG44 cell line, Clone 27, as part of an expression system, the Apollo platform, for the 
production of recombinant proteins. To be able to assess the potential of syntaxin/SNAP 
engineering in the Clone 27 host cell line, new genetic constructs needed to be generated. 
Indeed, Clone 27, being derived from a CHO-DG44 cell line uses metabolic DHFR 
overexpression and MTX supplementation to select for cells that have incorporated the 
DNA of interest. The platform uses a proprietary plasmid system, the pAVE system, which 
includes the different required elements for recombinant protein expression and selection 
of Clone 27 derived cell lines.  
When the product of interest is an antibody, the pAVE system starts with the generation of 
two different plasmids, one containing the heavy chain gene and one containing the light 
chain gene, which are then ligated together to form a unique expression vector, the Double 
Gene Vector or DGV. To avoid a dual selection process with the co-transfection of two 
plasmids, one for the recombinant model protein and one for the SNARE protein, the 
targets of interest were cloned into the DGV. To do so, a gene present for hygromycin B 
resistance in the DGV but not used as a selection marker, was replaced by the gene coding 
for the different SNARE proteins. Some modifications to the vector were necessary for this 
strategy, notably a change of promoter and polyA tail of the resistance gene. The 
hygromycin resistance gene was under the control of a HSV mini-TK promoter and a HSV TK 
polyA tail which tend to result in low expression of genes compared to a CMV promoter 
(Ede et al. 2016). Information about the ectopic expression of the SNARE proteins under 
control of a promoter other than CMV was not available so it was decided to switch the 
promoter and polyA tail to a CMV promoter and a bGH polyA tail as used in the proof-of-
concept studies described in Chapter 4. Two sets of recombinant gene containing 
constructs were also generated, one expressing Adalimumab and one expressing 
Blosozumab. Blosozumab, an IgG4 used for the treatment of osteoporosis (Mccolm et al. 
2014), is the standard model molecule used at FDB for process evaluation. In order to 
further analyse the impact of the eGFP tag on the fused proteins, plasmids were designed 
to express the protein of interest with or without an eGFP tag. Plasmids were also 
generated with the gene of interest under the control of a TK promoter and TK polyA tail to 
determine any impact of promoters of different strengths. The details of the different 
genetic vectors generated in the work described in this chapter are detailed in Table 5.1. 
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To generate the pAVE HC ADA vector containing the coding sequence for the heavy chain 
(HC) of the Adalimumab antibody, the HC coding sequence was obtained by PCR using the 
Adalimumab plasmid as a template and ligated into the pAVE931 plasmid. Primers for PCR 
were designed to amplify the coding sequence of the HC gene of Adalimumab (1426 bp) 
with restriction sites AflII and BamHI (Figure 5.1A). For ligation into the pAVE931 vector, 
the PCR product and acceptor pAVE931 vector were digested using AflII and BamHI 
restriction enzymes. After digestion, two bands were obtained at the expected size of 7515 
bp and 426 bp for the backbone as determined by agarose gel electrophoresis analysis 
(Figure 5.1A). The upper band containing the desired portion of pAVE931 was extracted 
from the gel and purified before being ligated with the purified and digested PCR product. 
Ligation was successful using a 3:1 ratio (insert: vector) and several colonies obtained were 
used to extract DNA. From analytical digestion with AflII and BamHI, two fragments at 7509 
bp and 1426 bp were expected for successful ligations, one colony showed the required 
DNA pattern (Figure 5.1B). The region containing the Adalimumab heavy chain gene was 
then sequenced to check for any anomalies in the sequence, such as point mutations, and 






To generate the pAVE LC ADA vector containing the coding sequence for the light chain (LC) 
of the Adalimumab antibody, the coding sequence was again amplified by PCR using the 
Adalimumab plasmid as a template and the resulting product ligated into the pAVE1062 
plasmid. PCR primers were designed to obtain the coding sequence of the light chain gene 
of Adalimumab (717 bp long) with EcoRI and BamHI restriction sites (Figure 5.1C). For 
ligation into the pAVE1062 vector, the PCR product and the acceptor plasmid were 
digested using EcoRI and BamHI restriction enzymes. After digestion of the pAVE1062 
plasmid, two bands were obtained at the expected size of 6074 bp and 495 bp as 
determined by agarose gel electrophoresis analysis (Figure 5.1A). The upper band 
containing the desired portion of pAVE1062 was extracted from the gel and purified before 
being ligated to the digested and purified PCR product. Ligation was successful using a 3:1 
ratio (insert:vector) and several colonies obtained were used to extract DNA. From 
analytical digestion with EcoRI and BamHI enzymes, two fragments at 6074 bp and 717 bp 
were expected for successful ligations, one colony showed the required DNA pattern 
(Figure 5.1D). Sequencing was performed on the region containing Adalimumab light chain 
gene to confirm presence of the correct sequence. 
The DGV, pAVE ADA, was obtained by ligating together a fragment of pAVE HC ADA and 
pAVE LC ADA using BssHII and PmEI as restriction enzymes. After digestion of pAVE HC 
ADA, three fragments at the respective sizes of 5158 bp, 3752 bp and 10 bp were obtained 
as determined by agarose gel electrophoresis analysis. The upper band (5158 bp), 
containing the desired sequence, was excised from the gel and purified before ligation with 
pAVE LC ADA, referred to as the backbone, previously digested with the same enzymes. 
Ligation was successful using a 3:1 ratio (insert: vector) and several colonies obtained were 
used to extract DNA. When performing a test digest with BamHI, two fragments at 8818 bp 
and 3112 bp were expected for a successful ligation. One colony showed the corresponding 







Generation of the pAVE ADA CMV construct was performed by insertion of a CMV 
promoter to replace the promoter driving the hygromycin resistance cassette gene. The 
CMV promoter sequence with the desired restriction sites was obtained by PCR with 
appropriate primers using pcDNA3.1/Hygro(+) vector as a template. A 615 bp fragment was 
obtained (Figure 5.2BͿ ǁith ϱ͛ BstBI aŶd ϯ͛ MluI ƌestƌiĐtioŶ sites as demonstrated by 
agarose gel electrophoresis analysis. A complementary PmlI site was also added at the ϯ͛ 
during this operation. The PCR product was digested using BstBI and MluI restriction 
enzymes, purified and then ligated to the backbone pAVE ADA previously digested with the 
same set of enzymes. Ligation was successful using a 3:1 ratio (insert: vector) and several 
colonies obtained were used to extract DNA. One colony showed the required DNA pattern 
as determined by agarose gel electrophoresis analysis, with two bands expected at 10210 
bp and 615 bp after analytical digestion with BstBI and MluI (Figure 5.2C). The region 
containing the new CMV promoter was confirmed as correct by sequence analysis. 
The pAVE ADA CMVbGH was created by introduction of a bGH polyA tail downstream of 
the introduced CMV promoter in pAVE ADA CMV. The bGH polyA tail was obtained by PCR 
using the pcDNA3.1/Hygro(+) vector as a template with designed primers. A fragment of 
258 bp was expected as demonstrated by agarose gel electrophoresis analysis (Figure 
5.3A). The primers for amplification contained the restriction sites, PŵlI aŶd NotI iŶ ϱ͛ aŶd 
MluI iŶ ϯ͛. The PC‘ fƌagŵeŶt ǁas digested usiŶg PŵlI aŶd MluI ƌestƌiĐtioŶ eŶzǇŵes, Đut 
from the agarose gel and then ligated with pAVE ADA CMV previously digested with PmlI 
and MluI. Ligation was successful using a 3:1 ratio (insert: vector) and several colonies 
obtained were used to extract DNA. A successful ligation pattern when digesting with BstBI 
and NotI was two bands at 10442 bp and 604 bp as showed in Figure 5.3B. Successful 




Vectors pAVE ADA CMV STX7, pAVE ADA CMV STX17, pAVE ADA CMV STX18, pAVE ADA 
CMV SNAP29 and pAVE ADA CMV eGFP were generated in a similar manner, by inserting 
DNA fragments containing the gene of interest into the pAVE ADA CMVbGH. For the 
different SNARE genes, PCR primers were design to only amplify the syntaxin gene 
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(omitting the eGFP) and to add ĐoŵpleŵeŶtaƌǇ ƌestƌiĐtioŶ sites ;PŵlI iŶ ϱ͛ aŶd NotI iŶ ϯ͛Ϳ. 
The plasmids pMRXIP-STX7, pMRXIP-STX17, pMRXIP-STX18 and pMRXIP-SNAP29 were used 
as templates to obtain the desired PCR fragments of 807 bp, 930 bp, 1029 bp and 798 bp 
for STX7, STX17, STX18 and SNAP29 genes as demonstrated by agarose gel analysis (Figure 
5.3C). The eGFP gene was obtained by PCR amplification using pcDNA3.1Hygro/GFP as a 
template. A PCR product of 741 bp was expected as shown in Figure 5.2C. The different PCR 
products were digested using PmlI and NotI restriction enzymes, purified and then ligated 
into pAVE ADA CMVbGH plasmid previously digested with the same enzymes. Ligations 
were successful using a 3:1 ratio (insert: vector) and several colonies obtained were used to 
extract DNA. When test digested with PmlI and NotI the expected patterns were two bands 
at 11031 bp and 795 bp for pAVE ADA CMV STX7, 11031 bp and 918 bp for pAVE ADA CMV 
STX17, 11031 bp and 1017 bp for pAVE ADA CMV STX18, 11031 bp and 786 bp for pAVE 
ADA CMV SNAP29 and 11031 bp and 729 bp for pAVE ADA CMV GFP as highlighted by the 
successful ligations in Figure 5.4. The correct insertion of the different genes of interest was 




Plasmid pAVE ADA CMV STX17GFP and pAVE ADA CMV STX18GFP were generated by 
digesting the sequence containing the fused protein from pMRXIP-STX17 and pMRXIP-
STX18 using PmlI and NotI restriction enzymes. Three bands were obtained of 5687 bp, 
1779 bp and 325 bp sizes for pMRXIP-STX17 or 5687 bp, 1878 bp and 325 bp for pMRXIP-
STX18. The desired band (1779 bp for STX17 and 1878 bp for STX18), containing the gene of 
interest, was extracted from the agarose gel, purified and ligated into the pAVE ADA 
CMVbGH vector previously digested with PmlI and NotI. Ligations were successful using a 
3:1 ratio (insert: vector) and several of the resulting colonies were used to extract DNA. 
One colony for each construct showed the required DNA pattern as determined by agarose 
gel electrophoresis analysis, with two bands expected at 11031 bp and 1783 bp for pAVE 
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ADA CMV STX17GFP or 11031 bp and 1882 bp for pAVE ADA CMV STX18GFP after analytical 
digestion with PmlI and NotI (Figure 5.4).  
Plasmids with genes of interest (STX17 and STX18 with or without tag) with expression 
controlled by TK promoter and TK polyA tail were also generated to be able to compare 
against the CMV promoter. Indeed, the TK promoter is a weaker promoter than the CMV 
promoter. In order to integrate those into the DGV, sequences were designed and ordered 
from Twist Bioscience, USA. 
The plasmid pAVE ADA TK STX17, pAVE ADA TK STX17GFP, pAVE ADA TK STX18, pAVE ADA 
TK STX18GFP were generated by digesting pTwist TK STX17 and pTwist TK STX18 with BstBI 
and PmlI restriction enzymes or digesting pTwist TK STX17GFP and pTwist STX18GFP with 
BstBI, PvuI and PmlI. Plasmids pTwist TK STX17GFP and pTwist STX18GFP had to be 
digested with 3 enzymes to obtain bands of different size able to be distinguished after 
agarose gel analysis. After digestion, the desired bands ( 1150 bp for STX17, 1250 bp for 
STX18, 1956 bp for STX17GFP and 2031 bp for STX18GFP) were excised from the gel, 
purified and ligated into pAVE ADA CMV previously digested with BstBI and PmlI. Ligations 
were successful using a 3:1 ratio (insert: vector) and several of the resulting colonies were 
used to extract DNA. After test digest with BstBI and PmlI restriction enzymes, a pattern for 
successful ligation were two bands at 10264 bp and 1150 bp for pAVE ADA TK STX17, 10264 
bp and 1249 bp for pAVE ADA TK STX18, 10264 bp and 1954 bp for pAVE ADA TK STX17GFP 
and 10264 bp and 2029 bp for pAVE ADA TK STX18GFP as demonstrated by successful 




Generation of the control vector pAVE ADA TK GFP was achieved in two steps. First, 
generation of pAVE ADA TK D2GFP was undertaken by ligating TK D2GFP fragment into 
pAVE ADA. pTwist TK D2GFP was digested with MluI for extraction of a band of 1059 bp. 
The fragment containing the coding gene for D2GFP, a destabilised GFP, was purified and 
ligated into pAVE ADA previously digested with MluI. Ligation was successful using a 3:1 
ratio (insert: vector) and several of the resulting colonies were used to extract DNA. 
Successful test digest with PmlI and BamHI restriction enzymes was a pattern of three 
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bands, 6985 bp, 3112 bp and 1234 as demonstrated by one colony. The newly generated 
pAVE ADA TK D2GFP was digested with PmlI and NotI restriction enzymes and ligated with 
a purified and digested PCR fragment obtained by amplification of the GFP gene using 
appropriate primers and pcDNA3.1Hygro/GFP as a template (Figure 5.2C). Ligation was 
successful using a 3:1 ratio (insert: vector) and several of the resulting colonies were used 
to extract DNA. Following test digest with NotI and PmlI, one colony was observed with the 
required successful pattern of two bands at 10445 bp and 729 bp (Figure 5.5C). 
The equivalent vectors were generated from pAVE Bloso, a DGV expressing Blosozumab. 
The steps and enzymes were similar, only the sizes of the DNA fragments were different. All 








5.3. Generation of CHO-DG44 cell pools stably expressing the SNAREs 
and target model recombinant proteins 
5.3.1. Generation of stably expressing mini-pools 
Monoclonal cell lines are highly desired in industry in order to obtain homogenous cell line 
populations, but the generation of these monoclonal populations and validation of their 
monoclonality are expensive and time consuming processes. For bioprocess development 
approaches, industry therefore often uses mini-pools of recombinant cells as opposed to 
monoclonal cell lines. Mini-pools are recombinant cell pools generated from a small 
number of cells and are established based on the fact that the stable integration in the 
genome of DNA after transfection is a rare event. Hence, mini-pools may not be a 
homogenous population such as a monoclonal population but their heterogeneity is 
restrained by the small number of cells initially used to establish the pool and the rare 
event of stable integration. The establishment of mini-pools compared to monoclonal 
populations is more rapid and less work intensive giving the opportunity to generate and 
characterised cell pools with a set phenotype and obtain recombinant cells lines expressing 
the desired product much more quickly. Moreover, Fan et al. (2017) have shown that mini-
pools and monoclonal cell lines derived from the same mini-pool shared the same 
phenotype. 
The mini-pool generation process used at FDB is summarised in Figure 5.6. The process 
starts with transfection of cells with the desired vector for the expression of the 
recombinant protein of interest. Following transfection (electroporation), media with a 
selection agent is added to select for only stably expressing cell lines. Cells are then 
aliquoted into wells of a 96-well plate at 1000 cells/well and incubated over a period of 2-3 
weeks to allow for recovery and cell out growth. Typically in a cell line development 
project, up to 10 x 96-well plates are processed for each cell line. During the recovery 
period, cells are monitored regularly to check for contamination and confluency. When 
confluency of most of the wells reaches over 50%, wells with a monoclonal profile (growth 
of one colony in the well) are selected for titre screening. Mini-pools reaching the desired 
titre are progressed from 96-well plates to spin tubes in several steps. Once in spin tubes, 
populations are ranked again by titre. Selected cell lines are then assessed in a fed-batch 
over grow experiment in shaken 24-DWPs. During this experiment, only titre is monitored 
176 
 
over a period of 14 days. The results of the experiment are used to set up another FOG at 
larger scale to monitor not only titre, but also cell growth and viability. 
 
Generation of mini-pools was undertaken with the following constructs; pAVE ADA and 
pAVE ADA CMVbGH (both controls); pAVE ADA CMV STX7, pAVE ADA CMV STX17, pAVE 
ADA CMV STX18, pAVE ADA CMV SNAP29; pAVE Bloso, pAVE Bloso CMVbGH (both 
controls); pAVE Bloso CMV STX7, pAVE Bloso CMV STX17, pAVE Bloso CMV STX18 and pAVE 
Bloso CMV SNAP29. None of the different SNARE constructs contained an eGFP fused 
syntaxin/SNAP protein as in the proof-of-concept studies (i.e. the constructs contained the 
SNARE gene alone with no tag). 
A variety of cell pools were generated with the same plasmids for different purposes. To 
indicate the origin of a cell pool and how it was generated, cell pools were named using 
͞ŵp͟ ;e.g. ŵpDGϰϰ/ADA “TXϳ ϯ foƌ ŵiŶi-pool number 3 of Clone 27 cell line stably 
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transfected with the plasmid pAVE ADA CMV STX7) for mini-pools or ͞pool͟ foƌ pool Đell 
lines (e.g. poolDG44/ADA STX18 for a pool cell line generated with the plasmid pAVE ADA 
CMV STX18). The promoter utilised to drive the expression of the gene of interest was only 
used in the naming of cell lines when the promoter was other than CMV. No mini-pool was 
generated for the construct pAVE ADA CMV STX18. 
For each different construct, 5 x 96-well plates were processed. Following the 3 weeks 
recovery, confluency was determined using either a Cell Metric CLD (Solentim, UK) plate 
reader or visually. Figure 5.7 represents the output of the Cell Metric CLD plate reader for 
one plate. Criteria for selection were confluency between 50 and 70% and a high 
probability of monoclonality (presence of one colony in the well). Because the goal was to 
generate mini-pools, the monoclonality criterion was not stringent. From this first screen, 
48 mini-pools for each transfection were selected and progressed into 24 well plates. After 
a week of growth in 24 well plates, titre measurement for each mini-pool was achieved by 
harvesting 200 µL of supernatant. Results for the highest and lowest expressing mini-pool 
are displayed in Table 5.2A for each construct. Surprisingly, for all the cell pools co-
expressing a SNARE and a recombinant product, titre concentrations were too low to be 
measured. Low titres were expected at this stage due to the low number of cells and 
conditions of the screen, however it was expected that they would be measurable. 
Antibody titres were measurable for the cell lines transfected with the DGV expressing 
Adalimumab or Blosozumab alone. The lowest Blosozumab clone had a titre of 24.9 µg/mL 
whereas the best Adalimumab clone had a titre of 22.2 µg/mL suggesting higher titre for 
Blosozumab expressing cell pools. From this initial titre screen, 8 mini-pools for each 





At the spin tube stage, titre was again determined after 2-3 subcultures. The results for the 
highest 2 expressing mini-pools for each construct are reported in Table 5.2B for both 
Adalimumab and Blosozumab. An increase in titre in the spin tubes compared to the earlier 
well plate titres was observed for the all the constructs, with notably the highest expressing 
mpDG44/Bloso 6 pool having a titre of 70.6 µg/mL (2 times more than in 24-well plate) and 
the highest mpDG44/ADA 7 having a titre of 29.5 µg/mL. The cell pools engineering with 
the different SNAREs however, were still below reliable measurement. The SNARE 
engineered cell titres being so low, it was decided not to carry on with characterisation of 
these mini-pools. The top 2 mini-pools transfected with the DGV for both recombinant 
molecules were kept and cryopreserved for further experiments (see 5.5.2). 
Table 5.2. Titre measurement using an Octet instrument of the mini-pool and cell pools 
transfected with pAVE vectors expressing a model recombinant protein and a 
syntaxin/SNAP gene. 
 
A, titres at the first selection step for mini-pools. B, titres after 2-3 passages of the selected mini-
pools in spin tubes. C, Titres for the pool cell lines generated after 2-3 passages in flasks. No 
replicates were performed for the different measurements. 
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5.3.2. Generation of stably expressing antibody and syntaxin/SNAP pools using 
the DG44 Clone 27 host cell line 
Alongside the generation and selection of mini-pools, general cell pools were generated 
with the same vectors (pAVE ADA, pAVE ADA CMVbGH, pAVE ADA CMV STX7, pAVE ADA 
CMV STX17, pAVE ADA CMV STX18, pAVE ADA CMV SNAP29, pAVE Bloso, pAVE Bloso 
CMVbGH, pAVE Bloso CMV STX7, pAVE Bloso CMV STX17, pAVE Bloso CMV STX18 and 
pAVE Bloso CMV SNAP29). As described in 2.2.5.2, Clone 27 was electroporated with the 
desired constructs. The following day, selection reagent was added to the media for 
selection of stably expressing cells and cultures were left to recover for 2 weeks. Cultures 
were monitored regularly to check for contamination. After 2 weeks, and if the parameters 
were met (viability > 60% and cell concentration > 0.5 x 106 cells/mL), cells were progressed 
to spin tubes cultures. A titre measurement was processed on supernatant samples after 2-
3 passages and the results are displayed in Table 5.2C. Similar to the results of the mini-
pools (see 5.3.1), the cell pools engineering with SNAREs had low titre or were below the 
limit of quantification. Due to recurrent low titre with SNARE engineered cells, it was 
decided to not carry on experiments with the stably expressing cell pools. A different 
strategy was therefore investigated to try and overcome the problem as described in 5.5.2. 
The fact that appropriate titres were observed with the DGV transfected (24.6 and 14.4 
µg/mL for poolDG44/Bloso and poolDG44/ADA respectively) confirmed that the cell pool 
generation process was not flawed and there was either a problem with the genetic 
constructs or that the syntaxin burden/over-expression prevented secretion of the target 
recombinant protein. 
 
5.4. Transient transfection experiments to evaluate the impact of the 
use of different promoters and presence of the fluorescent tag 
on the expression of model recombinant protein 
In parallel to the generation and recovery of stable mini-pools described under section 1.3 
above, transient transfection experiments were undertaken. These experiments were 
undertaken to determine the impact of the promoter used to drive SNARE expression 
(using either the miniTK or CMV promoter) and of the presence of an eGFP tag when cells 
were overexpressing SNARE proteins. In the previous chapters, correct folding of the eGFP 
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tag and complete processing of the fused molecule was confirmed and control cell lines 
expressing only eGFP were generated to determine the effects due to the vector or the tag 
on cells. Here, a similar approach was undertaken with vectors generated in the pAVE 
system. Further analysis was also planned to determine the impact of the eGFP tag on the 
fusion protein and not only the cell line. SNAREs are membrane proteins so their 
conformation is important for their localisation and function. The addition of a tag may 
affect the folding and function of the protein (Miyawaki, Sawano, and Kogure 2003) as well 
as its localisation (Cui et al. 2016).By comparing overexpression of fused and non-fused 
syntaxin proteins, effects of the tag on the function of the protein might be detected. 
Moreover in Chapter 4, the impact of STX17 and SNAP29 over-expression on cells was 
dependent of their level of expression. Only relatively low expression (compared to the 
high expressing cells investigated) of SNAP29 had an effect on productivity while relatively 
high expression of STX17 had an effect on productivity and a low expression on cell 
survival. The comparison of promoters with different strength (CMV and miniTK promoter) 
was therefore undertaken to determine if promoters that should drive expression of the 
syntaxin genes at different amounts resulted in different impacts on the cell growth and 
productivity.  
Transient transfections were undertaken in spin tubes with vented caps using NovaCHOice 
as a transfection agent. Cells were cultivated for 6 days with sampling every other day from 
day 2. On sampling days, cell growth and culture viability was measured using a Vi-CELL 
instrument. The experiments was performed with the following constructs; pAVE ADA, 
pAVE ADA CMVbGH, pAVE ADA CMV STX17, pAVE ADA CMV STX17GFP, pAVE ADA CMV 
STX18, pAVE ADA CMV STX18GFP, pAVE ADA CMV GFP, pAVE ADA TK STX17, pAVE ADA TK 
STX17GFP, pAVE ADA TK STX18, pAVE ADA TK STX18GFP, pAVE ADA TK GFP. The 
experiment was also performed with the equivalent plasmids containing the genes for the 
recombinant model IgG protein Blosozumab.  
Figure 5.8 shows the Blosozumab and Adalimumab expression as determined by Octet on 
supernatant samples from day 6 when the Clone 27 cells were transfected with the 
different constructs. Surprisingly, all conditions had low titre or high variability, even with 




The parameters used for the transient transfection were similar to the experiments 
described in section 4.3 except that the host cell line and media were different. For each 
host cell line a method adapted for one might not be appropriate for another. Moreover, 
NovaCHOice reagent is greatly affected by the addition of supplements in the media such 
as pluronic acid. An optimisation experiment was therefore performed with different 
methods (electroporation and NovaCHOice) and parameters (volume reagent, viable cell 
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concentration) to identify more favourable conditions for transfection with regard to 
recombinant protein expression from the Clone 27 host. To monitor transfection efficiency, 
a GFP expressing vector was transfected (pcDNA3.1Hygro/GFP or pmaxGFP) and 
fluorescence from the cells monitored using a Cellometer Vision CBA device (Nexcelom, 
USA). The Cellometer instrument is a device able to estimate the transfection efficiency by 
determining the fluorescent population of cells among the total population. The different 
conditions investigated are detailed in Figure 5.9. Fluorescent measurements were 




The transfection efficiency, as determined by the percentage of cells expressing GFP 48 h 
post-transfection, when using the NovaCHOice reagent was close to zero with the Clone 27 
cell line for all the different conditions. In comparison, when using electroporation to 
transfect the cells, the transfection efficiency achieved was between 20 and 80%, 
depending on the parameters used and the GFP vector. The pmaxGFP plasmid is a plasmid 
provided by Lonza in the SF Cell line 4D-NuĐleofeĐtoƌ™ X Kit L as a control to check for 
transfection efficiency. The vector expressed a GFP under the control of a CMV promoter 
coupled to an intron. The difference in transfection efficiency between the two plasmids (2 
times more efficiency when using pmaxGFP compared to the pcDNA3.1Hygro/GFP) 
suggested that the vector construction had an impact on the transfection as well as the 
method, with the major difference being the presence of the intron in the pmaxGFP vector. 
It is noted that NovaCHOice transfection is a method heavily impacted by the composition 
of the media, notably the presence of pluronic. To check for the effect of the media on the 
efficiency of transfection when using the NovaCHOice reagent, an experiment with three 
different media was undertaken. The media compared were FDB-MAP and then CD-DG44 
with or without 0.18% pluronic. All the media were supplemented with 200 mM L-
glutamine and the plasmids pmaxGFP and pcDNA3.1Hygro/GFP were used for transfection. 
Transfection efficiency was determined using the Cellometer and the results are displayed 
in Figure 5.10 24 h post-transfection. Efficiency of transfection was determined to be 2 
times higher when using the pMaxGFP plasmid compared to pcDNA3.1Hygro/GFP but the 
levels of transfection efficiency were very low, all below 8%. This approach was therefore 





5.5. Generation of stably expressing CHO-DG44 cell pools co-
expressing a model protein and a syntaxin/SNAP protein by 
transfection of stably expressing recombinant biotherapeutic 
protein expressing cell pools with the different SNAREs 
The attempts to generate mini-pools or pools of DG44 Clone 27 engineered cells co-
expressing a recombinant model protein and one of the SNARE targets using a single vector 
containing both the recombinant protein of interest and the SNARE failed to generate cells 
expressing meaningful amounts of the target recombinant protein. The different results 
obtained suggested that the makeup of the vectors may be responsible for this (see 
discussion in this chapter). A new strategy to generate cell lines expressing both the SNARE 
and recombinant biotherapeutic of interest was therefore investigated involving 
transfection of the mini-pools generated with the DGV with constructs containing the 
target SNAREs. The 2 mini-pools expressing the highest amount of Adalimumab or 
Blosozumab were transfected with the pMRXIP-STX7, pMRXIP-STX17, pMRXIP-STX18, 
pMRXIP-SNAP29 and pMRXIP-STXGFP constructs that had been previously evaluated and 




5.5.1. Titration of puromycin to determine the appropriate amount that kills the 
mini-pools expressing Adalimumab or Blosozumab for use in stable cell 
line generation 
Genetic constructs in the pMRXIP GFP-Ci2 vector are selected for stable integration using 
the resistance gene for puromycin and addition of puromycin to the media. Appropriate 
amounts of puromycin need to be added to the media in order to obtain a stringent 
selection of stably expressing cells. A kill curve for puromycin was therefore realised with 
the cell line mpDG44/ADA 7 to determine the appropriate concentration of puromycin that 
would kill the cells in the absence of the selection marker. Cells were inoculated at 0.2 x 106 
cells/mL in 1 mL of FDB-MAP with 8 mM L-glutamine with different concentrations (0, 7.5, 
10 or 15 µg/mL) of puromycin in 24-ǁell plates. Plates ǁeƌe iŶĐuďated at ϯϳ˚C, ϭϬ% CO2, 
80% humidity for 5 days. At day 5, the viable cell concentration and culture viability were 
determined using a Vi-CELL instrument. 
Figure 5.11 presents the viable cell concentration and culture viability after incubation in 
media containing the different concentrations of puromycin for 5 days. A concentration of 
7.5 µg/mL of puromycin impacted the cell growth and culture viability compared to the 
control, however there was still many viable cells and the culture viability was over 80% at 
day 5. A concentration of 10 µg/mL did not kill the cells but prevented growth with a viable 
cell concentration of 0.25 x 106 cells/mL and a culture viability of 60% at day 5. The 
concentration that killed the most cells whilst allowing some to survive and rapidly 
decreased the culture viability was 15 µg/mL of puromycin which resulted in a decrease of 
the viable cell concentration to 0.08 x 106 cells/mL and a culture viability below 40%. The 





5.5.2. Transfection of mini-pools expressing model IgGs with pMRXIP plasmids 
for the generation of stably expressing cell lines expressing a model IgG 
recombinant protein and a target SNARE protein 
The mini-pools mpDG44/ADA 7 and mpDG44/Bloso 6 were transfected with pMRXIP-STX7, 
pMRXIP-STX17, pMRXIP-STX18, pMRXIP-SNAP29 or pMRXIP-STXGFP following the protocol 
outlined in section 2.2.5.2. Generation of 2 distinct pools for each construct was 
performed. One day after electroporation, the selection agent puromycin was added to the 
fresh media at a final concentration of 10 µg/mL. Cultures were then allowed to recover for 
2 weeks. Emerging cell pools were monitored from time to time to check for 
contamination. When cultures reached a viable cell concentration >0.5 x 106 cells/mL and 
culture viability >60%, cells were progressed into 125 mL Erlenmeyer flasks with vented 
caps. Cells transfected with the plasmid pMRXIP-STX18 never recovered. As such, the cell 
pools obtained were DG44/ADA+STX7, DG44/ADA+STX17, DG44/ADA+SNAP29 and 
DG44/ADA+GFP generated with the transfection of mpDG44/ADA 7 with the plasmids 
pMRXIP-STX7, pMRXIP-STX17, pMRXIP-STX18, pMRXIP-SNAP29 or pMRXIP-STXGFP 
respectively. Similar cell lines were generated with the transfection of mpDG44/Bloso 6; 
DG44/Bloso+STX7, DG44/Bloso+STX17, DG44/Bloso+SNAP29 and DG44/Bloso+GFP. 
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5.5.3. Determination of IgG titre and expression of the eGFP fused proteins in 
the SNARE engineered IgG expressing mini-pools 
The previous experiment (see section 5.3) failed to generate cells expressing both 
molecules of interest, the recombinant IgG model protein and a SNARE. In order to assess 
expression of both at an early stage, and to be able to react rapidly to titre and transfection 
efficiency, these were monitored at early stages. In this case, fluorescence measurements 
were possible because the transfected plasmids were design for the expression of fused 
proteins with an eGFP tag. 
Titre and transfection efficiency were initially monitored 5 days after transfection. The day 
following transfection, and before adding the selection agent, 1 mL of transfected cells was 
withdrawn and used to inoculate a 24-well plate. After incubation of the cultures for 5 days 
at ϯϳ˚C, ϭϬ% CO2 and 80% humidity IgG titre and fluorescence were measured. Figure 5.12 
presents the results for the transfection with each construct. No titre or fluorescence for 
the pool 1 of DG44/ADA+STX7 or DG44/Bloso+STX17 were obtained due to contamination 
of the wells. Values above the limit of quantification were obtained for the different cell 
lines. Higher titres were obtained for cell lines expressing the model protein Blosozumab 
compared to Adalimumab (2 times higher, Figure 5.12). Significantly higher values were 
observed for pools expressing SNAP29 and model recombinant protein, Adalimumab or 
Blosozumab, comparing to the eGFP expressing control. Similar results were observed for 
both DG44/ADA+STX18 pools, DG44/ADA+STX17 2, DG44/Bloso+STX17 2 and 
DG44/Bloso+STX18 2. Transfection efficiency was low for the different cell lines, below 
15%. The absence of selection agent might explain the low efficiency obtained after 5 days 









Another assessment for titre and transfection efficiency was performed after 2-3 passages 
of the stably expressing cell pools in 125 mL Erlenmeyer flasks. Figure 5.13 shows the 
results obtained for the different cell pools generated. No titre measurements were 
performed on both pools of DG44/Bloso+STX7 due to technical problems with the Octet 
instrument and no transfection efficiency was performed for DG44/Bloso+STX7 2 because 
the cell pool did not recover in time. Measurements in shaken flasks gave much higher titre 
that the measurement in a static environment a few days after transfection. Cell pools 
expressing Blosozumab had a higher titre than cell pools expressing Adalimumab again. The 
high transfection efficiency at over 70% for most cell pools suggested puromycin selection 
had been achieved and good expression of the fusion protein and stable integration of the 
pMRXIP plasmids in the majority of the cells. 
The combination of the transient and stable pool data suggested that the transfection of 
mpDG44/ADA 7 and mpDG44/Bloso 6 with vectors for the expression of the SNARE 
proteins of interest was an appropriate strategy to assess the impact of SNARE engineering. 
Cell pools expressing the model IgG protein and high transfection efficiency were obtained. 
Detection of expression of the full size fusion protein was still required and performed to 












5.5.4. Fed-batch over grow (FOG) assessment of the cell pools co-expressing a 
model IgG protein and a target eGFP-SNARE 
The results reported in section 5.5.3 provided evidence about the expression of both the 
recombinant IgG model protein and SNARE of interest was achieved in the newly generated 
cell pools. Fed-batch over grow experiments were therefore performed with one of the 
generated pools of each engineered target. The selection of the pool to be assessed was 
based on the viability of cultures when setting up the experiment with the pool with the 
highest culture viability used to inoculate the FOG experiment. Fed-batch over grow is a 
fed-batch culture approach routinely used at FDB for early material production or screening 
of cell pools and lines. Here, experiments were designed to monitor cell growth and culture 
viability daily from day 2 of culture whilst IgG titre was measured every second day from 
day 4. The concentration of glucose, glutamine, lactate, glutamate and ammonia in the cell 
culture supernatant were monitored daily from day 3. The fed strategy consisted of daily 
addition of Hyclone Cell Boost 7A and 7B at 2% (v/v) and 0.2% (v/v) amounts of the initial 
volume. Hyclone Cell Boost 7A is composed of amino acids, vitamins, salts, trace elements 
and glucose whereas feed 7B contains a concentrated solution of amino acids. Glutamine 
and glucose were also fed to the culture when amounts fell below 0.22 g/L and 3 g/L 
respectively. Glutamine feed consisted of 0.5% (v/v) of 200 mM L-glutamine whereas the 
glucose feed to add was calculated using the equation detailed in 2.2.11. Cells were 
inoculated at 0.2 x 106 viable cells/mL in 60 mL of FDB-MAP containing 8 mM L-glutamine. 
Cultuƌes ǁeƌe iŶĐuďated at ϯϳ˚C, ϭϮϱ ƌpŵ, ϱ% CO2 and 80% humidity for a period of 14 
days or until the culture viability declined to <70%. The cell pools assessed in this 
experiment were mpDG44/ADA 7, DG44/ADA+STX7, DG44/ADA+STX17, 
DG44/ADA+SNAP29, mpDG44/Bloso 6, DG44/Bloso+STX7, DG44/Bloso+STX17, 
DG44/Bloso+SNAP29. Cell pools DG44/ADA+GFP and DG44/Bloso+GFP were also assessed 
in this experiment as controls. 
Figure 5.14 reports the viable cell concentrations and culture viability across the different 
fed-batch cultures. No large differences were observed in the growth characteristics 
between the cell pools engineered with the different SNARE proteins. A difference was 
observed between the growth characteristics of the cell pools expressing Adalimumab or 
Blosozumab, suggesting an effect of the IgG target product on the cell pool phenotypes. 
Blosozumab expressing cell pools grew faster and the culture viability decreased rapidly 
from day 7 compared to the Adalimumab expressing cell pools. The culture viability of cells 
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pools expressing Blosozumab declined below 70% culture viability on day 12, two days 





Figure 5.15 reports the IgG titre measurements for each sampling day (day 4, 6, 8, 10, 12, 
14) for all the cell pools assessed. At day 12, no statistical difference was observed between 
the different cell pools when expressing the recombinant protein Blosozumab. All the cell 
pools achieved a titre over 1500 µg/mL with the highest titre at 1700 µg/m achieved by the 
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control cell pool co-expressing eGFP. No titre at day 14 was available for the different cell 
pools expressing Blosozumab because the FOG experiment was stopped at day 12 when 
they reached viabilities declined to <70%. 
 
For the cell pools expressing Adalimumab, titre at day 14 was approximately half of that for 
the cell pools expressing Blosozumab at day 12 (around 800 µg/mL for Adalimumab cell 
pools and 1600 µg/mL for Blosozumab cell pools). Little difference in titre was observed 
between the cell pools except for cell lines DG44/ADA-STXGFP and DG44/ADA-STX7 which 
appeared to express slightly less than the other cell pools. It was observed that for the 
different cell pools the titre increased until day 10 after which there was a reduced increase 
in IgG yield between day 10 and 14. For example, the titre in the DG44/ADA cultures went 
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from 430 to 690 µg/mL from day 8 to 10 (increase if 260 µg/mL over 2 days) but then only 
increased to 837 µg/mL from day 10 to 14 (increase of 145 µg/mL). This phenomenon was 
not observed in the cell pools expressing Blosozumab where titre increased more-or-less 
constantly every 2 days. When comparing the different specific productivities, no statistical 
difference was observed between the control cells and when expressing the different 
syntaxin/SNAP proteins. The noticeable difference was IgG specific between the cell pools 
expressing Blosozumab or Adalimumab. Blosozumab expressing cell pools had specific 
productivities more than twice that of the cell pools expressing Adalimumab. Specific 
productivity calculations take into account the viable cell concentration, suggesting that 
not only did the Blosozumab expressing cell pools grow faster but they also produced more 
molecule of interest. 
The metabolite consumption or production data are reported in Appendix 4. Cell pools 
expressing Blosozumab had a lower concentration of glutamine and glucose in the media 
compared to the cell lines expressing Adalimumab, suggesting that the cells used this more 
rapidly indicative of the faster growth. At the end of the experiments, cell pools expressing 
Adalimumab had a higher concentration of glutamate and ammonia in the media than 
pools expressing Blosozumab although the increased amount was not large. Amounts of 
lactate were similar between the different cell pools although cells producing Blosozumab 
tended to have a lower concentration of lactate from day 6.  
5.5.5. Analysis of the expression of the syntaxin/SNAP fused proteins in the 
DG44 cell pools co-expressing a model IgG recombinant protein  
When the IgG cell pools were engineered to co-express a target eGFP-SNARE fusion 
protein, no assessment was performed to determine if a full size fused syntaxin protein was 
expressed in these pools. Cellometer analysis was able to confirm fluorescence of the cells 
and hence the presence of a properly folded eGFP tag but no information on the SNARE 
part of the fused protein was accessible with the Cellometer results. Western blot analyses 
were therefore performed on total protein extracts from pellets harvested at day 4 and 10 
of culture during the FOG experiment. Proteins were extracted from cell pellets of the 
different cell pools producing either Blosozumab or Adalimumab and samples prepared 
under reduced conditions. Results of the western blot analysis are showed in Figure 5.16. 
After incubation of the different membranes with anti-GFP antibody, signal was detected at 
the expected size for the cell pools expressing STX7, STX17, SNAP29 and GFP and co-
expressing either blosozumab or Adalimumab on both days. No signal was detected for 
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mpDG44/ADA 7 or mpDG44/Bloso 6 (DGV controls) as expected as these were not 
engineered to express an eGFP fused protein or GFP. Comparison of the amounts of 
expression with β-acting gave an indication as to the relative level of expression in the 
different triplicates. No obvious difference in eGFP-SNARE fusion protein expression was 
observed between the different triplicates. A band corresponding to the eGFP tag alone 
was visible at day 10 for the cell pools expressing Blosozumab and SNAP29 implying 
cleavage of the tag. At day 10, cells expressing Blosozumab had a reduced culture viability 
indicating cell death. The signal for the eGFP tag alone might come from cells undergoing 
cell death and degrading their internal content in protein. 
 
 
5.6. Comparison of the endogenous amounts of the target SNAREs in 
the two CHO host cell lines, Clone 27 and CHO-S  
The CHO-S and CHO-DG44 host cell lines were derived from the same ancestor host cell line 
(Reinhart et al. 2018; Urlaub et al. 1983). However, as cell lines are originated from 
different sources, are under different selection pressures and grow in different media, they 
may not express the endogenous target engineered SNARE proteins at a similar amount. To 
compare the relative amounts of SNARE protein expressed between the two host cell lines 
examined in this study, western blot analysis was performed on pellets from Clone 27 cell 
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lines used at FDB and the CHO-S cell line used at the University of Kent. Specific antibodies 
against STX7, STX18 and SNAP29 were used. Two different protein extracts were analysed 
for each cell line. Figure 5.17 reports the different western blot analyses of these samples 
using specific antibodies for SNAP29, STX18 and STX7 on the protein extracts. When 
analysing for STX18 expression, a clear signal was obtained for both cell lines (band at 42 
kDa). When performing densitometry to quantify the relative level of expression of STX18 
in both cell lines, the analysis showed that the level of expression was similar. When 
probing with anti-STX7 and anti-SNAP29 antibodies a number of non-specific bands were 
observed (Figure 5.17), the expected sizes for STX7 and SNAP29 are 42 kDa and 29 kDa 
respectively. A faint band at the expected size was observed and densitometry performed 
on this band and the results are displayed in Figure 5.17. Expression levels of STX7 in Clone 
27 and CHO-S cell lines were similar when normalised with the signal for the house keeping 
pƌoteiŶ α-tubulin whereas higher levels of SNAP29 were detected in Clone 27 compared to 








This chapter reports on the implementation of the strategy validated in Chapter 4, for the 
enhancement of the secretory capacity of CHO cells by SNARE engineering, in an industrial 
environment. In collaboration with Fujifilm Diosynth Biotechnologies, an industrially 
optimised DG44 CHO host cell line known as ͞Clone 27͟ was engineering to overexpress 
SNARE proteins shown to have an effect on productivity and/or cell survival in the CHO-S 
host cell line (see Chapter 4). The experiments performed were carried out following 
procedures used at FDB in their own facilities. The aim was to determine whether the 
strategy validated in a CHO-S host cell line in the academic laboratory was reproducible and 
transferable to industry in another CHO host cell line. 
To try and avoid using plasmids unoptimised for use in the FDB host cell and to avoid a dual 
system of selection (the pMRXIP plasmid selection used in Chapter 4 is based on 
puromycin), the different syntaxin/SNAP genes were cloned into the DGV. The different 
genes coding for the SNARE of interest used for the construction of the different pAVE 
vectors were not fused to an eGFP tag as in the previous studies. In order to reduce the 
burden placed on the engineered host to a minimum and move the potential for any 
negative impact on the target function of the presence of the GFP tag, the fluorescent tag 
was removed. For the detection of the protein of interest, specific antibodies to the protein 
were required. Alternatively, qPCR for mRNA detection could be undertaken to confirm 
that at the transcript level elevated expression had been achieved. 
Two DGVs were used as backbones in the studies described in this chapter, one expressing 
the IgG Adalimumab and one expressing the IgG Blosozumab. As previously detailed, 
Adalimumab is an IgG1 molecule used to treat inflammatory arthritis. Adalimumab was 
kept as a model protein to be able to compare directly with the results previously reported 
in Chapter 4. Blosozumab is an IgG4 molecule developed for the treatment of osteoporosis 
by Eli Lilly (Reid 2017). Blosozumab is a standard molecule used by FDB to test new 
processes and strategies. Both molecules are type G immunoglobulins but from different 
classes, 1 and 4, with a principal difference in the number of disulphide bonds in the hinge 
region (Vidarsson, Dekkers, and Rispens 2014). Vectors for the expression of both 
molecules and the syntaxin proteins were generated.  
Additional vectors for syntaxin STX17 and STX18 fused to an eGFP tag expression were 
generated to be able to investigate any impact of the presence of the tag on the effect of 
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expression of the protein. Previously (Chapter 4), only verification of the correct folding of 
the fluorescent tag and expression of the full length fusion protein were performed. 
SNAREs are membrane proteins and important components of the vesicle traffic system in 
the cells and hence their function and localisation is important and could be impaired by 
the presence of a tag. The presence of the eGFP might disturb their function or localisation 
generating unexpected effects on the observed cell phenotype (Cui et al. 2016). A 
comparison between constructs expressing GFP fused and non-fused SNARE proteins 
would give information about any potential effect(s) of the tag on the cell phenotype. 
Other vectors expressing syntaxin STX17 and STX18 under the control of the HSV miniTK 
promoter were also generated. Indeed, the work in Chapter 4 had shown that the effect of 
SNARE expression on the CHO-S cell was dependent on the level of expression. In the case 
of STX17 higher expression was related to higher productivity and lower expression 
resulted in prolonged culture viability under batch culture conditions. All the different 
constructs generated in this chapter are detailed in Table 5.1. 
After generation of the vectors necessary for the different experiments, mini-pools stably 
expressing a model IgG protein and SNARE of interest were generated. Mini-pool 
generation is a strategy implemented in the industry as a first screening method for rapid 
generation of monoclonal like cell lines for phenotype studies. Generation of mini-pools is 
faster than the generation of monoclonal populations and gives phenotypes close to that of 
monoclonal populations. Mini-pools are therefore a rapid way to test strategies or obtain 
early material generation without the stringency of a monoclonal cell line generation 
process. 
Mini-pools generated were subjected to 3 selection steps, one based on confluency and 
monoclonality and two based on product titre. After transfection, dilution in 96-well plates 
and recovery, wells with culture viability between 50 and 70% and a monoclonal profile 
were selected for expansion into 24-well plate. To ensure sufficient diversity, 48 mini-pools 
were selected. After a week of growth in 24-well plates, mini-pools were screened on their 
titre concentration using an Octet device. The results demonstrated titre below the limit of 
quantification for the different mini-pools engineered with the SNAREs or eGFP control 
whereas mini-pools stably transfected with the DGV yielded detectable titres. Low titres 
were expected at this stage due to the conditions of the screen. Indeed, suspension cells 
were grown in an adherent culture and cells might still be recovering from the selection 
process. Moreover, only a low number of cells might be present. Nonetheless, detectable 
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titres are the norm from FDB experience with this process. Blosozumab expressing mini-
pools had higher titre levels than Adalimumab (24.9 µg/mL for the lowest Blosozumab 
expresser against 22.2 µg/mL for the best Adalimumab expresser). This trend was observed 
for all the different experiments suggesting that Blosozumab was aŶ ͞easier to eǆpƌess͟ 
molecule compared to Adalimumab. 
Because low titres were a possible outcome during the first selection step based on 
product titre, and that the process was different from the original FDB cell line 
development process, mini-pool selection was advanced further by the selection of the top 
8 mini-pools for each condition and progression in T25 flasks and then spin tubes. After a 
few passages of the mini-pools in spin tubes, titre was analysed again. The results still 
showed low/undetectable titres for the different mini-pools engineered with SNARE 
proteins whereas cells stably transfected with DGVs showed increased titres. Low titres for 
cells engineered with SNARE proteins using pAVE vectors were also observed in an 
attempted to generate bulk cell pools (section 5.3.2). The observation of low titres with all 
vectors with the co-expression of a model IgG and a SNARE protein in two different 
processes suggested that the limitation was either around the SNARE vectors or that in the 
CHO-DG44 cells over-expression of the SNAREs somehow prevented secretion of the target 
IgG molecule.  
Two possible events might explain the lack of expression of the model IgG protein from the 
constructs generated. When inserting the different SNARE genes and the elements for their 
expression (CMV promoter and bGH polyA tail) into the expression vector, options for 
cloning these in were limited in the DGV. Due to cloning constrains, two bGH polyA tails 
were present back to back with a relatively small distance between them, less than 100 bp 
(see Figure 5.18) in the final constructs generated. The two polyA tails were elements of 
the heavy chain and SNARE sequences. By their close proximity, and the single strand 
nature of the mRNA, possible hybridisation of the two tails could prevent translation of the 
mRNA into a protein. Another possibility is transcriptional interference. Transcriptional 
interference refers to direct negative impact of one transcriptional activity on another 
(Shearwin, Callen, and Egan 2005). Here, two promoters were convergent and in close 
proximity, the CMV promoter driving the expression of the syntaxin gene and the EF-ϭα 
promoter driving the expression of the heavy chain gene (Figure 5.18). Several reports 
suggest that the EF-ϭα pƌoŵoteƌ is more active than the CMV promoter in CHO cells (Kim 
et al. 2002; Wang et al. 2017). From the results observed when using the generated 
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constructs, no or little recombinant IgG model protein was expressed whilst no information 
was collected as to the expression of the SNARE protein. Undertaking qPCR to determine 
mRNA amounts of the IgG heavy chain in the presence/absence of the SNARE and 
associated polyA tail could be undertaken to confirm if there was transcriptional 
interference. Two different transcriptional interference mechanism could take place, 
collisioŶ ǁheƌe ĐoŶǀeƌgiŶg eloŶgatioŶ Đoŵpleǆes Đollide aŶd ͞fall off͟ oƌ ƌoadďloĐk ǁheŶ 
the converging elongation complex from the weaker promoter inhibits progression of the 
elongation complex from the strong promoter To determine if, and what kind of 
transcriptional interference might have been happening (collision or roadblock), further 
investigations about the transcriptional expression of the syntaxin gene would be required. 
 
Transient transfection performed to study the impact of the eGFP tag and of the use of 
different strength promoters gave unexpected results possibly linked to the vectors design. 
The experiments described in section 5.5.3 showed transient expression was possible in the 
CHO-DG44 cells and that the transient expression of the SNAREs in the stably expressing 
IgG mini-pools positively impacted on transient IgG yields (see Figure 5.12) but when the 
transient transfection was undertaken with a vector containing the IgG molecule and the 
syntaxin gene with the back-to-back polyA tails the IgG concentration observed was low. 
High variability was also observed for the conditions achieving higher product 
concentrations with the single vector transient expression. After the different experiments, 
no satisfactory transfection conditions were found for the transient transfection of Clone 
27 cells with NovaCHOice reagent. 
As the pAVE system vectors containing the SNARE genes did not give appropriate IgG 
yields, a different strategy was applied to obtain syntaxin/SNAP and IgG co-expressing cell 
lines. Mini-pools, which had the DGV integrated and were already expressing the IgG, were 
transfected with the plasmids used in Chapter 4, pMRXIP-STX7, pMRXIP-STX17, pMRXIP-
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STX18, pMRXIP-SNAP29 and pMRXIP-STXGFP. When using these vectors, selection using 
puromycin was used to obtain stably expressing target syntaxin cell pools. To determine 
the adequate concentration of puromycin to use with these pools, Clone 27 was cultured in 
the presence of different amounts of puromycin and the cell number and culture viability 
monitored. The results showed that a concentration of 10 µg/mL was sufficient for 
selection of stably expressing cell pools after recovery. This concentration was higher than 
the one used for the generation of stably expressing cell lines with CHO-S but as discussed 
before, CHO derived cell lines have a large genetic heterogeneity.  
Stably SNARE expressing cell pools were generated and early assessment of their 
productivity undertaken to detect any decrease in production compared to the parent pool 
of the recombinant model protein. Two pools were generated for each construct/SNARE. A 
first measurement of titre was assessed 5 days after transfection. The titres measured were 
low but detectable which was an improvement over the previous approach using a single 
vector containing the IgG and syntaxin/SNAP genes. Moreover, mini-pools transfected with 
SNAP29 notably demonstrated a positive effect on productivity over the eGFP expressing 
control when expressed transiently assenting with results from Chapter 4. When titre was 
measured again after 2-3 passages in shake flask (when stable cell lines for both the model 
recombinant molecule and the SNARE protein were established), no significant effect was 
observed .This observation might suggest a larger burden on the cells in transient 
conditions overcame by the overexpression of the eGFP-fused SNARE protein compared to 
stable expressing conditions. By measurement of cell fluorescence, low transfection 
efficiencies were also observed. Measurements were undertaken on cells 5 days after 
transfection in a media without selection agent (puromycin) and in a static environment. 
The absence of the selection agent and the short period of recovery since electroporation 
were probably the cause for low titre and observed transfection efficiency. Because no 
selection was added, the different cell lines did not integrate stably the plasmid into their 
genome diluting the expression of fluorescent protein by cell division and degradation of 
non-integrated plasmid. Moreover, cells were recovering from electroporation and 
probably directing their energy towards cell survival and division instead of recombinant 
protein production. Meanwhile, titres were detectable and cell pools were recovering in 
media containing selection agent to ensure the selection of cells where integration of the 
vectors into their genome had occurred. It is noted that no cells co-expressing eGFP-STX18 
and the model IgGs recovered after electroporation. Previously, only low expressers and 
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cells expressing a truncated fused protein were generated (see 4.2) suggesting that high 
levels of STX18 might be detrimental to the cells. 
After recovery of the cells and 2-3 passages in Erlenmeyer flasks, the titre and transfection 
efficiency were measured again. High titre and transfection efficiency were observed 
implying the success of the strategy, transfection of mini-pools expressing Adalimumab or 
Blosozumab with pMXRIP for expression of the target syntaxin/SNAP proteins. These 
results also provided further evidence that the design of the pAVE vectors was responsible 
for the lack of IgG expression when previously generating mini-pools and cell pools with the 
single pAVE vector approach. Fluorescence was assessed for the different cell pools 
demonstrating eGFP tag expression but no information was available about the expression 
of the full length fused SNARE protein from these data. In the previous experiments, no 
cleavage of the tag was observed except for the eGFP-STX18 fused protein giving 
confidence that it was likely the expression of the full length fused proteins occurred. Cells 
co-expressing the model IgG protein of choice and target SNARE proteins were therefore 
generated and used for further experiments, notably FOG experiments, to assess any 
impact on cell growth and productivity. 
Fed-batch over growth or FOG is a fed-batch culture approach widely used in industry for 
the screening purposes or the generation of early material. For screening, FOGs are mainly 
undertaken at small scale such as 24-DWP and in spin tubes and small shake flasks while 
larger scales are reserved for early material generation. Due to the number of cell pools to 
test, and the need of regular sampling, the initial volume of the FOG was 60 mL in 250 mL 
Erlenmeyer flasks with vented caps in this study. During the FOG, viable cell concentration, 
culture viability, IgG titre and specific metabolites levels were monitored.  
When the results for viable cell concentration, culture viability and titre were compared 
between the control and SNARE engineered mini-pools, any differences observed were 
between the model IgG proteins produced and not between the controls and mini-pools 
engineered with the different SNARE proteins. Thus, there was no impact of the 
overexpression of the SNARE proteins observed on growth, culture viability and IgG 
production when producing Adalimumab or Blosozumab. Faster growth, higher titre and 
cell specific productivity was observed for Blosozumab producing cell lines compared to cell 
pools producing Adalimumab. Adalimumab and Blosozumab are both antibodies but from 
two distinct subclasses, IgG1 and IgG4. Both IgG1 and IgG4 have similar structures but IgG4 
have less secondary structure complexity with fewer inter heavy chain disulphide bonds in 
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the hinge region compared to IgG1 (Vidarsson et al. 2014). This reduced complexity might 
be the explanation for the greater yield of product from cells producing Blosozumab 
compared to Adalimumab. Indeed, the presence of fewer disulphide bonds makes the 
molecule easier and faster to assemble, producing less stress on the cells and notably on 
the ER. It was also observed that cell lines producing Adalimumab had a reduction of 
recombinant protein expression from day 10 compared to cell lines producing Blosozumab 
which maintained their productivity through time. 
Metabolites levels between cell pools producing Adalimumab or Blosozumab can be linked 
to their different growth profiles. Cells producing Blosozumab grew faster and consumed 
more resources to maintain their division, this was linked to the lower concentrations of 
glucose, the main source of energy in the media, and glutamine, an important amino acid 
for protein production and also energy production, observed compared to the cells 
producing Adalimumab. The concentration of lactate diminished during the culture 
indicating an intake by the cells which happens when cells switch their metabolism in 
presence of low glucose concentration (Mulukutla, Gramer, and Hu 2012). A reduction of 
lactate reduction was more important in cells producing Blosozumab suggesting a higher 
consumption. Adalimumab expressing cell lines tended to have higher glutamate and 
ammonia concentrations in culture notably from day 10. Fast growing cells need more 
energy to divide, mainly provided by aerobic mitochondrial respiration. However, aerobic 
mitochondrial respiration is responsible for the generation of reactive oxygen species (ROS) 
(Cadenas and Davies 2000). To mitigate against the effects of ROS, cells have defence 
mechanisms, notably the production of reduced glutathione (Birben et al. 2012; Davies 
2000; Pereira et al. 2018). Two amino acids are essential for glutathione synthesis, 
glutamate and cysteine. Cancer cells with high proliferation rates can recycle ammonia 
(Spinelli et al. 2017) which may also happen in CHO cells with high growth rates. Cell pools 
producing Blosozumab might produce higher levels of reduced glutathione necessary to 
counterpart elevated oxidative stress due to faster growth. For this production, glutamate 
and ammonia intake would be necessary, explaining the difference in ammonia and 
glutamate concentration between cell pools producing Blosozumab and Adalimumab at the 
end of the experiment. Moreover, elevated oxidative stress in the stationary phase might 
explain the reduced productivity of cells expressing Adalimumab. It has been demonstrated 
that high oxidative levels downregulates gene expression (Morel and Barouki 1999).  
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No differences in the productivity between the different cell pools stably engineered with 
the syntaxin/SNAP and the controls were observed which did not agree with the findings in 
Chapter 3 and 4. No control of the actual expression of the fused protein was performed 
with the cell pools generated and used in the FOG experiment, hence an absence of the full 
size fused protein could have explained the absence of effect. Total protein extractions 
were then performed on 2 different days to determine if the fused protein were correctly 
expressed and not cleaved. After western blot analysis, expression for the different cell 
liŶes of the fused pƌoteiŶ ǁas ĐoŶfiƌŵed. Those ƌesults suggested that the eGFP tag ǁasŶ͛t 
cleaved and the full size fused protein was expressed but no confirmation of the correct 
folding and activity of the syntaxin protein was performed. 
A major difference between the assessments in Chapter 3 and 4 and that in this chapter is 
in how the assessment was undertaken. In the earlier work all assessment involved the 
transient expression of the recombinant molecule of interest, largely transfected into CHO-
S cell lines already engineered to over-express the SNARE protein of interest at a defined 
level. In this chapter, cell pools expressing the highest amounts of the target recombinant 
protein were selected and then the syntaxin/SNAP molecule over-expressed in these. This 
is a very different approach to the assessment. In the first approach, cells for engineering 
and assessment were selected based upon different exogenous syntaxin/SNAP expression 
and then assessed by their ability to transiently express a secretory recombinant protein. In 
this chapter, already high expressing pools of IgG were selected and then the SNARE was 
expressed in these cell pools with the result that there would be different amounts of 
syntaxin/SNAP expressed across the pool. As the amount of SNARE expressed in Chapter 4 
suggested this was important in observing an impact, the difference expression across cells 
may mean that no net effect is observed when in a pool. Therefore, cloning of these pools 
to identify monoclonal cell lines with different SNARE expression and then assessment of 
the growth and titre impacts might elucidate an impact of different syntaxin/SNAP 
expression amounts. In retrospect, and in order to more closely mirror the earlier studies, it 
may have been a better approach to select the 2 or 3 SNAREs with the greatest impact on 
titre from Chapter 4 and then make new host DG44 cell lines over-expressing these to 
different amounts. These could then have subsequently been assessed for their ability to 
transiently and stably express target secretory recombinant proteins. 
It is noted that the CHO-S and Clone 27 cell line hosts have a common ancestor but remain 
genetically different. Moreover, development of Clone 27 and the expression system and 
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bioprocess around this is the result of several years of cell line development to obtain a 
host suiting FDB needs. With that information in mind, the amount of endogenous 
syntaxin/SNAP could already be naturally upregulated in Clone 27 explaining the lack of 
effect. After western blot analysis and densitometry with specific antibodies on total 
protein extract of Clone 27 and host CHO-S cells, no significant difference was found in the 
expression of STX18 or STX7. A difference in the levels of SNAP29 was observed when 
measuring the expression levels by densitometry. Levels of expression were two times 
higher in Clone 27 cell line compared to CHO-S cell line. The bands used for the 
densitometry analysis were faint, implying a strong effect of the background signal on the 
values calculated. A hypothesis for the absence of effect in Clone 27 when engineered with 
SNARE proteins is the presence early on of a bottleneck in the secretory pathway such as in 
the ER capacity or transcriptional level.  
 
5.8. Conclusions 
This chapter reports on experiments undertaken to confirm the approach validated in 
Chapter 4 in an industrial environment and with a different host cell line. All experiments in 
this chapter were performed with Clone 27, a CHO-DG44 host cell line, at FDB facilities in 
order to be in conditions as close to an industrial cell line development process with the 
different targets identified in Chapter 4. After generating the different vectors using the 
pAVE platform, mini-pools and cell pools were transfected to obtain cells stably expressing 
a model protein, Adalimumab or Blosozumab, and a target SNARE, STX7, STX17, STX18 or 
SNAP29. Unfortunately the different cell pools generated using the pAVE plasmid set did 
not produce any recombinant protein when co-expressing a SNARE. By the close proximity 
and the convergence of a CMV promoter and an EF-ϭα pƌoŵoteƌ, tƌaŶsĐƌiptioŶal 
interference was thought to be reason for the absence of production. Further analyses 
were needed to confirm this hypothesis. Another strategy was implemented to generate 
co-expressing cell lines, the transfection of cell lines already producing Adalimumab or 
Blosozumab with vectors generated in Chapter 3. After validation of the expression of 
recombinant protein for the newly generated cell lines, FOG experiments were 
accomplished. Results showed no effect of the different overexpressed ectopic syntaxin 
target on the growth or productivity. Differences observed suggested that Blosozumab was 
aŶ ͞easieƌ͟ to produce molecule compared to Adalimumab with cells growing faster and 
producing more. Western blot analysis on pellets from the FOG experiment confirmed the 
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expression of a full size fused protein for the different SNARE targets and further analysis 
by western blot and densitometry on the host cell lines, Clone 27 and CHO-S, demonstrated 
no difference in the endogenous expression of the different SNAREs. The discussion of this 




CHAPTER 6: Overall Discussion, Conclusions and 
Future Work 
 
The work performed and reported in this thesis was focused around the investigation and 
manipulation of SNAREs, important proteins necessary for vesicle fusion, and the impact of 
their manipulation on the secretory capacity of CHO cells. To achieve this, vectors for the 
expression of eGFP fused SNARE proteins were designed and used to generate CHO-S cell 
lines stably expressing the different SNARE targets. The SNARE engineered cell lines were 
then characterised with respect to their growth characteristics and ability to secrete target 
recombinant proteins. To assess the later, transient transfection experiments were 
performed with model proteins, the IgG antibody Adalimumab and the Fc-TNFR fusion 
protein Etanercept, to determine SNARE manipulation effects on the secretory machinery. 
After initial validation of the strategy in the CHO-K1 derived CHO-S host cell line, a different 
industrial cell line, a CHO-DG44 derived cell line known as ͞Clone 27͟ developed by Fujifilm 
Diosynth Biotechnologies, was engineered with the same targets to investigate the 
transferability of the strategy across different host CHO cell lines. The main finding from 
the work was that expression of two SNAREs, STX17 and SNAP29, at particular amounts, 
extended culture longevity times and improved culture viability. An increase in the 
secretory productivity was also observed (up to 5-fold change for STX17 and 2.5-fold for 
SNAP29) in CHO-S cells engineered with STX17, SNAP29 and to a lesser extent STX18 when 
expressing model proteins in a transient manner. These results are in line with other 
studies using SNAREs to improve recombinant protein production (Peng et al. 2011; Peng 
and Fussenegger 2009) suggesting that SNARE engineering and more globally vesicle traffic 
and formation manipulation can enhance the secretory capacity of CHO cells.  
When generating eGFP-SNARE engineered CHO-S monoclonal cell populations of the 
different targets of choice, it was observed that the cell lines expressing VAMP fusion 
proteins expressed at lower amounts compared to the STX/SNAP engineered cell lines as 
determined by the relative eGFP expression. Moreover, after monoclonal selection and 
adaptation of the monoclonal cell lines most of the selected monoclonal cell lines 
expressing a target VAMP protein lost the majority of their expression suggesting this was 
unstable or that overexpression was toxic to cells and only those with very low exogenous 
expression survived prolonged culture. An siRNA screen (Gordon et al. 2010) demonstrated 
that none of the VAMP proteins were essential for constitutive secretion in HeLa cells 
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suggesting that other R-SNAREs are able to rescue the lost function of VAMP proteins 
although siRNA only knocks down expression and does not completely delete it. Thus, a 
small amount of VAMP protein may remain even under siRNA knockdown conditions that 
may be sufficient to undertake the required VAMP role. Moreover, it has been observed 
that overexpression of VAMP4 in HeLa cells impacts the regulation of VAMP4 (Laufman et 
al. 2011), suggesting that overexpressing a VAMP could interfere with its role and control 
of the secretory pathway, impacting on crucial steps requiring tight regulation for cell 
survival such as membrane homeostasis. However, generation of cell pools expressing 
exogenous VAMP has been performed with and without a GFP tag (Laufman et al. 2011; 
Peng et al. 2011) suggesting that some level of exogenous expression of VAMP is possible 
but no high expressing VAMP cell lines were generated. To investigate and potentially 
overcome any possible toxicity of the expression of exogenous VAMP, the generation of an 
inducible system could be applied, notably in the case of VAMP7 for which no viable stably 
expressing cells were generated.  
After generation of monoclonal cell populations expressing the eGFP-fused SNAREs at 
different amounts, growth profiles under batch culture conditions were generated to 
characterise any impact of the expression on the growth phenotype of the cells. The 
expression of the eGFP-SNAREs generally had no effect on the growth profiles in terms of 
the viable cell numbers achieved or the culture viability, except for cells engineered to 
express eGFP-STX17 or eGFP-SNAP29 in which case some of the cells showed an extended 
culture time and culture viability. In both cases these were cell lines that expressed the 
proteins of interest at a low level compared to other cell lines, suggesting that high levels of 
expression have detrimental effects. This could be linked to UPR overload leading to 
apoptosis but would need to be confirmed.  
STX17 and SNAP29 are both part of a trans-SNARE complex involved in the autophagy 
process, specifically the fusion of autophagosomes with lysosome (Hubert et al. 2016; 
Itakura et al. 2012). Autophagy is a mechanism involved in the degradation and recycling of 
elements in the cell such as unwanted proteins, damaged mitochondria, intracellular 
pathogens and in some cases protein aggregates, which is triggered by starvation 
conditions and notably lack of critical amino acids such as arginine, leucine, lysine or 
methionine (Han et al. 2011; Levine and Yuan 2005). While apoptosis is termed 
programmed cell death I (PCDI), autophagy is considered as programmed cell death II 
(PCDII) even if autophagy is more of a pro-survival mechanism. Indeed, by degradation of 
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membranes and proteins autophagy generates essential nutrients (amino acids and fatty 
acids) that can be reused by mitochondria for ATP production or for protein synthesis in the 
ER (Levine and Yuan 2005).  
The growth characterisation of the different monoclonal cell lines was performed under 
batch culture conditions where nutrient depleted conditions would be expected to be 
perceived by cells at the end of the culture (end of stationary phase). One hypothesis as to 
why specific amounts of over-expression of STX17 and SNAP29 might impact growth and 
productivity characteristics is that when tuned to particular amounts this may improve the 
cells recycling capacity by improving autophagy. As a result, more nutrients would be 
available to the cell which is able to maintain its integrity for longer. Whilst lower levels of 
STX17 and SNAP29 improve culture viability, higher levels may trigger too much autophagy 
leading to autophagy mediated apoptosis (Levine and Yuan 2005). This is in line with 
reported work on autophagy and apoptosis engineering, where overexpression of Bcl-2, an 
anti-apoptotic regulator, and Beclin-1, an autophagy inducer, led to increased culture 
period as well as higher viability during serum-free suspension culture but also protected 
the cells from cell death more efficiently when an insult was made to the cells. Collectively 
this supports the argument that ͚ĐoŶtƌolled͛ autophagy induction is a strategy that can 
improve culture longevity and viability in batch mode. While strategies to inhibit PCD by 
regulation of apoptosis and autophagy have been performed (Hwang and Lee 2009; Kim et 
al. 2009), a certain level of autophagy in the cells might be desirable to remove damaged 
membranes and proteins in order to recycle nutrients and energy to the cell (Zustiak et al. 
2008). 
When monoclonal cell populations overexpressing fused eGFP SNAREs were transiently 
transfected with plasmids for the production of the recombinant proteins Adalimumab or 
Etanercept, cells overexpressing STX17 and SNAP29 showed an increase in productivity of 
the recombinant molecule. Those cells expressing the eGFP-STX18 fusion also showed an 
increase in recombinant protein productivity but to a lesser extent. As discussed above, 
only a specific expression profile had an impact on productivity, that being the relatively 
high expression of STX17 (compared to the other eGFP-STX17 expressing cell lines) and low 
expresser of SNAP29. There was no impact of cell lines expressing high levels of SNAP29 
observed on productivity, suggesting that higher levels resulted in a cancelling out of the 
impact of a more moderate over-expression whilst lower levels of STX17 had less impact on 
productivity than higher levels of STX17, suggesting a tuning effect dependent on STX17 
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levels of expression. Again, collectively these data show that there is likely to be an 
͚optiŵuŵ͛ aŵouŶt of “NA‘E oǀeƌ-expression that helps tune the overall secretory capacity 
of the cell that is probably dependent upon the make up of the secretory capacity of a 
particular cell line. It should also be noted that although 3 different monoclonal cell lines 
were generally investigated, it is possible that a particular monoclonal cell lines happens to 
have an overall ͚eŶhaŶĐed͛ seĐƌetoƌǇ ĐapaĐitǇ that ǁas Ŷot due to “NA‘E eŶgiŶeeƌiŶg.  
Only monoclonal cells expressing low levels of eGFP-SNAP29 had an increase in secreted 
recombinant protein productivity with a reduced effect observed in fed-batch culture 
experiments, once again suggesting that the increase of productivity under batch 
conditions could be linked to autophagy activity as described for the effect on culture 
viability. Indeed, during fed-batch culture, media is supplemented with essential nutrients 
in order to support cell growth. Under those conditions, the cells are presumably not under 
starvation conditions, implying low levels of autophagy and hence overexpression of 
SNAP29, involved in the fusion of autophagosomes and lysosomes, would have less impact. 
By increasing the level of autophagy activity and hence the number of autophagosomes 
and their fusion with lysosomes, cells overexpressing SNAP29 might be expected to impact 
amino acid recycling in particular by increasing the fusion events between autophagosome 
and lysosome. High levels of SNAP29 however, could be detrimental to cells by over-
activating degradation of proteins and cell components.  
Impacting of recycling through autophagy might not be the only potential effect of SNAP29 
over-expression. It is suggested that SNAP29 is a regulator of SNARE complex disassembly 
via its capacity to bind to a large range of syntaxins and thereby enhancing its binding to 
vesicles when interacting with a syntaxin. Low levels of SNAP29 might improve productivity 
by generally enhancing vesicle formation and disassembly steps where SNAP29 is involved. 
On-the-other-hand, high levels of SNAP29 might be detrimental by reducing the availability 
of STX to form complexes. Indeed, SNAP29 presence might increase the number of futile 
cycles where trans-SNARE complexes are formed but no fusion event is performed (Baker 
and Hughson 2016). Disassembly of trans-SNARE complexes necessitates the intervention 
of α-SNAP in an ATP dependent process, making the increase of futile cycles an energy 
expensive process for the cell (Hong and Lev 2014). To determine if the effect of SNAP29 on 
productivity is due to its interaction with other STX and ability to form complexes or its 
improvement of autophagy, it would be interesting to carry experiments with autophagy 
inhibitors such as Bafilomycin or 3-methyladenine (Zustiak et al. 2008) and observe 
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whether the effects on productivity are maintained. Immunofluorescence and co-
immunoprecipitation to determine where and with what proteins SNAP29 interacts are 
also experiments that could be performed in order to help elucidate the mechanism of 
action. Electron microscopy experiments could also be performed to determine the 
number and the maturation of the autophagosomes in cell lines overexpressing SNAP29 
compared to control cell lines in order to evaluate if the increase of the likelihood of fusion 
events reduce the number of autophagosomes. 
Another SNARE protein whose over-expression as an eGFP-fusion to impact positively on 
the secretion of target recombinant proteins from the engineered cells compared to the 
control cells was syntaxin17. Relatively low expression of STX17 compared to other 
engineered cell lines resulted in extended culture longevity, whereas higher levels of STX17 
had a positive effect on productivity. It is important to note that lower levels of STX17 also 
had a positive effect on secretory productivity, but to a lesser extent than higher expressing 
STX17 engineered cells, suggesting an effect dependent on the proportion of expression. 
STX17, as for SNAP29 is involved in autophagy, but it is also known to participate in 
mitochondria fission in nutrient rich conditions by interacting with Drp1.  
Mitochondria are the central organelle for the generation of energy where ATP production 
is performed and are necessary for a wide range of cellular functions. Being an essential 
organelle, mitochondria possess their own mechanism for damage repair and recycling, 
fusion and fission. Indeed, impaired mitochondria can be toxic to the cell by producing 
excessive amounts of ROS, ATP consumption through reversal of ATP synthetase or 
interfering in other metabolic processes (Youle and van der Bliek 2012). Fusion promotes 
exchange of healthy material while fission separates damaged parts of mitochondria to 
ensure a healthy mitochondrial network is maintained and for regulation of morphology 
and to facilitate mitochondrial traffic. Damaged mitochondria resulting from fission can be 
directed to autophagosomes to perform mitophagy, a specific degradation of the 
mitochondrion (Ni, Williams, and Ding 2015). 
Before a fission event, Drp1 is recruited by mitochondrial receptors such as Mff, MiD49 and 
MiD51/MIEF1 from the cytosol and oligomerises and folds around the mitochondria. GTP 
hydrolysis of Drp1 leads to constriction and separation of the mitochondrial membrane to 
yield two mitochondria by fission. GTP hydrolysis of Drp1 releases Drp1 from the 
mitochondria. STX17 promotes fission in nutrient rich conditions by directly interacting 
with Drp1 and also Rab32 to avoid Drp1 phosphorylation (Arasaki et al. 2015). Despite 
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being involved in the autophagy pathway, STX17 has not been demonstrated to be 
indispensable for mitophagy (Juhász 2016; McLelland et al. 2016) but only observed to be 
involved in complex with SNAP29 and VAMP7 in the degradation of mitochondria derived 
vesicles via fusion with lysosomes. Modification of mitochondrion dynamics, fusion and 
fission events, is assimilated with degeneration of the cells (Chen and Chan 2009; Knott and 
Bossy-Wetzel 2008) although some work has demonstrated that an increased fission leads 
to an increase in the lifespan of flies and proliferation in vascular smooth muscle cells 
(Marsboom et al. 2012; Rana et al. 2017), suggesting possible positive impact on 
enhancement of mitochondrial fission.  
Promotion of mitochondrial fission in cells overexpressing STX17 might lead to the 
presence of more mitochondria in each cell, possibly providing a greater power house for 
the cell and the ability to produce more energy when required. Moreover, fission is closely 
linked to mitophagy (Twig et al. 2008), suggesting that increased fission in cells would also 
lead to increase mitophagic events which would result in improved recycling of damaged 
mitochondria and making more resources available for protein production. Increased 
mitophagy might also be linked to increased culture viability or cell growth. Indeed, during 
respiration mitochondria are damaged by the generation of ROS yet generation of ROS is 
more important in high proliferating or aging cells. Thus, increased mitophagy would 
improve recycling of damaged mitochondria and positively affect cell growth and culture 
viability. 
As STX17 may have an influence on mitochondrial fission and autophagy in addition to 
SNARE activity, further experiments could be undertaken to determine which, if any of 
these, functions underpins the improvement in secretory recombinant protein productivity 
observed. Mutations of the hydrophobic C-terminal domain of STX17, which is used for its 
interaction with Drp1 (Arasaki et al. 2015), could give an indication as to a role in 
mitochondrial fission in the observed increase in productivity. To determine if the increase 
in productivity upon STX17 overexpression is as a result of augmentation of the energy 
supply of the cell or better recycling of damaged mitochondria, measuring the ATP 
production of cells overexpressing STX17 or specifically block mitophagy with inhibitors are 
suitable experiments to address these scientific questions. Determination of the number of 
mitochondria in cells overexpressing STX17 could also give information about the viability 
of engineering mitochondrial fission. 
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With regard to overexpression of STX17 and SNAP29 and their effect on culture time and 
culture viability, the fact this could be due to increased autophagy has been discussed 
above but this could also underpin the observed impact on productivity too. Indeed, work 
using rapamycin as an inducer of autophagy has demonstrated that this can result in an 
increased final antibody titre under batch condition but no difference under fed-batch 
culture conditions (Han et al. 2011), which mirrors the results reported in this work upon 
overexpression of STX17 and SNAP29.  
To a lesser extent than SNAP29 and STX17, overexpression of STX18 also had a positive 
impact on productivity, notably when transiently producing the IgG Adalimumab. STX18 is a 
SNARE involved in the recycle traffic between the Golgi and the ER and has been suggested 
to be important for the organisation of the ER exit sites (ERES) (Iinuma et al. 2009). ERES 
are subdomains of the ER where COPII complexes form (Budnik and Stephens 2009) and as 
such are key for organisation of traffic leaving the ER. Overexpression of STX18 might have 
a positive effect on productivity by generating or accelerating the turnover at the ERES 
sites. It has been observed that in response to chronic protein overload, cells generate 
more ERES (Farhan et al. 2008). The same phenomenon may happen when overexpressing 
STX18 which would generate more ERES sites, increasing the formation of COPII complexes 
and hence the anterograde transport from the ER. To verify this hypothesis, confocal 
microscopy could be undertaken to determine the number of ERES sites in cells 
overexpressing STX18 and co-immunoprecipitation experiments to observe the partners of 
STX18.  
Interestingly, overexpression of STX18 had a larger effect on secreted Adalimumab 
amounts than Etanercept production which might be linked to the nature of the protein. 
Indeed, Etanercept is a fusion protein which might be more difficult to express than 
Adalimumab generating a bottleneck in the folding and assembly steps rather than the 
secretion and trafficking. The nature of the impact of STX18 overexpression might explain 
the generation of only low STX overexpressing cells. Overexpression of high levels of STX18 
would potentially lead to a high number of ERES being formed, disturbing the balance 
between antero- and retrograde traffic. Membranes might accumulate on one side slowly 
disturbing membrane balance until critical levels that result in cell death are achieved. 
The last results chapter (Chapter 5) investigated transfer of the results observed in Chapter 
4 in the CHO-S host cell line under batch culture conditions to a different host cell line in an 
industrial context at FDB. Mini-pools stably expressing a model recombinant protein were 
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transfected with the plasmids generated in Chapter 3 to create cell pools stably expressing 
an eGFP fused SNARE and a model recombinant protein, Blosozumab or Adalimumab. The 
resulting cell pools were assessed in standard FOG experiments used at FDB to assess cell 
performance. When analysing the growth or productivity of these, there was no impact of 
the different SNAREs being overexpressed compared to the controls. A possible 
explanation for this is the mode of culture for the assessment in Chapter 5, fed-batch over 
grow and the impact of this as opposed to batch culturing as described previously. As 
described above, STX17 and SNAP29 are suspected to have an impact on autophagy which 
might result in increased culture time and increase of productivity. Under batch culture, 
cells are likely to be under starvation conditions towards the end of the culture which 
would trigger autophagy. However, under fed-batch conditions when following the FDB 
feeding regime cells are more likely to stay in nutrient rich conditions, hence autophagy is 
not likely to be activated to the same extent as that under batch conditions. The effect of 
STX17 and SNAP29 in cells with little activated autophagy might therefore be little.  
Another important parameter that could explain the difference in observation between the 
two cell lines and culture conditions is the strategy used. In Chapter 3, cells were first 
engineered to stably express an eGFP-SNARE protein and then selected depending on their 
expression levels before determining their secretory capacity by transient transfection of 
model proteins. On the other hand in Chapter 5, stably expressing eGFP-SNARE pools were 
generated using selected high secretory recombinant protein producing mini-pools. This 
implied that cells expressed different level of SNARE while we showed in Chapter 4 the 
importance of specific level of expression of the different SNARE proteins on the impact on 
the cells regarding culture viability and productivity. Moreover, the selected high producers 
may already have appropriate secretion and bottlenecks may be at a different place (e.g. 
ER located). CHO-S and Clone 27, even if having a common ancestor, are different host cell 
lines and could therefore contain different genetic and phenotypic characteristics. 
Determination of the expression of endogenous levels of some of the overexpressed 
SNAREs was performed. Only expression of SNAP29 might be considered as different 
between the two host cell lines, but more precise quantification would be required to 
determine if this was the case as Western analysis is semi-quantitative at best. 
The use of a transient (Chapter 4) and a stable (Chapter 5) strategy might also provide 
some explanation as to the differences observed. Various studies have shown that 
differences of effect in cell engineering strategies are possible between transient and 
219 
 
stable expression of a model recombinant protein. This phenomenon has been observed 
when engineering CHO cells with XBP-1; overexpression of XBP-1 in CHO cells had only a 
positive impact on productivity upon transient expression of EPO (Ku et al. 2008). The 
authors suggested that XBP-1 demonstrates a positive effect only in EPO-saturated cells 
that occurs during transient expression when numerous copies of vector for expression of 
the model recombinant proteins are present in the cell leading to protein overload in the 
ER. These observations are similar to the results observed in Chapter 4 but also the 
observation of a possible positive effect of SNARE overexpression, notably SNAP29, when 
transiently transfected in CHO-DG44 mini-pools expressing a model protein. Under these 
conditions, cells might be under more stress for protein production that in stable 
expression, so the effect of the overexpressed SNARE is observed under such conditions. In 
order to obtain directly comparable results between those of Chapter 4 and 5 with the two 
different host cell lines, CHO-DG44 cell lines overexpressing the desired SNARE should have 
been generated and selected regarding their level of SNARE expression before testing their 
performance when transiently transfecting model recombinant proteins. 
 
Future Work 
Although there is some promising findings from the work reported here, more work needs 
to be performed to confirm the localisation and function of the different eGFP-tagged 
fusion proteins. Use of specific sub-localisation stains for the different compartment and 
microscopy analysis would allow determination of the correct localisation of the different 
fusion proteins. Different in vitro or in vivo assays with the fusion proteins should be 
performed to determine that they can perform their role in the trans-SNARE complex and 
complete fusion of vesicles membranes. 
To determine if the effects on productivity and culture viability are linked to the 
overexpression of the different SNAREs and not due to the selection of cell lines with 
inherent enhanced secretory characteristics, knock down/out experiments of the 
integrated SNARE gene by siRNA or CRISPR could be performed. Indeed, the limiting 
dilution procedure could result in the selection of cell lines with enhanced recombinant 
protein production capacity that is improved by mechanisms other than enhanced 
secretory pathway capacity. Return to the parental phenotype after knock out of the 
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SNARE gene in the engineered cell lines would confirm the effect of the overexpression on 
the enhancement of recombinant protein production. 
Manipulation of trans-SNARE complexes instead of single SNAREs by multiple over-
expression could also be an interesting approach. Overexpression of the different elements 
of a trans-SNARE complex would allow determination as to whether a specific vesicle fusion 
step could be improved without limiting the effect of individual SNAREs. Nonetheless, this 
approach needs to be conducted with care as the overexpression of multiple proteins 
might trigger the UPR leading to apoptosis of the cells. 
 
Overall Conclusions 
The work described in this thesis outlines the successful manipulation of SNARE proteins as 
an approach for the engineering of the secretory capacity of mammalian cells, specifically 
CHO cells. The outcomes demonstrate that under batch culture conditions, an 
enhancement of culture longevity and prolonged culture viability is observed by the 
overexpression of STX17 and SNAP29, potentially by acting on autophagy activity. Most 
industrial processes are fed-batch processes for biotherapeutic production in order to 
improve the maximum viable cell concentration and secreted recombinant protein 
productivity. Specific engineering of the autophagy pathway to improve the recycling of 
amino acids within the cells without leading to autophagy related apoptosis would be an 
interesting strategy to alter or reduce the feed used. With further study of the mechanistic 
details that underpin how SNARE engineering can deliver enhanced phenotypes in CHO 
cells for recombinant protein production, it might also be possible to improve productivity 
further. The different experiments detailed here reveal the importance of fine tuning 
expression of engineered cells in order to deliver the desired impact on the cell. Indeed, 
only specific levels of the target SNARE had the desired effects, suggesting a different 
approach regarding the use of strong promoters for high levels of overexpression of 
exogenous proteins in cells. Engineering of cell lines already at their full capacity or with 
non-targeted bottleneck will probably result in failure of any engineering strategy. 
Regarding the secretory pathway, high throughput microscopy approaches combining 
automated microscopy and screening could be seen as particularly powerful methods to 
detect bottlenecks (Mathias et al. 2018; Simpson 2009) and if this work is to be taken 
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further forward such an approach would be very beneficial in identifying and delivering 
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length of amplified 
fragment(bp)
Fragment details Tm (
0
C)
Forward HC Adalimumab ATA CTTAAG ATGGAGTTTGGGCTGAGCTGGG (spacer, AflII) 61.9
Backward HC Adalimumab TAT GGATCC TCAGCCGGGGCT (spacer, BamHI) 62.7
Forward LC Adalimumab ATA GAATTC ATG GAC ATG AGG GTC CCT GCT CAG (spacer, EcoRI) 62.5
Backward LC Adalimumab TAT GGATCC TCAGCACTCGCCCCGGTT (spacer, BamHI) 62.5
Forward CMV ATA TTCGAA GACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGG (spacer, BstBI) 58.4
Backward CMV TAT ACGCGT TATATA CACGTG AGCTCTGCTTATATAGACCTCCCACC (spacer, PmlI, MluI) 59.2
Forward bGH ATA CACGTG TATATA GCGGCCGC CTGTGCCTTCTAGTTGCCAGCC (spacer, PmlI, NotI) 60.5
Backward bGH TAT ACGCGT CCATAGAGCCCACCGCATCC (spacer, MluI) 60.5
Forward STX7 ATA CACGTG ATGTCTTACACTCCAGGAGTTGGTGG (spacer, PmlI) 60
Backward STX7 TAT GCGGCCGC TCAGTGGTTCAATCCCCATATGATGAGACT (spacer, NotI) 60.5
Forward STX17 ATA CACGTG ATGTCTGAAGATGAAGAAAAAGTGAAATTACGCCG (spacer, PmlI) 60.4
Backward STX17 TAT GCGGCCG CTTAACTGCATTTCTTGTCAGTTTGGCTGG (spacer, NotI) 61.4
Forward STX18 ATA CACGTG ATGGCGGTGGACATCACGC (spacer, PmlI) 61
Backward STX18 TAT GCGGCCGC CTAGCTGTCGTACCAGTCGAGGAAG (spacer, NotI) 60
Forward SNAP29 ATA CACGTG ATGTCAGCTTACCCTAAAAGCTACAATCCG (spacer, PmlI) 60
Backward SNAP29 TAT GCGGCCGC TCAGAGTTGTCGAACTTTTCTTTCTGTGCT (spacer, NotI) 59.9
Forward GFP ATA CACGTG ATGGTGAGCAAGGGCGAGGA (spacer, PmlI) 61.4






























Appendix 2. Vectors maps 
For the different inserted sequences, several elements are highlighted; yellow for the 
restriction sites used, green for the eGFP sequence, purple for the linker sequence of the 
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Appendix 3. List of generated cell lines. 
 
Plasmid selection Host type Product of interest Recombinant antibody comments section
CHO/V3 pcDNA3.1Hygro/VAMP3 Hygromycin CHO-S Pool eGFP-VAMP3 Chapter 3
CHO/V4 pcDNA3.1Hygro/VAMP4 Hygromycin CHO-S Pool eGFP-VAMP4 Chapter 3
CHO/V7 pcDNA3.1Hygro/VAMP7 Hygromycin CHO-S Pool eGFP-VAMP7 Chapter 3
CHO/V8 pcDNA3.1Hygro/VAMP8 Hygromycin CHO-S Pool eGFP-VAMP8 Chapter 3
CHO/3.1HGFP pcDNA3.1Hygro/GFP Hygromycin CHO-S Pool eGFP Control vector Chapter 3
CHO/STX7 pMRXIP-STX7 Puromycin CHO-S Pool eGFP-STX7 Chapter 3
CHO/STX17 pMRXIP-STX17 Puromycin CHO-S Pool eGFP-STX17 Chapter 3
CHO/STX18 pMRXIP-STX18 Puromycin CHO-S Pool eGFP-STX18 Chapter 3
CHO/SNAP29 pMRXIP-SNAP29 Puromycin CHO-S Pool eGFP-SNAP29 Chapter 3
CHO/MRXIP-GFP pMRXIP-GFP Puromycin CHO-S Pool eGFP Control vector Chapter 3
CHO/STX7 A pMRXIP-STX7 Puromycin CHO-S Monoclonal eGFP-STX7 Chapter 3, 4
CHO/STX7 B pMRXIP-STX7 Puromycin CHO-S Monoclonal eGFP-STX7 Chapter 3, 4
CHO/STX7 C pMRXIP-STX7 Puromycin CHO-S Monoclonal eGFP-STX7 Chapter 3, 4
CHO/STX17 J pMRXIP-STX17 Puromycin CHO-S Monoclonal eGFP-STX17 Chapter 3, 4
CHO/STX17 K pMRXIP-STX17 Puromycin CHO-S Monoclonal eGFP-STX17 Chapter 3, 4
CHO/STX18 C pMRXIP-STX18 Puromycin CHO-S Monoclonal eGFP-STX18 Chapter 3, 4
CHO/STX18 H pMRXIP-STX18 Puromycin CHO-S Monoclonal eGFP-STX18 Chapter 3, 4
CHO/STX18 F pMRXIP-STX18 Puromycin CHO-S Monoclonal eGFP-STX18 Chapter 3, 4
CHO/SNAP29 A pMRXIP-SNAP29 Puromycin CHO-S Monoclonal eGFP-SNAP29 Chapter 3, 4
CHO/SNAP29 B pMRXIP-SNAP29 Puromycin CHO-S Monoclonal eGFP-SNAP29 Chapter 3, 4
CHO/MRXIP-GFP H pMRXIP-GFP Puromycin CHO-S Monoclonal eGFP Chapter 3, 4
CHO/MRXIP-GFP L pMRXIP-GFP Puromycin CHO-S Monoclonal eGFP Chapter 3, 4
mpDG44/ADA pAVE ADA MTX Clone 27/CHO-DG44 Mini pool Adalimumab Chapter 5
mpDG44/ADA CMVbGH pAVE ADA CMVbGH MTX Clone 27/CHO-DG44 Mini pool Adalimumab control vector Chapter 5
mpDG44/ADA STX7 pAVE ADA CMV STX7 MTX Clone 27/CHO-DG44 Mini pool eGFP-STX7 Adalimumab Chapter 5
mpDG44/ADA STX17 pAVE ADA CMV STX17 MTX Clone 27/CHO-DG44 Mini pool eGFP-STX17 Adalimumab Chapter 5
mpDG44/ADA SNAP29 pAVE ADA CMV SNAP29 MTX Clone 27/CHO-DG44 Mini pool eGFP-SNAP29 Adalimumab Chapter 5
mpDG44/BLOSO pAVE BLOSO MTX Clone 27/CHO-DG44 Mini pool Blosozumab Chapter 5
mpDG44/BLOSO CMVbGH pAVE BLOSO CMVbGH MTX Clone 27/CHO-DG44 Mini pool Blosozumab control vector Chapter 5
mpDG44/BLOSO STX7 pAVE BLOSO CMV STX7 MTX Clone 27/CHO-DG44 Mini pool eGFP-STX7 Blosozumab Chapter 5
mpDG44/BLOSO STX17 pAVE BLOSO CMV STX17 MTX Clone 27/CHO-DG44 Mini pool eGFP-STX17 Blosozumab Chapter 5
mpDG44/BLOSO STX18 pAVE BLOSO CMV STX18 MTX Clone 27/CHO-DG44 Mini pool eGFP-STX18 Blosozumab Chapter 5
mpDG44/BLOSO SNAP29 pAVE BLOSO CMV SNAP29 MTX Clone 27/CHO-DG44 Mini pool eGFP-SNAP29 Blosozumab Chapter 5
poolDG44/ADA pAVE ADA MTX Clone 27/CHO-DG44 Pool Adalimumab Chapter 5
poolDG44/ADA CMVbGH pAVE ADA CMVbGH MTX Clone 27/CHO-DG44 Pool Adalimumab control vector Chapter 5
poolDG44/ADA STX7 pAVE ADA CMV STX7 MTX Clone 27/CHO-DG44 Pool eGFP-STX7 Adalimumab Chapter 5
poolDG44/ADA STX17 pAVE ADA CMV STX17 MTX Clone 27/CHO-DG44 Pool eGFP-STX17 Adalimumab Chapter 5
poolDG44/ADA STX18 pAVE ADA CMV STX18 MTX Clone 27/CHO-DG44 Pool eGFP-STX18 Adalimumab Chapter 5
poolDG44/ADA SNAP29 pAVE ADA CMV SNAP29 MTX Clone 27/CHO-DG44 Pool eGFP-SNAP29 Adalimumab Chapter 5
poolDG44/BLOSO pAVE BLOSO MTX Clone 27/CHO-DG44 Pool Blosozumab Chapter 5
poolDG44/BLOSO CMVbGH pAVE BLOSO CMVbGH MTX Clone 27/CHO-DG44 Pool Blosozumab control vector Chapter 5
poolDG44/BLOSO STX7 pAVE BLOSO CMV STX7 MTX Clone 27/CHO-DG44 Pool eGFP-STX7 Blosozumab Chapter 5
poolDG44/BLOSO STX17 pAVE BLOSO CMV STX17 MTX Clone 27/CHO-DG44 Pool eGFP-STX17 Blosozumab Chapter 5
poolDG44/BLOSO STX18 pAVE BLOSO CMV STX18 MTX Clone 27/CHO-DG44 Pool eGFP-STX18 Blosozumab Chapter 5
poolDG44/BLOSO SNAP29 pAVE BLOSO CMV SNAP29 MTX Clone 27/CHO-DG44 Pool eGFP-SNAP29 Blosozumab Chapter 5
DG44/ADA+STX7 pMRXIP-STX7 MTX+Puromycin mpDG44/ADA 7 Pool eGFP-STX7 Adalimumab Chapter 5
DG44/ADA+STX17 pMRXIP-STX17 MTX+Puromycin mpDG44/ADA 7 Pool eGFP-STX17 Adalimumab Chapter 5
DG44/ADA+SNAP29 pMRXIP-SNAP29 MTX+Puromycin mpDG44/ADA 7 Pool eGFP-SNAP29 Adalimumab Chapter 5
DG44/ADA+GFP pMRXIP-GFP MTX+Puromycin mpDG44/ADA 7 Pool eGFP Adalimumab control vector Chapter 5
DG44/BLOSO+STX7 pMRXIP-STX7 MTX+Puromycin mpDG44/BLOSO 6 Pool eGFP-STX7 Blosozumab Chapter 5
DG44/BLOSO+STX17 pMRXIP-STX17 MTX+Puromycin mpDG44/BLOSO 6 Pool eGFP-STX17 Blosozumab Chapter 5
DG44/BLOSO+SNAP29 pMRXIP-SNAP29 MTX+Puromycin mpDG44/BLOSO 6 Pool eGFP-SNAP29 Blosozumab Chapter 5
DG44/BLOSO+GFP pMRXIP-GFP MTX+Puromycin mpDG44/BLOSO 6 Pool eGFP Blosozumab control vector Chapter 5
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Appendix 4. Metabolites results from the FOG 
experiment. 
During the FOG experiment, metabolites were analysed daily from day 3. Error bars 
represent the standard deviation. Error bars show the standard deviation from the mean 
(n=3). 
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